U.S. patent application number 11/601252 was filed with the patent office on 2007-03-29 for tetrazole derivatives and methods of treatment of metabolic-related disorders thereof.
Invention is credited to Steven L. Colletti, Tawfik Gharbaoui, Jason E. Imbriglio, Jae-Kyu Jung, Rui Liang, Subharekha Raghavan, Darby Schmidt, Thomas Schrader, Graeme Semple, Philip J. Skinner, James R. Tata.
Application Number | 20070072924 11/601252 |
Document ID | / |
Family ID | 34572875 |
Filed Date | 2007-03-29 |
United States Patent
Application |
20070072924 |
Kind Code |
A1 |
Semple; Graeme ; et
al. |
March 29, 2007 |
Tetrazole derivatives and methods of treatment of metabolic-related
disorders thereof
Abstract
The present invention relates to certain tetrazole derivatives
of Formula (I), and pharmaceutically acceptable salts thereof,
which exhibit useful pharmacological properties, for example, as
agonists for the RUP25 receptor. ##STR1## Also provided by the
present invention are pharmaceutical compositions containing
compounds of the invention, and methods of using the compounds and
compositions of the invention in the treatment of metabolic-related
disorders, including dyslipidemia, atherosclerosis, coronary heart
disease, insulin resistance, type 2 diabetes, Syndrome-X and the
like. In addition, the present invention also provides for the use
of the compounds of the invention in combination with other active
agents such as those belonging to the class of .alpha.-glucosidase
inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA
reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL
catabolism enhancers, angiotensin converting enzyme (ACE)
inhibitors, insulin secretion enhancers and the like.
Inventors: |
Semple; Graeme; (San Diego,
CA) ; Schrader; Thomas; (La Jolla, CA) ;
Skinner; Philip J.; (San Diego, CA) ; Colletti;
Steven L.; (Princeton Junction, NJ) ; Gharbaoui;
Tawfik; (Escondido, CA) ; Imbriglio; Jason E.;
(Piscataway, NJ) ; Jung; Jae-Kyu; (San Diego,
CA) ; Liang; Rui; (East Brunswick, NJ) ;
Raghavan; Subharekha; (Teaneck, NJ) ; Schmidt;
Darby; (Clark, NJ) ; Tata; James R.;
(Westfield, NJ) |
Correspondence
Address: |
COZEN O'CONNOR, P.C.
1900 MARKET STREET
PHILADELPHIA
PA
19103-3508
US
|
Family ID: |
34572875 |
Appl. No.: |
11/601252 |
Filed: |
November 17, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10535345 |
Feb 15, 2006 |
|
|
|
PCT/US04/35927 |
Oct 29, 2004 |
|
|
|
11601252 |
Nov 17, 2006 |
|
|
|
60516238 |
Oct 31, 2003 |
|
|
|
Current U.S.
Class: |
514/381 ;
548/253 |
Current CPC
Class: |
A61P 3/06 20180101; A61P
43/00 20180101; A61P 3/10 20180101; C07D 495/04 20130101; A61P 9/12
20180101; C07D 491/04 20130101; C07D 403/04 20130101; A61P 3/04
20180101; A61P 3/00 20180101; A61P 9/00 20180101; A61P 5/50
20180101; A61P 9/10 20180101; A61P 9/02 20180101 |
Class at
Publication: |
514/381 ;
548/253 |
International
Class: |
A61K 31/416 20060101
A61K031/416; C07D 403/04 20060101 C07D403/04 |
Claims
1. A compound of Formula (I): ##STR116## wherein: X is NH or O;
R.sub.1 is selected from the group consisting of H, halogen,
hydroxy, thioxy, cyano, nitro, C.sub.1-4 haloalkyl, amino,
C.sub.1-4 alkylamino, C.sub.2-8 dialkylamino, C.sub.1-4 alkyl,
C.sub.1-4 alkoxy, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, C.sub.3-5
cycloalkyl, C.sub.1-4 haloalkoxy, C.sub.1-4 alkylthio, C.sub.1-4
alkylsulfinyl, C.sub.1-4 alkylsulfonyl, C.sub.1-4 haloalkylthio,
C.sub.1-4 haloalkylsulfinyl and C.sub.1-4 haloalkylsulfonyl;
R.sub.2 is selected from the group consisting of H, halogen,
hydroxy, thioxy, cyano, nitro, C.sub.1-4 haloalkyl, amino,
C.sub.1-4 alkylamino, C.sub.2-8 dialkylamino, C.sub.1-4 alkyl,
C.sub.1-4 alkoxy, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, C.sub.3-5
cycloalkyl, C.sub.1-4 haloalkoxy, C.sub.1-4 alkylthio, C.sub.1-4
alkylsulfinyl, C.sub.1-4 alkylsulfonyl, C.sub.1-4 haloalkylthio,
C.sub.1-4 haloalkylsulfinyl and C.sub.1-4 haloalkylsulfonyl; or
R.sub.2 is absent; is a single bond when R.sub.2 is present, or is
a double bond when R.sub.2 is absent; and Ring A is a 5, 6 or
7-membered carbocyclic ring or a 5, 6 or 7-membered heterocyclic
ring optionally substituted with 1 to 4 substituents selected from
the group consisting of halogen, hydroxy, thioxy, cyano, nitro,
C.sub.1-4 haloalkyl, amino, C.sub.1-4 alkylamino, C.sub.2-8
dialkylamino, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.2-4 alkenyl,
C.sub.2-4 alkynyl, C.sub.3-5 cycloalkyl, C.sub.1-4 haloalkoxy,
C.sub.1-4 alkylthio, C.sub.1-4 alkylsulfinyl, C.sub.1-4
alkylsulfonyl, C.sub.1-4 haloalkylthio, C.sub.1-4 haloalkylsulfinyl
and C.sub.1-4 haloalkylsulfonyl; or a pharmaceutically acceptable
salt, solvate or hydrate thereof.
2. The compound according to claim 1 wherein: X is NH; R.sub.1 is H
or hydroxy; R.sub.2 is H or absent; is a single bond when R.sub.2
is H, or is a double bond when R.sub.2 is absent; and Ring A is a
5-membered carbocyclic ring or a 5-membered heterocyclic ring
optionally substituted with 1 to 4 substituents selected from the
group consisting of halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy and
C.sub.3-5 cycloalkyl; or a pharmaceutically acceptable salt,
solvate or hydrate thereof.
3. The compound according to claim 1 having Formula (If):
##STR117## wherein: R.sub.1 is H or hydroxy; and Ring A is
optionally substituted with 1 or 2 substituents selected from the
group consisting of halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy and
C.sub.3-5 cycloalkyl; or a pharmaceutically acceptable salt,
solvate or hydrate thereof.
4. The compound according to claim 1 having Formula (Ih):
##STR118## wherein: Ring A is optionally substituted with 1 or 2
substituents selected from the group consisting of halogen,
C.sub.1-4 alkyl, C.sub.1-4 alkoxy and C.sub.3-5 cycloalkyl; or a
pharmaceutically acceptable salt, solvate or hydrate thereof.
5. The compound according to claim 1 having Formula (Ih):
##STR119## wherein: Ring A is unsubstituted or is substituted with
ethyl; or a pharmaceutically acceptable salt, solvate or hydrate
thereof.
6. The compound according to claim 1 having Formula (Ih):
##STR120## wherein: Ring A is substituted with 1 or 2 substituents
selected from the group consisting of halogen, n-propyl, n-butyl,
C.sub.1-4 alkoxy and C.sub.3-5 cycloalkyl; or a pharmaceutically
acceptable salt, solvate or hydrate thereof.
7. The compound according to claim 1 that is
3-(1H-Tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a
pharmaceutically acceptable salt, solvate or hydrate thereof.
8. The compound according to claim 1 that is
3-(1H-Tetrazol-5-yl)-2,6-dihydro-4H-thieno[3,4-c]pyrazole or a
pharmaceutically acceptable salt, solvate or hydrate thereof.
9. The compound according to claim 1 that is
6-Methyl-3-(1H-tetrazol-5-yl)-2,6-dihydro-4H-furo[3,4-c]pyrazole or
a pharmaceutically acceptable salt, solvate or hydrate thereof.
10. The compound according to claim 1 that is
3-(1H-Tetrazol-5-yl)-2,4-dihydro-cyclopentapyrazole or a
pharmaceutically acceptable salt, solvate or hydrate thereof.
11. The compound according to claim 1 that is
3-(1H-Tetrazol-5-yl)-2,6-dihydro-cyclopentapyrazole or a
pharmaceutically acceptable salt, solvate or hydrate thereof.
12. The compound according to claim 1 that is
3-(1H-Tetrazol-5-yl)-2,6-dihydro-4H-furo[3,4-c]pyrazole or a
pharmaceutically acceptable salt, solvate or hydrate thereof.
13. The compound according to claim 1 that is
5-Ethyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
or a pharmaceutically acceptable salt, solvate or hydrate
thereof.
14. The compound according to claim 1 that is
5-Butyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
or a pharmaceutically acceptable salt, solvate or hydrate
thereof.
15. The compound according to claim 1 that is
5-Methyl-3-(1H-tetrazol-5-yl)-2,6-dihydro-cyclopentapyrazole or a
pharmaceutically acceptable salt, solvate or hydrate thereof.
16. The compound according to claim 1 that is
5-Methyl-3-(1H-tetrazol-5-yl)-2,4-dihydro-cyclopentapyrazole or a
pharmaceutically acceptable salt, solvate or hydrate thereof.
17. The compound according to claim 1 that is
5-Propyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
or a pharmaceutically acceptable salt, solvate or hydrate
thereof.
18. The compound according to claim 1 that is
5-Propoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
or a pharmaceutically acceptable salt, solvate or hydrate
thereof.
19. The compound according to claim 1 that is
5-Cyclopentyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
or a pharmaceutically acceptable salt, solvate or hydrate
thereof.
20. The compound according to claim 1 that is
5-Fluoro-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
or a pharmaceutically acceptable salt, solvate or hydrate
thereof.
21. The compound according to claim 1 that is
5-Isobutoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
or a pharmaceutically acceptable salt, solvate or hydrate
thereof.
22. The compound according to claim 1 that is
5-Butoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
or a pharmaceutically acceptable salt, solvate or hydrate
thereof.
23. The compound according to claim 1 that is
3-(1H-Tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazol-6-ol or a
pharmaceutically acceptable salt, solvate or hydrate thereof.
24. The compound according to claim 1 that is
5-Methoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
or a pharmaceutically acceptable salt, solvate or hydrate
thereof.
25. The compound according to claim 1 that is
5,5-Difluoro-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
or a pharmaceutically acceptable salt, solvate or hydrate
thereof.
26. The compound according to claim 1 that is
5-Ethoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
or a pharmaceutically acceptable salt, solvate or hydrate
thereof.
27. A pharmaceutical composition comprising a compound according to
claim 1 in combination with a pharmaceutically acceptable
carrier.
28. A method of treatment of a metabolic-related disorder
comprising administering to an individual in need of such treatment
a therapeutically-effective amount of a compound according to claim
1.
29. The method according to claim 28 wherein said metabolic-related
disorder is selected from the group consisting of dyslipidemia,
atherosclerosis, coronary heart disease, insulin resistance and
type 2 diabetes.
30. The method according to claim 28 wherein said metabolic-related
disorder is atherosclerosis.
31. A method of raising HDL in an individual comprising
administering to said individual a therapeutically-effective amount
of a compound according to claim 1.
32. A compound according to claim 1 for use in a method of
treatment of the human or animal body by therapy.
33. A compound according to claim 1 for use in a method of
treatment of a metabolic-related disorder of the human or animal
body by therapy.
34. A compound according to claim 1 for use in a method of
treatment of a metabolic-related disorder of the human or animal
body by therapy wherein said metabolic-related disorder is selected
from the group consisting of dyslipidemia, atherosclerosis,
coronary heart disease, insulin resistance and type 2 diabetes.
35. A compound according to claim 1 for use in a method of
treatment of atherosclerosis of the human or animal body by
therapy.
36. A compound according to claim 1 for use in a method of raising
HDL of the human or animal body by therapy.
37. Use of a compound according to claim 1 for the manufacture of a
medicament for use in the treatment of a metabolic-related
disorder.
38. Use of a compound according to claim 1 for the manufacture of a
medicament for use in the treatment of a metabolic-related disorder
selected from the group consisting of dyslipidemia,
atherosclerosis, coronary heart disease, insulin resistance and
type 2 diabetes.
39. Use of a compound according to claim 1 for the manufacture of a
medicament for use in the treatment of atherosclerosis.
40. Use of a compound according to claim 1 for the manufacture of a
medicament for use in raising HDL in an individual.
41. A method of producing a pharmaceutical composition comprising
admixing a compound according to claim 1 and a pharmaceutically
acceptable carrier.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to certain tetrazole
derivatives, and pharmaceutically acceptable salts thereof, which
exhibit useful pharmacological properties, for example as agonists
for the nicotinic acid receptor, RUP25. Also provided by the
present invention are pharmaceutical compositions containing one or
more compounds of the invention, and methods of using the compounds
and compositions of the invention in the treatment of
metabolic-related disorders, including dyslipidemia,
atherosclerosis, coronary heart disease, insulin resistance, type 2
diabetes, Syndrome-X and the like. In addition, the present
invention also provides for the use of the compounds of the
invention in combination with other active agents such as those
belonging to the class of .alpha.-glucosidase inhibitors, aldose
reductase inhibitors, biguanides, HMG-CoA reductase inhibitors,
squalene synthesis inhibitors, fibrates, LDL catabolism enhancers,
angiotensin converting enzyme (ACE) inhibitors, insulin secretion
enhancers, thiazolidinedione and the like.
BACKGROUND OF THE INVENTION
Compounds of the Invention as Antilipolytic Agents
[0002] Atherosclerosis and stroke are the numbers one and number
three leading causes of death of both men and women in the United
States. Type 2 diabetes is a public health problem that is serious,
widespread and increasing. Elevated levels of low density
lipoprotein (LDL) cholesterol or low levels of high density
lipoprotein (HDL) cholesterol are, independently, risk factors for
atherosclerosis and associated cardiovascular pathologies. In
addition, high levels of plasma free fatty acids are associated
with insulin resistance and type 2 diabetes. One strategy for
decreasing LDL-cholesterol, increasing HDL-cholesterol, and
decreasing plasma free fatty acids is to inhibit lipolysis in
adipose tissue. This approach involves regulation of hormone
sensitive lipase, which is the rate-limiting enzyme in lipolysis.
Lipolytic agents increase cellular levels of cAMP, which leads to
activation of hormone sensitive lipase within adipocytes. Agents
that lower intracellular cAMP levels, by contrast, would be
antilipolytic.
[0003] It is also worth noting in passing that an increase in
cellular levels of cAMP down-regulates the secretion of adiponectin
from adipocytes [Delporte, M L et al. Biochem J (2002) July].
Reduced levels of plasma adiponectin have been associated with
metabolic-related disorders, including atherosclerosis, coronary
heart disease, insulin resistance and type 2 diabetes [Matsuda, M
et al. J Biol Chem (2002) July and reviewed therein].
[0004] Nicotinic acid (niacin, pyridine-3-carboxylic acid) is a
water-soluble vitamin required by the human body for health, growth
and reproduction; a part of the Vitamin B complex. Nicotinic acid
is also one of the oldest used drugs for the treatment of
dyslipidemia. It is a valuable drug in that it favorably affects
virtually all of the lipid parameters listed above [Goodman and
Gilman's Pharmacological Basis of Therapeutics, editors Harmon J G
and Limbird L E, Chapter 36, Mahley R W and Bersot T P (2001) pages
971-1002]. The benefits of nicotinic acid in the treatment or
prevention of atherosclerotic cardiovascular disease have been
documented in six major clinical trials [Guyton J R (1998) Am J
Cardiol 82:18U-23U]. Nicotinic acid and related derivatives, such
as, acipimox have recently been discussed [Lorenzen, A et al (2001)
Molecular Pharmacology 59:349-357]. Structure and synthesis of
additional analogs or derivatives of nicotinic acid are discussed
throughout the Merck Index, An Encyclopedia of Chemicals, Drugs,
and Biologicals, Tenth Edition (1983), which is incorporated herein
by reference in its entirety.
[0005] Nicotinic acid inhibits the production and release of free
fatty acids from adipose tissue, likely via an inhibition of
adenylyl cyclase, a decrease in intracellular cAMP levels, and a
concomitant decrease in hormone sensitive lipase activity. Agonists
that down-regulate hormone sensitive lipase activity leading to a
decrease in plasma free fatty acid levels are likely to have
therapeutic value. The consequence of decreasing plasma free fatty
acids is two-fold. First, it will ultimately lower LDL-cholesterol
and raise HDL-cholesterol levels, independent risk factors, thereby
reducing the risk of mortality due to cardiovascular incidence
subsequent to atheroma formation. Second, it will provide an
increase in insulin sensitivity in individuals with insulin
resistance or type 2 diabetes. Unfortunately, the use of nicotinic
acid as a therapeutic is partially limited by a number of
associated, adverse side-effects. These include flushing, free
fatty acid rebound, and liver toxicity.
[0006] The rational development of novel, nicotinic acid receptor
agonists that have fewer side-effects will be valuable, but to date
this has been hindered by the inability to molecularly identify the
nicotinic acid receptor. Furthermore, other receptors of the same
class may exist on the surface of adipocytes and similarly decrease
hormone sensitive lipase activity through a reduction in the level
of intracellular cAMP but without the elicitation of adverse
effects such as flushing, thereby representing promising novel
therapeutic targets. Recent work suggests that nicotinic acid
probably acts through a specific GPCR [Lorenzen A, et al. (2001)
Molecular Pharmacology 59:349-357 and reviewed therein]. Further
work has suggested that the effects of nicotinic acid on
macrophages, spleen and probably adipocytes are mediated via this
specific GPCR [Lorenzen A, et al. (2002) Biochemical Pharmacology
64:645-648 and reviewed therein].
SUMMARY OF THE INVENTION
[0007] One aspect of the present invention encompasses tetrazole
derivatives as shown in Formula (I): ##STR2## wherein:
[0008] X is NH or O;
[0009] R.sub.1 is selected from the group consisting of H, halogen,
hydroxy, thioxy, cyano, nitro, C.sub.1-4 haloalkyl, amino,
C.sub.1-4 alkylamino, C.sub.2-8 dialkylamino, C.sub.1-4 alkyl,
C.sub.1-4 alkoxy, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, C.sub.3-5
cycloalkyl, C.sub.1-4 haloalkoxy, C.sub.1-4 alkylthio, C.sub.1-4
alkylsulfinyl, C.sub.1-4 alkylsulfonyl, C.sub.1-4 haloalkylthio,
C.sub.1-4 haloalkylsulfinyl and C.sub.1-4 haloalkylsulfonyl;
[0010] R.sub.2 is selected from the group consisting of H, halogen,
hydroxy, thioxy, cyano, nitro, C.sub.1-4 haloalkyl, amino,
C.sub.1-4 alkylamino, C.sub.2-8 dialkylamino, C.sub.1-4 alkyl,
C.sub.1-4 alkoxy, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, C.sub.3-5
cycloalkyl, C.sub.1-4 haloalkoxy, C.sub.1-4 alkylthio, C.sub.1-4
alkylsulfinyl, C.sub.1-4 alkylsulfonyl, C.sub.1-4 haloalkylthio,
C.sub.1-4 haloalkylsulfinyl and C.sub.1-4 haloalkylsulfonyl; or
R.sub.2 is absent;
[0011] is a single bond when R.sub.2 is present, or is a double
bond when R.sub.2 is absent; and
[0012] Ring A is a 5, 6 or 7-membered carbocyclic ring or a 5, 6 or
7-membered heterocyclic ring optionally substituted with 1 to 4
substituents selected from the group consisting of halogen,
hydroxy, thioxy, cyano, nitro, C.sub.1-4 haloalkyl, amino,
C.sub.1-4 alkylamino, C.sub.2-8 dialkylamino, C.sub.1-4 alkyl,
C.sub.1-4 alkoxy, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, C.sub.3-5
cycloalkyl, C.sub.1-4 haloalkoxy, C.sub.1-4 alkylthio, C.sub.1-4
alkylsulfinyl, C.sub.1-4 alkylsulfonyl, C.sub.1-4 haloalkylthio,
C.sub.1-4 haloalkylsulfinyl and C.sub.1-4 haloalkylsulfonyl; or
[0013] a pharmaceutically acceptable salt, solvate or hydrate
thereof.
[0014] One aspect of the present invention encompasses
pharmaceutical compositions comprising at least one compound
according to Formula (I), as described herein.
[0015] In some embodiments, the pharmaceutical composition further
comprises one or more agents selected from the group consisting of
.alpha.-glucosidase inhibitor, aldose reductase inhibitor,
biguanide, HMG-CoA reductase inhibitor, squalene synthesis
inhibitor, fibrate, LDL catabolism enhancer, angiotensin converting
enzyme inhibitor, insulin secretion enhancer and
thiazolidinedione.
[0016] One aspect of the present invention pertains to methods of
treatment of a metabolic-related disorder comprising administering
to an individual in need of such treatment a
therapeutically-effective amount of a compound according to Formula
(I), as described herein, or a pharmaceutical composition
thereof.
[0017] One aspect of the present invention pertains to methods of
modulating a RUP25 receptor comprising contacting the receptor with
a compound according to Formula (I), as described herein.
[0018] One aspect of the present invention pertains to methods of
modulating a RUP25 receptor for the treatment of a
metabolic-related disorder in an individual in need of such
modulation comprising contacting said receptor with a
therapeutically-effective amount of a compound according to Formula
(I), as described herein.
[0019] One aspect of the present invention pertains to methods of
raising HDL in an individual comprising administering to the
individual a therapeutically-effective amount of a compound
according to Formula (I), as described herein.
[0020] One aspect of the present invention pertains to a compound
of Formula (I), as described herein, for use in a method of
treatment of the human or animal body by therapy.
[0021] One aspect of the present invention pertains to a compound
of Formula (I), as described herein, for use in a method of
treatment of a metabolic-related disorder of the human or animal
body by therapy.
[0022] One aspect of the present invention pertains to the use of
compounds of Formula (I), as described herein, for the manufacture
of a medicament for use in the treatment of a metabolic-related
disorder.
[0023] In some embodiments of the present invention, the
metabolic-related disorder is of the group consisting of
dyslipidemia, atherosclerosis, coronary heart disease, insulin
resistance, obesity, impaired glucose tolerance, atheromatous
disease, hypertension, stroke, Syndrome X, heart disease and type 2
diabetes. In some embodiments the metabolic-related disorder is
dyslipidemia, atherosclerosis, coronary heart disease, insulin
resistance and type 2 diabetes. In some embodiments the
metabolic-related disorder is dyslipidemia. In some embodiments the
metabolic-related disorder is atherosclerosis. In some embodiments
the metabolic-related disorder is coronary heart disease. In some
embodiments the metabolic-related disorder is insulin resistance.
In some embodiments the metabolic-related disorder is type 2
diabetes.
[0024] One aspect of the present invention encompasses a method of
producing a pharmaceutical composition comprising admixing at least
one compound according to Formula (I), as described herein, and a
pharmaceutically acceptable carrier or excipient.
[0025] These and other aspects of the invention disclosed herein
will be set forth in greater detail as the patent disclosure
proceeds.
DETAILED DESCRIPTION OF THE INVENTION
[0026] The scientific literature has adopted a number of terms, for
consistency and clarity, the following definitions will be used
throughout this patent document.
[0027] AGONISTS shall mean moieties that interact and activate the
receptor, such as the RUP25 receptor and initiates a physiological
or pharmacological response characteristic of that receptor. For
example, when moieties activate the intracellular response upon
binding to the receptor, or enhance GTP binding to membranes.
[0028] AMINO ACID ABBREVIATIONS used herein are set out in TABLE 1:
TABLE-US-00001 TABLE 1 ALANINE ALA A ARGININE ARG R ASPARAGINE ASN
N ASPARTIC ACID ASP D CYSTEINE CYS C GLUTAMIC ACID GLU E GLUTAMINE
GLN Q GLYCINE GLY G HISTIDINE HIS H ISOLEUCINE ILE I LEUCINE LEU L
LYSINE LYS K METHIONINE MET M PHENYLALANINE PHE F PROLINE PRO P
SERINE SER S THREONINE THR T TRYPTOPHAN TRP W TYROSINE TYR Y VALINE
VAL V
[0029] The term ANTAGONISTS is intended to mean moieties that
competitively bind to the receptor at the same site as agonists
(for example, the endogenous ligand), but which do not activate the
intracellular response initiated by the active form of the
receptor, and can thereby inhibit the intracellular responses by
agonists or partial agonists. Antagonists do not diminish the
baseline intracellular response in the absence of an agonist or
partial agonist.
[0030] ATHEROSCLEROSIS is intended herein to encompass disorders of
large and medium-sized arteries that result in the progressive
accumulation within the intima of smooth muscle cells and
lipids.
[0031] CHEMICAL GROUP, MOIETY OR RADICAL: [0032] The term
"C.sub.1-4 acyl" denotes a C.sub.1-4 alkyl radical attached to a
carbonyl wherein the definition of alkyl has the same definition as
described herein; some examples include but not limited to, acetyl,
propionyl, n-butanoyl, iso-butanoyl, sec-butanoyl, t-butanoyl
(i.e., pivaloyl), pentanoyl and the like. [0033] The term
"C.sub.1-4 acyloxy" denotes an acyl radical attached to an oxygen
atom wherein acyl has the same definition has described herein;
some examples include but not limited to acetyloxy, propionyloxy,
butanoyloxy, iso-butanoyloxy, sec-butanoyloxy, t-butanoyloxy and
the like. [0034] The term "C.sub.2-4 alkenyl" denotes a radical
containing 2 to 4 carbons wherein at least one carbon-carbon double
bond is present, some embodiments are 2 to 3 carbons, and some
embodiments have 2 carbons. Both E and Z isomers are embraced by
the term "alkenyl." Furthermore, the term "alkenyl" includes
di-enes. Accordingly, if more than one double bond is present, then
the bonds may be all E or Z or a mixtures of E and Z. Examples of
an alkenyl include vinyl, propenyl, allyl, isopropenyl,
2-methyl-propenyl 1-methyl-propenyl, but-1-enyl, but-2-enyl,
but-3-enyl, buta-1,3-dienyl, and the like. [0035] The term
"C.sub.1-4 alkoxy" denotes an alkyl radical, as defined herein,
attached directly to an oxygen atom. Examples include methoxy,
ethoxy, n-propoxy, iso-propoxy, n-butoxy, t-butoxy, iso-butoxy,
sec-butoxy and the like. [0036] The term "C.sub.1-4 alkyl" denotes
a straight or branched carbon radical containing the number of
carbons as indicated, for examples, in some embodiments, alkyl is a
"C.sub.1-4 alkyl" and the group contains 1 to 4 carbons. In some
embodiments alkyl contains 1 to 13 carbons, some embodiments
contain 1 to 2 carbons, some embodiments contain 1 carbon. Examples
of an alkyl include, but not limited to, methyl, ethyl, n-propyl,
iso-propyl, n-butyl, iso-butyl, t-butyl, sec-butyl, and the like.
[0037] The term "C.sub.1-4 alkylsulfinyl" denotes a C.sub.1-4 alkyl
radical attached to a sulfoxide radical of the formula: --S(O)--
wherein the alkyl radical has the same definition as described
herein. Examples include, but not limited to, methylsulfinyl,
ethylsulfinyl, n-propylsulfinyl, iso-propylsulfinyl,
n-butylsulfinyl, sec-butylsulfinyl, iso-butylsulfinyl, t-butyl, and
the like. [0038] The term "C.sub.1-4 alkylsulfonyl" denotes a
C.sub.1-4 alkyl radical attached to a sulfone radical of the
formula: --S(O).sub.2-- wherein the alkyl radical has the same
definition as described herein. Examples include, but not limited
to, methylsulfonyl, ethylsulfonyl, n-propylsulfonyl,
iso-propylsulfonyl, n-butylsulfonyl, sec-butylsulfonyl,
iso-butylsulfonyl, t-butylsulfonyl, and the like. [0039] The term
"C.sub.1-4 alkylthio" denotes a C.sub.1-4 alkyl radical attached to
a sulfide group of the formula: --S-- wherein the alkyl radical has
the same definition as described herein. Examples include, but not
limited to, methylsulfanyl (i.e., CH.sub.3S--), ethylsulfanyl,
n-propylsulfanyl, iso-propylsulfanyl, n-butylsulfanyl,
sec-butylsulfanyl, iso-butylsulfanyl, t-butyl, and the like. [0040]
The term "C.sub.2-4 alkynyl" denotes a radical containing 2 to 4
carbons and at least one carbon-carbon triple bond, some
embodiments are 2 to 3 carbons, and some embodiments have 2
carbons. Examples of an alkynyl include, but not limited to,
ethynyl, prop-1-ynyl, 3-prop-2-ynyl, but-1-ynyl,
1-methyl-prop-2-ynyl, buta-1,3-diynyl, and the like. The term
"alkynyl" includes di-ynes. [0041] The term "amino" denotes the
group --NH.sub.2. [0042] The term "C.sub.1-4 alkylamino" denotes
one alkyl radical attached to an amino radical wherein the alkyl
radical has the same meaning as described herein. Some examples
include, but not limited to, methylamino, ethylamino,
n-propylamino, iso-propylamino, n-butylamino, sec-butylamino,
iso-butylamino, t-butylamino, and the like. Some embodiments are
"C.sub.1-2 alkylamino." [0043] The term "aryl" denotes an aromatic
ring radical containing 6 to 10 ring carbons. Examples include
phenyl and naphthyl. [0044] The term "carbo-C.sub.1-4-alkoxy"
denotes a C.sub.1-4 alkyl ester of a carboxylic acid, wherein the
alkyl group is as defined herein. Examples include, but not limited
to, carbomethoxy, carboethoxy, carbopropoxy, carboisopropoxy,
carbobutoxy, carbo-sec-butoxy, carbo-iso-butoxy, carbo-t-butoxy,
and the like. [0045] The term "carboxamide" refers to the group
--CONH.sub.2. [0046] The term "carboxy" or "carboxyl" denotes the
group --CO.sub.2H; also referred to as a carboxylic acid group.
[0047] The term "cyano" denotes the group --CN. [0048] The term
"C.sub.3-5 cycloalkyl" denotes a saturated ring radical containing
3 to 6 carbons; some embodiments contain 3 to 5 carbons; some
embodiments contain 3 to 4 carbons. Examples include, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl. [0049] The term "C.sub.2-8
dialkylamino" denotes an amino substituted with two of the same or
different alkyl radicals wherein alkyl radical has the same
definition as described herein. A C.sub.2-8 dialkylamino may be
represented by the following groups: ##STR3## Examples of C.sub.2-8
dialkylamino include, but not limited to, dimethylamino,
methylethylamino, diethylamino, methylpropylamino,
methylisopropylamino, and the like. [0050] The term "C.sub.1-4
haloalkoxy" denotes a haloalkyl, as defined herein, which is
directly attached to an oxygen atom. Examples include, but not
limited to, difluoromethoxy, trifluoromethoxy,
2,2,2-trifluoroethoxy, pentafluoroethoxy and the like. [0051] The
term "C.sub.1-4 haloalkyl" denotes an alkyl group wherein the alkyl
is substituted with halogen ranging from one to fully substituted,
wherein a fully substituted haloalkyl can be represented by the
formula C.sub.hL.sub.2h+1 wherein L is a halogen and "h" represents
the number of carbon atoms; when more than one halogen is present
then the halogens may be the same or different and selected from
the group consisting of F, Cl, Br and I; it is understood that the
terms "alkyl" and "halogen" have the same definition as found
herein. In some embodiments, haloalkyl is a "C.sub.1-4 haloalkyl"
and the group contains 1 to 4 carbons, some embodiments contain 1
to 3 carbons, some embodiments contain 1 to 2 carbons, some
embodiments contain 1 carbon. When the haloalkyl is fully
substituted with halogen atoms, this group is referred herein as a
perhaloalkyl, one example, is an alkyl fully substituted with
fluorine atoms and is referred to herein as a "perfluoroalkyl." In
some embodiments, examples of a haloalkyl include, but not limited
to, difluoromethyl, fluoromethyl, 2,2,2-trifluoro-ethyl,
2,2-difluoro-ethyl, 2-fluoro-ethyl, 1,2,2-trifluoro-ethyl,
1,2-difluoro-ethyl, 1,1-difluoro-ethyl, 1,1,2-trifluoro-ethyl,
3,3,3-trifluoro-propyl, 2,2-difluoro-propyl, 3,3-difluoro-propyl,
3-fluoro-propyl, 2,3,3-trifluoro-propyl, 2,3-Difluoro-propyl,
2,2,3,3,3-pentafluoro-propyl, 2,2,3,3-tetrafluoro-propyl,
2,2,3-trifluoro-propyl, 1,2,3,3-tetrafluoro-propyl,
1,2,3-trifluoro-propyl, 3,3-difluoro-propyl,
1,2,2,3-tetrafluoro-propyl, 4,4-difluoro-butyl, 3,3-difluoro-butyl,
4,4,4-trifluoro-butyl, 3,3-difluoro-butyl, and the like. In some
embodiments, examples of a perfluoroalkyl include, but not limited
to, trifluoromethyl, pentafluoroethyl, heptafluoropropyl,
1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl, and the like. [0052]
The term "C.sub.1-4 haloalkylsulfinyl" denotes a haloalkyl radical
attached to a sulfoxide group of the formula: --S(O)-- wherein the
haloalkyl radical has the same definition as described herein.
[0053] The term "C.sub.1-4 haloalkylsulfonyl" denotes a haloalkyl
radical attached to a sulfone group of the formula: --S(O).sub.2--
wherein haloalkyl has the same definition as described herein.
[0054] The term "C.sub.1-4 haloalkylthio" denotes a haloalkyl
radical directly attached to a sulfur atom wherein the haloalkyl
has the same meaning as described herein. [0055] The term "halogen"
or "halo" denotes to a fluoro, chloro, bromo or iodo group. [0056]
The term "hydroxyl" denotes the group --OH. [0057] The term "nitro"
denotes the group --NO.sub.2. [0058] The term "thioxy" denotes the
group --SH. [0059] The acronym DMF denotes dimethylformamide.
[0060] The acronym DMSO denotes dimethylsulfoxide. [0061] The
acronym THF denotes tetrahydrofuran. [0062] The acronym DCM denotes
dichloromethane. [0063] The acronym Hex denotes hexanes. [0064] The
acronym TBDMS denotes tert-butyldimethylsilyl. [0065] The acronym
PTSA denotes para-toluenesulfonic acid. [0066] The acronym LDA
denotes lithium diisopropylamide. [0067] The acronym LHMDS denotes
lithium hexamethyldisilazane. [0068] The acronym TFA denotes
trifluoroacetic acid. [0069] The acronym EDC denotes
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride. [0070]
The acronym dppf denotes 1,1'-bis(diphenylphosphino)ferrocene.
[0071] The term CODON shall mean a grouping of three nucleotides
(or equivalents to nucleotides) which generally comprise a
nucleoside (adenosine (A), guanosine (G), cytidine (C), uridine (U)
and thymidine (T)) coupled to a phosphate group and which, when
translated, encodes an amino acid.
[0072] The term COMPOSITION shall mean a material comprising at
least two compounds or two components; for example, and without
limitation, a Pharmaceutical Composition is a Composition
comprising a compound of the present invention and a
pharmaceutically acceptable carrier.
[0073] The term COMPOUND EFFICACY shall mean a measurement of the
ability of a compound to inhibit or stimulate receptor
functionality, as opposed to receptor binding affinity.
[0074] The term CONSTITUTIVELY ACTIVATED RECEPTOR shall mean a
receptor subject to constitutive receptor activation.
[0075] The term CONSTITUTIVE RECEPTOR ACTIVATION shall mean
stabilization of a receptor in the active state by means other than
binding of the receptor with its endogenous ligand or a chemical
equivalent thereof.
[0076] The terms CONTACT or CONTACTING shall mean bringing the
indicated moieties together, whether in an in vitro system or an in
vivo system. Thus, "contacting" a RUP25 receptor with a compound of
the invention includes the administration of a compound of the
present invention to an individual, for example a human, having a
RUP25 receptor, as well as, for example, introducing a compound of
the invention into a sample containing a cellular or more purified
preparation containing a RUP25 receptor.
[0077] CORONARY HEART DISEASE is intended herein to encompass
disorders comprising a narrowing of the small blood vessels that
supply blood and oxygen to the heart. Coronary heart disease
usually results from the build up of fatty material and plaque. As
the coronary arteries narrow, the flow of blood to the heart can
slow or stop. Coronary heart disease can cause chest pain (stable
angina), shortness of breath, heart attack, or other symptoms.
[0078] DECREASE is used to refer to a reduction in a measurable
quantity and is used synonymously with the terms "reduce",
"diminish", "lower", and "lessen".
[0079] DIABETES as used herein is intended to encompass the usual
diagnosis of DIABETES made from any of the methods including, but
not limited to, the following list: symptoms of diabetes (e.g.,
polyuria, polydipsia, polyphagia) plus casual plasma glucose levels
of greater than or equal to 200 mg/dl, wherein casual plasma
glucose is defined any time of the day regardless of the timing of
meal or drink consumption; 8 hour fasting plasma glucose levels of
less than or equal to 126 mg/dl; and plasma glucose levels of
greater than or equal to 200 mg/dl 2 hours following oral
administration of 75 g anhydrous glucose dissolved in water.
[0080] The phrase DISORDERS OF LIPID METABOLISM is intended herein
to include, but not be limited to, dyslipidemia.
[0081] The term DYSLIPIDEMIA is intended herein to encompass
disorders comprising any one of elevated level of plasma free fatty
acids, elevated level of plasma cholesterol, elevated level of
LDL-cholesterol, reduced level of HDL-cholesterol, and elevated
level of plasma triglycerides.
[0082] The phrase IN NEED OF TREATMENT, as used herein, refers to a
judgment made by a caregiver (e.g. physician, nurse, nurse
practitioner, etc. in the case of humans; veterinarian in the case
of animals, including non-human mammals) that an individual or
animal requires or will benefit from treatment. This judgment is
made based on a variety of factors that are in the realm of a
caregiver's expertise, that includes the knowledge that the
individual is ill, or will be ill, as the result of a disease,
condition or disorder that is treatable by the compounds of the
invention. Further, the phrase "in need of treatment" also refers
to the "prophylaxis" of an individual which is the judgment made by
the caregiver that the individual will become ill. In this context,
the compounds of the invention are used in a protective or
preventive manner. Accordingly, "in need of treatment" refers to
the judgment of the caregiver that the individual is already ill or
will become ill and the compounds of the present invention can be
used to alleviate, inhibit, ameliorate or prevent the disease,
condition or disorder.
[0083] The term INDIVIDUAL as used herein refers to any animal,
including mammals, for example, mice, rats, other rodents, rabbits,
dogs, cats, swine, cattle, sheep, horses, or primates, and in one
embodiment, humans.
[0084] The terms INHIBIT or INHIBITING, in relationship to the term
"response" shall mean that a response is decreased or prevented in
the presence of a compound as opposed to in the absence of the
compound.
[0085] INSULIN RESISTANCE as used herein is intended to encompass
the usual diagnosis of insulin resistance made by any of a number
of methods, including but not restricted to: the intravenous
glucose tolerance test or measurement of the fasting insulin level.
It is well known that there is an excellent correlation between the
height of the fasting insulin level and the degree of insulin
resistance. Therefore, one could use elevated fasting insulin
levels as a surrogate marker for insulin resistance for the purpose
of identifying which normal glucose tolerance (NGT) individuals
have insulin resistance. A diagnosis of insulin resistance can also
be made using the euglycemic glucose clamp test.
[0086] The term INVERSE AGONISTS shall mean moieties that bind the
endogenous form of the receptor or to the constitutively activated
form of the receptor, and which inhibit the baseline intracellular
response initiated by the active form of the receptor below the
normal base level of activity which is observed in the absence of
agonists or partial agonists, or decrease GTP binding to membranes.
In some embodiments, the baseline intracellular response is
inhibited in the presence of the inverse agonist by at least 30%,
in other embodiments, by at least 50%, and in still other
embodiments, by at least 75%, as compared with the baseline
response in the absence of the inverse agonist.
[0087] The term LIGAND shall mean an endogenous, naturally
occurring molecule specific for an endogenous, naturally occurring
receptor.
[0088] The phrase METABOLIC-RELATED DISORDERS is intended herein to
include, but not be limited to, dyslipidemia, atherosclerosis,
coronary heart disease, insulin resistance, obesity, impaired
glucose tolerance, atheromatous disease, hypertension, stroke,
Syndrome X, heart disease and type 2 diabetes.
[0089] As used herein, the terms MODULATE or MODULATING shall mean
to refer to an increase or decrease in the amount, quality,
response or effect of a particular activity, function or
molecule.
[0090] The term PHARMACEUTICAL COMPOSITION shall mean a composition
for preventing, treating or controlling a disease state or
condition comprising at least one active compound, for example, a
compound of the present invention including pharmaceutically
acceptable salts, pharmaceutically acceptable solvates and/or
hydrates thereof, and at least one pharmaceutically acceptable
carrier.
[0091] The term PHARMACEUTICALLY ACCEPTABLE CARRIER or EXCIPIENT
shall mean any substantially inert substance substance used as a
diluent or vehicle for a compound of the present invention.
[0092] The phrase THERAPEUTICALLY-EFFECTIVE AMOUNT as used herein
refers to the amount of active compound or pharmaceutical agent
that elicits the biological or medicinal response in a tissue,
system, animal, individual or human that is being sought by a
researcher, veterinarian, medical doctor or other clinician, which
includes one or more of the following:
[0093] (1) Preventing the disease; for example, preventing a
disease, condition or disorder in an individual that may be
predisposed to the disease, condition or disorder but does not yet
experience or display the pathology or symptomatology of the
disease,
[0094] (2) Inhibiting the disease; for example, inhibiting a
disease, condition or disorder in an individual that is
experiencing or displaying the pathology or symptomatology of the
disease, condition or disorder (i.e., arresting further development
of the pathology and/or symptomatology), and
[0095] (3) Ameliorating the disease; for example, ameliorating a
disease, condition or disorder in an individual that is
experiencing or displaying the pathology or symptomatology of the
disease, condition or disorder (i.e., reversing the pathology
and/or symptomatology).
Compounds of the Invention
[0096] One aspect of the present invention encompasses tetrazole
derivatives as shown in Formula (I): ##STR4##
[0097] wherein: [0098] X is NH or O; [0099] R.sub.1 is selected
from the group consisting of H, halogen, hydroxy, thioxy, cyano,
nitro, C.sub.1-4 haloalkyl, amino, C.sub.1-4 alkylamino, C.sub.2-8
dialkylamino, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.2-4 alkenyl,
C.sub.2-4 alkynyl, C.sub.3-5 cycloalkyl, C.sub.1-4 haloalkoxy,
C.sub.1-4 alkylthio, C.sub.1-4 alkylsulfinyl, C.sub.1-4
alkylsulfonyl, C.sub.1-4 haloalkylthio, C.sub.1-4 haloalkylsulfinyl
and C.sub.1-4 haloalkylsulfonyl; [0100] R.sub.2 is selected from
the group consisting of H, halogen, hydroxy, thioxy, cyano, nitro,
C.sub.1-4 haloalkyl, amino, C.sub.1-4 alkylamino, C.sub.2-8
dialkylamino, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.2-4 alkenyl,
C.sub.2-4 alkynyl, C.sub.3-5 cycloalkyl, C.sub.1-4 haloalkoxy,
C.sub.1-4 alkylthio, C.sub.1-4 alkylsulfinyl, C.sub.1-4
alkylsulfonyl, C.sub.1-4 haloalkylthio, C.sub.1-4 haloalkylsulfinyl
and C.sub.1-4 haloalkylsulfonyl; or R.sub.2 is absent; [0101] is a
single bond when R.sub.2 is present, or is a double bond when
R.sub.2 is absent; and [0102] Ring A is a 5, 6 or 7-membered
carbocyclic ring or a 5, 6 or 7-membered heterocyclic ring
optionally substituted with 1 to 4 substituents selected from the
group consisting of halogen, hydroxy, thioxy, cyano, nitro,
C.sub.1-4 haloalkyl, amino, C.sub.1-4 alkylamino, C.sub.2-8
dialkylamino, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.2-4 alkenyl,
C.sub.2-4 alkynyl, C.sub.3-5 cycloalkyl, C.sub.1-4 haloalkoxy,
C.sub.1-4 alkylthio, C.sub.1-4 alkylsulfinyl, C.sub.1-4
alkylsulfonyl, C.sub.1-4 haloalkylthio, C.sub.1-4 haloalkylsulfinyl
and C.sub.1-4 haloalkylsulfonyl; or [0103] a pharmaceutically
acceptable salt, solvate or hydrate thereof.
[0104] Compounds of the present invention may exist in various
tautomeric forms. For example, it is well appreciated to those of
skill in the art that tetrazoles can exist in at least two
tautomeric forms and although Formula (I) represents one form it is
understood that all tautomeric forms are embraced by the present
invention; by way of illustration, two possible tautomers for the
tetrazole in Formula (I) are shown below: ##STR5##
[0105] Another example includes embodiments wherein X is NH. It is
well appreciated to those of skill in the art that pyrazole
heterocycles can exist in at least two tautomeric forms and
although Formula (I) represents one form it is understood that all
tautomeric forms are embraced by the present invention; by way of
illustration, two possible tautomers for the pyrazole wherein X is
NH in Formula (I) are shown below: ##STR6## Further, it is
understood that when X is NH then tautomers can exist for both Ring
B and also the tetrazole ring in combination. It is understood that
all tautomers that can exist for the compounds disclosed herein are
within the scope of the invention.
[0106] The present invention also encompasses diastereomers as well
as optical isomers, e.g. mixtures of enantiomers including racemic
mixtures, as well as individual enantiomers and diastereomers,
which arise as a consequence of structural asymmetry in certain
compounds of the present invention. In some embodiments, compounds
of the present invention are R. In some embodiments, compounds of
the present are S. In some embodiments, compounds of the present
invention are racemic mixtures.
[0107] It is appreciated that certain features of the invention,
which are, for clarity, described in the context of separate
embodiments, may also be provided in combination in a single
embodiment. Conversely, various features of the invention which
are, for brevity, described in the context of a single embodiment,
may also be provided separately or in any suitable
subcombination.
[0108] As used herein, "substituted" indicates that at least one
hydrogen atom of the chemical group is replaced by a non-hydrogen
substituents or group. When a chemical group herein is
"substituted" it may have up to the full valance of substitution;
for example, a methyl group can be substituted by 1, 2, or 3
substituents, a methylene group can be substituted by 1 or 2
substituents, a phenyl group can be substituted by 1, 2, 3, 4, or 5
substituents, and the like.
[0109] One embodiment of the present invention pertains to
compounds of Formula (I) wherein X is NH. This embodiment can be
represented by Formula (Ia) as illustrated below: ##STR7## wherein
each variable in Formula (Ia) has the same meaning as described
herein, supra and infra.
[0110] One embodiment of the present invention pertains to compound
of Formula (I) wherein X is NH, R.sub.1 is H or hydroxy; R.sub.2 is
H or absent; is a single bond when R.sub.2 is H, or is a double
bond when R.sub.2 is absent; and Ring A is a 5-membered carbocyclic
ring or a 5-membered heterocyclic ring optionally substituted with
1 to 4 substituents selected from the group consisting of halogen,
C.sub.1-4 alkyl, C.sub.1-4 alkoxy and C.sub.3-5 cycloalkyl; or a
pharmaceutically acceptable salt, solvate or hydrate thereof.
[0111] One embodiment of the present invention pertains to
compounds of Formula (I) wherein X is O. This embodiment can be
represented by Formula (Ic) as illustrated below: ##STR8## wherein
each variable in Formula (Ic) has the same meaning as described
herein, supra and infra.
[0112] One embodiment of the present invention pertains to
compounds of Formula (I) wherein R.sub.1 is selected from the group
consisting of H, halogen, hydroxy, C.sub.1-4 haloalkyl, C.sub.1-4
alkyl, C.sub.1-4 alkoxy, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl,
C.sub.1-4 alkylthio, and C.sub.1-4 haloalkoxy. In some embodiments,
R.sub.1 is selected from the group consisting of H, halogen,
C.sub.1-4 haloalkyl, and C.sub.1-4 alkyl. In some embodiments,
R.sub.1 is F. In some embodiments, R.sub.1 is H.
[0113] One embodiment of the present invention pertains to
compounds of Formula (I) wherein R.sub.2 is selected from the group
consisting of H, halogen, hydroxy, C.sub.1-4 haloalkyl, C.sub.1-4
alkyl, C.sub.1-4 alkoxy, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl,
C.sub.1-4 alkylthio, and C.sub.1-4 haloalkoxy. In some embodiments,
R.sub.2 is selected from the group consisting of H, halogen,
C.sub.1-4 haloalkyl, and C.sub.1-4 alkyl. In some embodiments,
R.sub.2 is F. In some embodiments, R.sub.2 is H.
[0114] One embodiment of the present invention pertains to
compounds of Formula (I) wherein R.sub.1 and R.sub.2 are both
H.
[0115] One embodiment of the present invention pertains to
compounds of Formula (I) wherein Ring A is a 5, 6 or 7-membered
carbocyclic ring. The term "5, 6 or 7-membered carbocyclic ring"
denotes a ring containing 5, 6 or 7 ring carbons wherein two ring
carbons are shared by rings A and B. Ring A can be saturated (i.e.
no ring double bonds), unsaturated (i.e., containing ring double
bonds) or a combination thereof. In some embodiments, is a single
bond and R.sub.2 is present. This embodiment can be represented by
Formula (Ie) as illustrated below: ##STR9## wherein each variable
in Formula (Ie) has the same meaning as described herein, supra and
infra.
[0116] One embodiment of the present invention pertains to
compounds having Formula (If): ##STR10##
[0117] wherein:
[0118] R.sub.1 is H or hydroxy; and Ring A is optionally
substituted with 1 or 2 substituents selected from the group
consisting of halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy and
C.sub.3-5 cycloalkyl; or a pharmaceutically acceptable salt,
solvate or hydrate thereof.
[0119] In some embodiments, Ring A is a 5-membered carbocyclic
ring. In one embodiment, Ring A is a 5-membered carbocyclic ring
and can be represented by Formula (Ig) as illustrated below:
##STR11## wherein each variable in Formula (Ig) has the same
meaning as described herein, supra and infra. In some embodiments,
R.sub.1 is C.sub.1-4 alkoxy. In some embodiments, R.sub.1 is
C.sub.1-4 alkyl. In some embodiments, R.sub.1 and R.sub.2 are both
H.
[0120] One embodiment of the present invention pertains to
compounds having Formula (Ih): ##STR12##
[0121] wherein:
[0122] Ring A is optionally substituted with 1 or 2 substituents
selected from the group consisting of halogen, C.sub.1-4 alkyl,
C.sub.1-4 alkoxy and C.sub.3-5 cycloalkyl; or a pharmaceutically
acceptable salt, solvate or hydrate thereof.
[0123] One embodiment of the present invention pertains to
compounds having Formula (Ih): ##STR13##
[0124] wherein:
[0125] Ring A is substituted with 1 or 2 substituents selected from
the group consisting of halogen, n-propyl, n-butyl, C.sub.1-4
alkoxy and C.sub.3-5 cycloalkyl; or a pharmaceutically acceptable
salt, solvate or hydrate thereof.
[0126] One embodiment of the present invention pertains to
compounds having Formula (Ih): ##STR14##
[0127] wherein:
[0128] Ring A is unsubstituted or is substituted with ethyl; or a
pharmaceutically acceptable salt, solvate or hydrate thereof.
[0129] In one embodiment, Ring A is a 5-membered carbocyclic ring
and is further unsaturated (i.e., a ring double bond). This
embodiment can be represented by Formula (Ii) as illustrated below:
##STR15## wherein each variable in Formula (Ii) has the same
meaning as described herein, supra and infra.
[0130] One embodiment of the present invention pertains to
compounds of Formula (I) wherein Ring A is a 6-membered carbocyclic
ring. This embodiment can be represented by Formula (Ik) as
illustrated below: ##STR16## wherein each variable in Formula (Ik)
has the same meaning as described herein, supra and infra.
[0131] One embodiment of the present invention pertains to
compounds of Formula (I) wherein Ring A is a 7-membered carbocyclic
ring. This embodiment can be represented by Formula (Im) as
illustrated below: ##STR17## wherein each variable in Formula (Im)
has the same meaning as described herein, supra and infra.
[0132] One embodiment of the present invention pertains to
compounds of Formula (I) wherein Ring A is a 5, 6 or 7-membered
carbocyclic ring, as described herein supra. In some embodiments,
is a double bond and R.sub.2 is absent. This embodiment can be
represented by Formula (Io) as illustrated below: ##STR18## wherein
each variable in Formula (Io) has the same meaning as described
herein, supra and infra. In some embodiments, Ring A is a
5-membered carbocyclic ring. This embodiment can be represented by
Formula (Iq) as illustrated below: ##STR19## wherein each variable
in Formula (Iq) has the same meaning as described herein, supra and
infra. In some embodiments, Ring A is a 6-membered carbocyclic
ring. In some embodiments, Ring A is a 6-membered carbocyclic ring
provided that Ring A is not aromatic. In some embodiments, Ring A
is a 7-membered carbocyclic ring.
[0133] One embodiment of the present invention pertains to
compounds of Formula (I) wherein Ring A is a 5, 6 or 7-membered
heterocyclic ring. The term "5, 6 or 7-membered heterocyclic ring"
denotes a 5, 6 or 7-membered carbocyclic ring, as described herein
supra, wherein 1, 2 or 3 ring carbons not shared by Rings A and B
are independently replaced with --O--, --S--, --S(O)--, or
--S(O).sub.2--. For clarity, as described herein supra, Ring A can
be saturated (i.e. no ring double bonds), unsaturated (i.e.,
containing ring double bonds) or a combination thereof. In some
embodiments, is a single bond and R.sub.2 is present. In some
embodiments, Ring A is a 5-membered heterocyclic ring. In some
embodiments, one ring carbon of the 5-membered heterocyclic ring is
replaced with a ring oxygen atom; these embodiments can be
represented by the following Formulae (Is) and (It): ##STR20##
wherein each variable in Formulae (Is) and (It) have the same
meaning as described herein, supra and infra. In some embodiments,
compounds of the present invention are of Formula (Is) wherein X is
NH. In some embodiments, compounds of the present invention are of
Formula (Is) wherein X is O (an oxygen atom). In some embodiments,
compounds of the present invention are of Formula (It) wherein X is
NH. In some embodiments, compounds of the present invention are of
Formula (It) wherein X is O (an oxygen atom). In some embodiments,
compounds of the present invention are of Formula (Is) wherein
R.sub.1 is C.sub.1-4 alkyl and R.sub.2 is H. In some embodiments,
compounds of the present invention are of Formula (Is) wherein both
R.sub.1 and R.sub.2 are H. In some embodiments, compounds of the
present invention are of Formula (It) wherein R.sub.1 is C.sub.1-4
alkyl and R.sub.2 is H. In some embodiments, compounds of the
present invention are of Formula (It) wherein both R.sub.1 and
R.sub.2 are H. In some embodiments, one ring carbon of the
5-membered heterocyclic ring is replaced with a ring sulfur atom;
these embodiments can be represented by the following Formulae (Iu)
and (Iv): ##STR21## wherein each variable in Formulae (Iu) and (Iv)
have the same meaning as described herein, supra and infra. In some
embodiments, the ring sulfur in Formulae (Iu) and (Iv) is further
oxidized to a sulfoxide (i.e., --S(O)--). In some embodiments, the
ring sulfur in Formulae (Iu) and (Iv) is further oxidized to a
sulfone (i.e., --S(O).sub.2--). In some embodiments, compounds of
the present invention are of Formula (Iu) wherein X is NH. In some
embodiments, compounds of the present invention are of Formula (Iu)
wherein X is O (an oxygen atom). In some embodiments, compounds of
the present invention are of Formula (Iv) wherein X is NH. In some
embodiments, compounds of the present invention are of Formula (Iv)
wherein X is O (an oxygen atom). In some embodiments, Ring A is a
6-membered heterocyclic ring. In some embodiments, one ring atom of
the 6-membered heterocyclic ring is replaced by a ring oxygen atom;
these embodiments can be represented by the following Formulae
(Ix), (Iy), and (Iz): ##STR22## wherein each variable in Formulae
(Ix), (Iy), and (Iz) have the same meaning as described herein,
supra and infra. In some embodiments, Ring A is a 7-membered
heterocyclic ring.
[0134] One embodiment of the present invention pertains to
compounds of Formula (I) wherein Ring A is a 5, 6 or 7-membered
heterocyclic ring. In some embodiments, is a double bond and
R.sub.2 is absent. In some embodiments, Ring A is a 5-membered
heterocyclic ring. This embodiment can be represented by Formula
(IIa) as illustrated below: ##STR23## wherein each variable in
Formula (l a) has the same meaning as described herein, supra and
infra, and Z is --O--, --S--, --S(O)--, or --S(O).sub.2--.
[0135] In some embodiments, Ring A is a 6-membered heterocyclic
ring. In some embodiments, the 6-membered heterocyclic ring is a
dihydro-pyranyl ring (i.e., one ring carbon is replaced by an
oxygen atom); these embodiments can be represented by the following
Formulae (IIc) and (IId): ##STR24## wherein each variable in
Formulae (IIc) and (IId) have the same meaning as described herein,
supra and infra. In some embodiments, Ring A is a 7-membered
heterocyclic ring.
[0136] One embodiment of the present invention pertains to
compounds of Formula (I), and subgenera disclosed herein, wherein
Ring A is optionally substituted with substituents selected from
the group consisting of halogen, hydroxy, C.sub.1-4 haloalkyl,
C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.2-4 alkenyl, C.sub.2-4
alkynyl, C.sub.1-4 alkylthio, and C.sub.1-4 haloalkoxy. In some
embodiments, Ring A is optionally substituted with substituents
selected from the group consisting of halogen, C.sub.1-4 haloalkyl,
and C.sub.1-4 alkyl. In some embodiments, Ring A is optionally
substituted with F. In some embodiments, Ring A is optionally
substituted with 1 to 4 substituents. In some embodiments, Ring A
is optionally substituted with 1 to 3 substituents. In some
embodiments, Ring A is optionally substituted with 1 to 2
substituents. In some embodiments, Ring A is optionally substituted
with 1 substituent. In some embodiments, Ring A is not
substituted.
Chemistry of the Present Invention
Synthesis of Compounds of Formula (I)
[0137] In one embodiment of the present invention is a synthetic
process for the preparation of novel tetrazoles of Formula (I). The
compounds of the present invention can be readily prepared
according to this novel process utilizing a variety of starting
materials that are commercially available or readily prepared by
synthetic regimes which would be familiar to one skilled in the
art. In the illustrated syntheses outlined below, unless stated
otherwise, the labeled substituents have the same identifications
as set out in the definitions of the compound described above for
Formula (I).
[0138] One method that can be used to prepare compounds of the
invention wherein X is NH (i.e., Ring B is a pyrazole) utilizes
intermediates derived from the cyclic ketone of Formula (A) as
illustrated in Reaction Scheme I below: ##STR25## Compounds of
Formula (Ia) can be prepared by reacting a cyclic ketone of Formula
(A) with dialkyloxalate of formula (C(O)OR.sub.10).sub.2, wherein
R.sub.10 is a C.sub.1-8 alkyl, in the presence of a base and a
polar solvent such as, but not limited to, C.sub.1-8 alkanol,
methanol, ethanol, butanol, pentanol, hexanol, 2-methoxyethanol,
isopropanol, THF, DMF and the like to give ketoester of Formula
(B). Suitable bases include alkali metal alkoxides, for example,
sodium methoxide, sodium ethoxide, potassium ethoxide, potassium
t-butoxide, and the like; alkali metal amides (i.e., alkali
metal-NR.sub.11 wherein R.sub.11 is C.sub.1-8 alkyl or
silyl-C.sub.1-8-alkyl), for example, lithium diisopropylamide,
lithium hexamethyldisilazane, sodium hexamethyldisilazane,
potassium hexamethyldisilazane and like bases. Ketoester (B) is
reacted with hydrazine, either protected or unprotected hydrazine
can be used, under suitable conditions to give pyrazole ester of
Formula (C). Optionally, the pyrazole can be protected, for
example, with a benzyl group and the like. The ester is converted
to amide of Formula (D) using methods known to one of skill in the
art, for example, treating with ammonia in a polar solvent at
temperature from room temperature to the boiling point of the
solvent. Amide (D) is reacted with a dehydrating reagent, such as
phosphorous oxychloride, phosphorous pentoxide, thionyl chloride,
and the like, either neat or in the presence of a nonprotic
solvent, such as acetonitrile, DMF, and the like, to give nitrile
(E). Nitrile (E) is reacted with an azide (i.e., N.sub.3) or azide
equivalent, such as, sodium azide, potassium azide, trimethylsilyl
azide (i.e., (CH.sub.3)SiN.sub.3), and the like to give tetrazole
of Formula (Ia). In some instances it can be beneficial to include
the presence of a Lewis acid, for example, AlCl.sub.3, ZnBr.sub.2,
and the like, in a suitable solvent, such as, DMF and the like.
[0139] One method that can be used to prepare compounds of Formula
(I) wherein X is a ring oxygen (i.e., Ring B is a isoxazole)
utilizes intermediates derived from the alkynyl alcohol of Formula
(J) as illustrated in Reaction Scheme II below: ##STR26## Compounds
of Formula (Ic) can be prepared by protecting an alkynyl alcohol of
Formula (J) with a suitable protecting group, for example, THP,
TBDMS, and the like to give alkynyl (K). Alkynyl (K) is converted
to an alkynyl ester of Formula (L, wherein R.sub.15 is C.sub.1-8
alkyl) by treatment with a strong base followed by reacting with a
C.sub.1-8 alkyl chloroformate. A suitable strong base is an alkyl
lithium, for example but not limited to, n-butyl lithium, t-butyl
lithium and the like. Intermediate (L) is subsequently deprotected
using methods known to those of skill in the art, for example, the
THP group can typically be removed via treatment with an acid (e.g.
PTSA) and TBDMS group can typically be removed via treatment with a
tetra-alkylammonium fluoride. The resulting alcohol is oxidized to
aldehyde (M) using any variety of methods, for example, Dess-Martin
periodinane (i.e.,
1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one), Swern
Oxidation, Corey oxidation with NCS or any other suitable method as
described by Hudlicky, M. in Oxidations in Organic Chemistry, ACS
Monograph 186 (1990). Aldehyde (M) is treated with hydroxylamine in
the presence of a base, followed by NCS and Base to give isoxazole
alkylester (N). Isoxazole (N) can be converted to compounds of
Formula (Ic) in a substantially similar manner as described above
in Reaction Scheme I, (i.e.,
--CO.sub.2--C.sub.1-8-alkyl.fwdarw.--CONH.sub.2.fwdarw.--C.ident.N-
.fwdarw.-tetrazole).
[0140] One method that can be used to prepare certain compounds of
Formula (I) utilizes intermediate (AJ) as illustrated in Reaction
Schemes III and IV below: ##STR27##
[0141] Compounds of the structure (AJ) (wherein R is C.sub.1-4
alkyl, C.sub.2-4 alkenyl, and C.sub.2-4 alkynyl) can be prepared by
treating the unsaturated pyrazole (AA) with benzyl bromide in a
suitable solvent like THF in the presence of NaOH as the base to
give the N-benzyl pyrazole (AB). The pyrazole (AB) can be
saponified using methods known to one of skill in the art, for
example, treating with aqueous sodium hydroxide in a solvent
mixture such as THF/MeOH. The acid (AC) is coupled with N-hydroxy
succinimide using a coupling reagent such as EDC. The ester (AD) is
converted to the amide (AE) by treatment with concentrated
NH.sub.4OH solution in a solvent such as 1,4-dioxane. The amide
(AE) can be reacted with a dehydrating reagent such as cyanuric
chloride, trifluro acetic anhydride, thionyl chloride and like, in
the presence of a non protic solvent such as DMF to give the
nitrile (AF). The nitrile (AF) is treated with an excess of
borane-THF solution in a solvent like THF at low temperature,
followed by oxidation with hydrogen peroxide in the presence of
sodium hydroxide to give a 1:1 mixture of alcohols shown as (AG')
and (AG'').
[0142] Utilizing either alcohol (AG') or alcohol (AG'') a variety
of ethers can be prepared. A representative synthesis is shown in
Reaction Scheme IV using alcohol (AG'). It is understood that a
similar synthetic scheme can be utilized starting with alcohol
(AG''). ##STR28##
[0143] Compounds of the structure (AH) can be prepared by treating
the alcohol intermediate (AG') with an excess of alkyl halide in
the presence of a base such as sodium hydride in an aprotic solvent
such as DMF. The nitrile (AH) is reacted with an azide such as
sodium azide, in the presence of a Lewis acid such as zinc bromide,
to give the tetrazole of the structure (AI). Final compounds can be
prepared by removal of the benzyl protecting group under oxidative
conditions in a solvent like DMSO using a base such as potassium
t-butoxide and oxygen gas.
[0144] One method that can be used to prepare certain compounds of
Formula (I) utilizes intermediate (AS) as illustrated in Reaction
Scheme V below: ##STR29## ##STR30##
[0145] Compounds of the structure (AV) can be prepared from
3-ethoxy-cyclopentenone by treatment with dialkyloxalate such as
di-tert-butyl oxalate or diethyloxalate in the presence of a
non-nucleophilic base such as LDA or LHMDS in a solvent such as THF
to give the keto-ester (AM). The keto ester (AM) is reacted with
benzyl hydrazine under reflux in a polar solvent, such as ethanol
or methanol containing glacial acetic acid to give the pyrazole
(AN). Alternatively, the keto-ester (AM) can be reacted with
hydrazine, followed by alkylation of the pyrazole with benzyl
bromide using cesium carbonate as the base in a non-protic solvent
such as DMF. The pyrazole ester (AN) can be converted to the
nitrile (AR) using a similar sequence of steps described for (AG').
The ketone (AR) is converted to the vinyl triflate (AS) using
Commins' reagent in the presence of LDA in a solvent such as
THF.
[0146] Utilizing compound (AS), a variety of substituents (wherein
R' is C.sub.1-4 alkyl, C.sub.2-4 alkenyl, and C.sub.2-4 alkynyl)
can be introduced at C-5 as shown in Reaction Scheme VI.
##STR31##
[0147] The triflate (AS) can be reacted with a suitable stannane
reagent in the presence of a base such as lithium chloride and a
catalyst such as tetrakis triphenyl phosphine palladium (0) in a
suitable solvent such as THF or toluene. Alternatively, the
triflate (AS) can be reacted with a suitable alkenyl boronic acid
in the presence of a base such as potassium phosphate and a
catalyst such as tetrakis triphenyl phosphine palladium (0) in a
suitable solvent such as 1,4-dioxane. The nitrile (AT) is reacted
with an azide such as sodium azide, in the presence of a Lewis acid
such as zinc bromide, to give the tetrazole of the structure (AU).
Final compounds are prepared by the removal of the benzyl
protecting group that can be performed under reductive conditions
using palladium black in a polar solvent such as methanol or
ethanol and acid such as formic acid or concentrated hydrochloric
acid.
[0148] Alternatively, alcohol (AG') may be fluorinated using
methods known to those skilled in the art, such as DAST
[(diethylamino)sulfur trifluoride], to provide a fluoro compound
which can be elaborated to its tetrazole derivative and deprotected
using methods described herein.
[0149] One method that can be used to prepare certain compounds of
Formula (I) is illustrated in Reaction Scheme VII below: ##STR32##
##STR33##
[0150] A compound of the structure (BF) can be prepared from the
keto ester (AM) by reacting with hydrazine hydrate in a polar
solvent such as ethanol containing glacial acetic acid to give the
pyrazole (AW). The pyrazole (AW) can be reacted with a sulfonyl
chloride such as p-toluene sulfonyl chloride in a solvent such as
CH.sub.2Cl.sub.2 in the presence of a base such as pyridine to give
the N-sulfonylated derivative (AX). The pyrazole ester (AX) can be
deprotected under acidic conditions using an acid such as TFA in
CH.sub.2Cl.sub.2 to form (AY). The pyrazole acid (AY) can be
converted to the nitrile (BB) using a similar sequence of steps
described for (AG'). The ketone (BB) can be converted to the vinyl
triflate (BC) using Commins' reagent in the presence of a base such
as LDA in a solvent such as THF.
[0151] The triflate (BC) can be coupled with tetramethyltin in the
presence of a base such as lithium chloride and a catalyst such as
tetrakis triphenyl phosphine palladium (0) in a suitable solvent
such as THF or toluene. The p-toluene sulfonyl group can be removed
by reacting with tetra butyl ammonium fluoride solution in a
solvent such as THF to give the pyrazole (BE). The final compound
is prepared by reacting the nitrile (BE) with an azide such as
sodium azide, in the presence of a Lewis acid such as zinc bromide,
to give the tetrazole (BF).
[0152] The various organic group transformations and protecting
groups utilized herein can be performed by a number of procedures
other than those described above. References for other synthetic
procedures that can be utililized for the preparation of
intermediates or compounds disclosed herein can be found in, for
example, Smith, M. B.; and March, J., Advanced Organic Chemistry,
5.sup.th Edition, Wiley-Interscience (2001); Larock, R. C.,
Comprehensive Organic Transformations, A Guide to Functional Group
Preparations, 2.sup.nd Edition, VCH Publishers, Inc. (1999), or
Wuts, P. G. M.; Greene, T. W.; Protective Groups in Organic
Synthesis, 3.sup.rd Edition, John Wiley and Sons, (1999), all three
incorporated herein by reference in their entirety.
[0153] Compounds of Formula (I) may have one or more chiral
centers, and therefore exist as enantiomers or diastereomers. The
invention is understood to extend to all such enantiomers,
diastereomers and mixtures thereof, including racemates. Formula
(I) and the formulae described herein, supra, are intended to
represent all individual isomers and mixtures thereof, unless
stated or shown otherwise.
[0154] Racemic mixtures can be resolved into the optical pure
enantiomers by known methods, for example, by separation of
diastereomeric salts thereof with an optically active acid, and
liberating the optically active amine compound by treatment with a
base. Another method for resolving racemates into the optical pure
enatiomers is based upon chromatography on an optically active
matrix or chiral support. Certain racemic compounds of the present
invention can thus be resolved into their optical antipodes, e.g.,
by fractional crystallization of d- or l- (tartrates, mandelates,
or camphorsulphonate) salts for example. The compounds of the
present invention may also be resolved by the formation of
diastereomeric amides or ester by reaction of the compounds of the
present invention with an optically active activated carboxylic
acid such as that derived from (+) or (-) phenylalanine, (+) or (-)
phenylglycine, (+) or (-) camphanic acid or by the formation of
diastereomeric carbamates by reaction of the compounds of the
present invention with an optically active chloroformate or the
like subsequently hydrolyzed.
[0155] Additional methods for the resolution of optical isomers
known to those skilled in the art can be used and will be apparent
to the average worker skilled in the art. Such methods include
those discussed by J. Jaques, A. Collet, and S. Wilen in
"Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New
York (1981).
[0156] It is understood that the chemistry described herein is
representative and is not intended to be limiting in any
manner.
[0157] Representative examples of compound of Formula (I) are shown
below in TABLE A. TABLE-US-00002 TABLE A Cmpd # Structure Chemical
Name 1 ##STR34## 3-(1H-Tetrazol-5-yl)-2,4,5,6-
tetrahydro-cyclopentapyrazole 2 ##STR35##
3-(1H-Tetrazol-5-yl)-2,6-dihydro- 4H-thieno[3,4-c]pyrazole 3
##STR36## 6-Methyl-3-(1H-tetrazol-5-yl)-2,6-
dihydro-4H-furo[3,4-c]pyrazole 4 ##STR37##
3-(1H-Tetrazol-5-yl)-2,4-dihydro- cyclopentapyrazole 5 ##STR38##
3-(1H-Tetrazol-5-yl)-2,6-dihydro- cyclopentapyrazole 6 ##STR39##
3-(1H-Tetrazol-5-yl)-2,6-dihydro- 4H-furo[3,4-c]pyrazole 7
##STR40## 5-Ethyl-3-(1H-tetrazol-5-yl)-2,4,5,6-
tetrahydro-cyclopentapyrazole 8 ##STR41##
5-Butyl-3-(1H-tetrazol-5-yl)-2,4,5,6- tetrahydro-cyclopentapyrazole
9 ##STR42## 5-Methyl-3-(1H-tetrazol-5-yl)-2,6-
dihydro-cyclopentapyrazole 10 ##STR43##
5-Methyl-3-(1H-tetrazol-5-yl)-2,4- dihydro-cyclopentapyrazole 11
##STR44## 5-Propyl-3-(1H-tetrazol-5-yl)- 2,4,5,6-tetrahydro-
cyclopentapyrazole 12 ##STR45## 5-Propoxy-3-(1H-tetrazol-5-yl)-
2,4,5,6-tetrahydro- cyclopentapyrazole 13 ##STR46##
5-Cyclopentyl-3-(1H-tetrazol-5-yl)- 2,4,5,6-tetrahydro-
cyclopentapyrazole 14 ##STR47## 5-Fluoro-3-(1H-tetrazol-5-yl)-
2,4,5,6-tetrahydro- cyclopentapyrazole 15 ##STR48##
5-Isobutoxy-3-(1H-tetrazol-5-yl)- 2,4,5,6-tetrahydro-
cyclopentapyrazole 16 ##STR49## 5-Butoxy-3-(1H-tetrazol-5-yl)-
2,4,5,6-tetrahydro- cyclopentapyrazole 17 ##STR50##
3-(1H-Tetrazol-5-yl)-2,4,5,6- tetrahydro-cyclopentapyrazol-6-ol 18
##STR51## 5-Methoxy-3-(1H-tetrazol-5-yl)- 2,4,5,6-tetrahydro-
cyclopentapyrazole 19 ##STR52## 5,5-Difluoro-3-(1H-tetrazol-5-yl)-
2,4,5,6-tetrahydro- cyclopentapyrazole 20 ##STR53##
5-Ethoxy-3-(1H-tetrazol-5-yl)- 2,4,5,6-tetrahydro-
cyclopentapyrazole
Methods and Uses
[0158] Compounds of the present invention are useful in the
inhibition of the production of free fatty acids. Further,
compounds of the present invention are useful in the inhibition of
the production of free fatty acids while resulting in substantially
lower or in some instances no measurable flushing side effects,
which effects are commonly associated with the administration of
niacin. Compounds of the present invention typically do not cause
vasodilation at doses as high as about 300 mpk as measured using
methods know in the art, such as the method shown in Example 7.
[0159] In some embodiments, compounds of the present invention
cause essentially no measurable flushing in an individual compared
to an essentially equally effective dose of niacin. In other
embodiments compounds of the present invention cause less than
about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%,
20%, 15%, 10%, 5%, or 1% measurable flushing in an individual
compared to an essentially equally effective dose of niacin.
[0160] Compounds of the present invention can modulate the activity
of the RUP25 receptor. The term "modulate" is meant to refer to the
ability to increase or decrease activity of the receptor. In some
embodiments, compounds of the invention can be used in methods of
modulating a RUP25 receptor by contacting the receptor with any one
or more of the compound as described herein. In still other
embodiments, compounds of the invention can be used in methods of
method of modulating a RUP25 receptor for the treatment of a
metabolic-related disorder in an individual in need of such
modulation comprising contacting the receptor with a
therapeutically-effective amount of a compound of Formula (I). In
some embodiments, compounds of the invention increase activity of
the RUP25 receptor. In further embodiments, compounds of the
invention are agonists of the RUP25 receptor. The term "agonist",
as used herein, refers to agents that can stimulate activity of the
receptor (i.e., activate), like the RUP25 receptor. In some
embodiments, compounds of the invention are partial agonists of the
RUP25 receptor.
[0161] Another aspect of the present invention pertains to methods
of treatment of a metabolic-related disorder comprising
administering to an individual in need of such treatment a
therapeutically-effective amount of a compound of Formula (I).
[0162] Another aspect of the present invention pertains to methods
of raising HDL in an individual comprising administering to said
individual a therapeutically-effective amount of a compound of
Formula (I).
[0163] Another aspect of the present invention pertains to
compounds of Formula (I), as described herein, for use in a method
of treatment of the human or animal body by therapy.
[0164] Another aspect of the present invention pertains to
compounds of Formula (I), as described herein, for use in a method
of treatment of a metabolic-related disorder of the human or animal
body by therapy.
[0165] Another aspect of the present invention pertains to
compounds of Formula (I), as described herein, for use in a method
of treatment of a metabolic-related disorder of the human or animal
body by therapy wherein said metabolic-related disorder is selected
from the group consisting of dyslipidemia, atherosclerosis,
coronary heart disease, insulin resistance, obesity, impaired
glucose tolerance, atheromatous disease, hypertension, stroke,
Syndrome X, heart disease and type 2 diabetes.
[0166] Another aspect of the present invention pertains to
compounds of Formula (I), as described herein, for use in a method
of treatment of a metabolic-related disorder of the human or animal
body by therapy wherein said metabolic-related disorder is selected
from the group consisting of dyslipidemia, atherosclerosis,
coronary heart disease, insulin resistance and type 2 diabetes.
[0167] Another aspect of the present invention pertains to
compounds of Formula (I), as described herein, for use in a method
of treatment of atherosclerosis of the human or animal body by
therapy.
[0168] Another aspect of the present invention pertains to
compounds of Formula (I), as described herein, for use in a method
of raising HDL of the human or animal body by therapy.
[0169] Another aspect of the present invention pertains to uses of
the compounds of Formula (I), as described herein, for the
manufacture of a medicament for use in the treatment of a
metabolic-related disorder.
[0170] Another aspect of the present invention pertains to uses of
the compounds of Formula (I), as described herein, for the
manufacture of a medicament for use in the treatment of a
metabolic-related disorder selected from the group consisting of
dyslipidemia, atherosclerosis, coronary heart disease, insulin
resistance, obesity, impaired glucose tolerance, atheromatous
disease, hypertension, stroke, Syndrome X, heart disease and type 2
diabetes.
[0171] Another aspect of the present invention pertains to uses of
the compounds of Formula (I), as described herein, for the
manufacture of a medicament for use in the treatment of
atherosclerosis.
[0172] Another aspect of the present invention pertains to uses of
the compounds of Formula (I), as described herein, for the
manufacture of a medicament for use in raising HDL in an
individual.
[0173] Some embodiments of the present invention relate to methods
of treatment of metabolic-related disorders. In some embodiments
the metabolic-related disorder is of the group consisting of
dyslipidemia, atherosclerosis, coronary heart disease, insulin
resistance, obesity, impaired glucose tolerance, atheromatous
disease, hypertension, stroke, Syndrome X, heart disease and type 2
diabetes. In some embodiments the metabolic-related disorder is
dyslipidemia, atherosclerosis, coronary heart disease, insulin
resistance and type 2 diabetes. In some embodiments the
metabolic-related disorder is dyslipidemia. In some embodiments the
metabolic-related disorder is atherosclerosis. In some embodiments
the metabolic-related disorder is coronary heart disease. In some
embodiments the metabolic-related disorder is insulin resistance.
In some embodiments the metabolic-related disorder is type 2
diabetes.
[0174] In some embodiments related to methods of the present
invention, the individual is a mammal. In further embodiments, the
mammal is a human.
[0175] Another aspect of the present invention pertains to methods
of producing a pharmaceutical composition comprising admixing or
combining a compound of Formula (I), as described herein, and a
pharmaceutically acceptable carrier.
Compositions of the Present Invention
[0176] Some embodiments of the present invention include
pharmaceutical compositions comprising a compound according to
Formula (I) in combination with a pharmaceutically acceptable
carrier.
[0177] Some embodiments of the present invention include a method
of producing a pharmaceutical composition comprising admixing at
least one compound according to any of the compound embodiments
disclosed herein and a pharmaceutically acceptable carrier.
[0178] Formulations can be prepared by any suitable method,
typically by uniformly mixing the active compound(s) with liquids
or finely divided solid carriers, or both, in the required
proportions, and then, if necessary, forming the resulting mixture
into a desired shape.
[0179] Conventional excipients, such as binding agents, fillers,
acceptable wetting agents, tabletting lubricants, and disintegrants
can be used in tablets and capsules for oral administration. Liquid
preparations for oral administration can be in the form of
solutions, emulsions, aqueous or oily suspensions, and syrups.
Alternatively, the oral preparations can be in the form of dry
powder that can be reconstituted with water or another suitable
liquid vehicle before use. Additional additives such as suspending
or emulsifying agents, non-aqueous vehicles (including edible
oils), preservatives, and flavorings and colorants can be added to
the liquid preparations. Parenteral dosage forms can be prepared by
dissolving the compound of the invention in a suitable liquid
vehicle and filter sterilizing the solution before filling and
sealing an appropriate vial or ampoule. These are just a few
examples of the many appropriate methods well known in the art for
preparing dosage forms.
[0180] A compound of the present invention can be formulated into
pharmaceutical compositions using techniques well known to those in
the art. Suitable pharmaceutically-acceptable carriers, outside
those mentioned herein, are known in the art; for example, see
Remington, The Science and Practice of Pharmacy, 20.sup.th Edition,
2000, Lippincott Williams & Wilkins, (Editors: Gennaro, A. R.,
et al.).
[0181] While it is possible that a compound for use in the
treatment of the present invention may, in an alternative use, be
administered as a raw or pure chemical, it is preferable however to
present the compound or "active ingredient" as a pharmaceutical
formulation or composition further comprising a pharmaceutically
acceptable carrier. Therefore, one aspect of the present invention
encompasses pharmaceutical compositions comprising a
pharmaceutically acceptable carrier in combination with at least
one compound according to Formula (I).
[0182] The invention provides pharmaceutical formulations
comprising a compound of the invention or a pharmaceutically
acceptable salt, hydrate or solvate thereof together with one or
more pharmaceutically acceptable carriers therefor. The carrier(s)
must be "acceptable" in the sense of being compatible with the
other ingredients of the formulation and not overly deleterious to
the recipient thereof.
[0183] Pharmaceutical formulations include those suitable for oral,
rectal, nasal, topical (including buccal and sub-lingual), vaginal
or parenteral (including intramuscular, sub-cutaneous and
intravenous) administration or in a form suitable for
administration by inhalation, insufflation or by a transdermal
patch. Transdermal patches dispense a drug at a controlled rate by
presenting the drug for absorption in an efficient manner with a
minimum of degradation of the drug. Typically, transdermal patches
comprise an impermeable backing layer, a single pressure sensitive
adhesive and a removable protective layer with a release liner. One
of ordinary skill in the art will understand and appreciate the
techniques appropriate for manufacturing a desired efficacious
transdermal patch based upon the needs of the artisan.
[0184] The compounds of the invention, together with a conventional
adjuvant, carrier, or diluent, may thus be placed into the form of
pharmaceutical formulations and unit dosages thereof, and in such
form can be employed as solids, such as tablets or filled capsules,
or liquids such as solutions, suspensions, emulsions, elixirs, gels
or capsules filled with the same, all for oral use, in the form of
suppositories for rectal administration; or in the form of sterile
injectable solutions for parenteral (including subcutaneous) use.
Such pharmaceutical compositions and unit dosage forms thereof may
comprise conventional ingredients in conventional proportions, with
or without additional active compounds or principles, and such unit
dosage forms may contain any suitable effective amount of the
active ingredient commensurate with the intended daily dosage range
to be employed.
[0185] For oral administration, the pharmaceutical composition can
be in the form of, for example, a tablet, capsule, suspension or
liquid. The pharmaceutical composition is preferably made in the
form of a dosage unit containing a particular amount of the active
ingredient. Examples of such dosage units are capsules, tablets,
powders, granules or a suspension, with conventional additives such
as lactose, mannitol, corn starch or potato starch; with binders
such as crystalline cellulose, cellulose derivatives, acacia, corn
starch or gelatins; with disintegrators such as corn starch, potato
starch or sodium carboxymethyl-cellulose; and with lubricants such
as talc or magnesium stearate. The active ingredient may also be
administered by injection as a composition wherein, for example,
saline, dextrose or water can be used as a suitable
pharmaceutically acceptable carrier.
[0186] Compounds of the present invention or a solvate or
physiologically functional derivative thereof can be used as active
ingredients in pharmaceutical compositions, specifically as RUP25
receptor agonists. By the term "active ingredient" is defined in
the context of a "pharmaceutical composition" and shall mean a
component of a pharmaceutical composition that provides the primary
pharmacological effect, as opposed to an "inactive ingredient"
which would generally be recognized as providing no pharmaceutical
benefit.
[0187] The dose when using the compounds of the present invention
can vary within wide limits, and as is customary and is known to
the physician, it is to be tailored to the individual conditions in
each individual case. It depends, for example, on the nature and
severity of the illness to be treated, on the condition of the
patient, on the compound employed or on whether an acute or chronic
disease state is treated is conducted or on whether further active
compounds are administered in addition to the compounds of the
present invention. Representative doses of the present invention
include, but not limited to, about 0.001 mg to about 5000 mg, about
0.001 to about 2500 mg, about 0.001 to about 1000 mg, 0.001 to
about 500 mg, 0.001 mg to about 250 mg, about 0.001 mg to 100 mg,
about 0.001 mg to about 50 mg, and about 0.001 mg to about 25 mg.
Multiple doses can be administered during the day, especially when
relatively large amounts are deemed to be needed, for example 2, 3
or 4, doses. Depending on the individual and as deemed appropriate
from the patient's physician or care-giver it may be necessary to
deviate upward or downward from the doses described herein.
[0188] The amount of active ingredient, or an active salt or
derivative thereof, required for use in treatment will vary not
only with the particular salt selected but also with the route of
administration, the nature of the condition being treated and the
age and condition of the patient and will ultimately be at the
discretion of the attendant physician or clinician. In general, one
skilled in the art understands how to extrapolate in vivo data
obtained in a model system to another, for example, an animal model
to a human. Typically, animal models include, but are not limited
to, the rodents diabetes models as described in Example 1, infra;
the mouse atherosclerosis model as described in Example 2, infra;
or the in vivo animal athosclerosis model as described in Example
5, infra. In some circumstances, these extrapolations may merely be
based on the weight of the animal model in comparison to another,
such as a mammal, preferably a human, however, more often, these
extrapolations are not simply based on weight differences, but
rather incorporate a variety of factors. Representative factors
include the type, age, weight, sex, diet and medical condition of
the patient, the severity of the disease, the route of
administration, pharmacological considerations such as the
activity, efficacy, pharmacokinetic and toxicology profiles of the
particular compound employed, whether a drug delivery system is
utilized, on whether an acute or chronic disease state is being
treated is conducted or on whether further active compounds are
administered in addition to the compounds of the Formula (I) and as
part of a drug combination. The dosage regimen for treating a
disease condition with the compounds and/or compositions of this
invention is selected in accordance with a variety factors, such
as, those cited above. Thus, the actual dosage regimen employed may
vary widely and therefore may deviate from a preferred dosage
regimen and one skilled in the art will recognize that dosage and
dosage regimen outside these typical ranges can be tested and,
where appropriate, can be used in the methods of this
invention.
[0189] The desired dose may conveniently be presented in a single
dose or as divided doses administered at appropriate intervals, for
example, as two, three, four or more sub-doses per day. The
sub-dose itself can be further divided, e.g., into a number of
discrete loosely spaced administrations. The daily dose can be
divided, especially when relatively large amounts are administered
as deemed appropriate, into several, for example 2, 3 or 4, part
administrations. If appropriate, depending on individual behavior,
it can be necessary to deviate upward or downward from the daily
dose indicated.
[0190] The compounds of the present invention can be administrated
in a wide variety of oral and parenteral dosage forms. It will be
obvious to those skilled in the art that the following dosage forms
may comprise, as the active component, either a compound of the
invention or a pharmaceutically acceptable salt of a compound of
the invention.
[0191] For preparing pharmaceutical compositions from the compounds
of the present invention, pharmaceutically acceptable carriers can
be either solid or liquid. Solid form preparations include powders,
tablets, pills, capsules, cachets, suppositories, and dispersible
granules. A solid carrier can be one or more substances which may
also act as diluents, flavouring agents, solubilizers, lubricants,
suspending agents, binders, preservatives, tablet disintegrating
agents, or an encapsulating material.
[0192] In powders, the carrier is a finely divided solid which is
in a mixture with the finely divided active component.
[0193] In tablets, the active component is mixed with the carrier
having the necessary binding capacity in suitable proportions and
compacted to the desire shape and size.
[0194] The powders and tablets may contain varying percentage
amounts of the active compound. A representative amount in a powder
or tablet may contain from 0.5 to about 90 percent of the active
compound; however, an artisan would know when amounts outside of
this range are necessary. Suitable carriers for powders and tablets
are magnesium carbonate, magnesium stearate, talc, sugar, lactose,
pectin, dextrin, starch, gelatin, tragacanth, methylcellulose,
sodium carboxymethylcellulose, a low melting wax, cocoa butter, and
the like. The term "preparation" is intended to include the
formulation of the active compound with encapsulating material as
carrier providing a capsule in which the active component, with or
without carriers, is surrounded by a carrier, which is thus in
association with it. Similarly, cachets and lozenges are included.
Tablets, powders, capsules, pills, cachets, and lozenges can be
used as solid forms suitable for oral administration.
[0195] For preparing suppositories, a low melting wax, such as an
admixture of fatty acid glycerides or cocoa butter, is first melted
and the active component is dispersed homogeneously therein, as by
stirring. The molten homogenous mixture is then poured into
convenient sized molds, allowed to cool, and thereby to
solidify.
[0196] Formulations suitable for vaginal administration can be
presented as pessaries, tampons, creams, gels, pastes, foams or
sprays containing in addition to the active ingredient such
carriers as are known in the art to be appropriate.
[0197] Liquid form preparations include solutions, suspensions, and
emulsions, for example, water or water-propylene glycol solutions.
For example, parenteral injection liquid preparations can be
formulated as solutions in aqueous polyethylene glycol solution.
Injectable preparations, for example, sterile injectable aqueous or
oleaginous suspensions can be formulated according to the known art
using suitable dispersing or wetting agents and suspending agents.
The sterile injectable preparation may also be a sterile injectable
solution or suspension in a nontoxic parenterally acceptable
diluent or solvent, for example, as a solution in 1,3-butanediol.
Among the acceptable vehicles and solvents that can be employed are
water, Ringer's solution, and isotonic sodium chloride solution. In
addition, sterile, fixed oils are conventionally employed as a
solvent or suspending medium. For this purpose any bland fixed oil
can be employed including synthetic mono- or diglycerides. In
addition, fatty acids such as oleic acid find use in the
preparation of injectables.
[0198] The compounds according to the present invention may thus be
formulated for parenteral administration (e.g. by injection, for
example bolus injection or continuous infusion) and can be
presented in unit dose form in ampoules, pre-filled syringes, small
volume infusion or in multi-dose containers with an added
preservative. The compositions may take such forms as suspensions,
solutions, or emulsions in oily or aqueous vehicles, and may
contain formulatory agents such as suspending, stabilizing and/or
dispersing agents. Alternatively, the active ingredient can be in
powder form, obtained by aseptic isolation of sterile solid or by
lyophilization from solution, for constitution with a suitable
vehicle, e.g. sterile, pyrogen-free water, before use.
[0199] Aqueous solutions suitable for oral use can be prepared by
dissolving the active component in water and adding suitable
colorants, flavours, stabilizing and thickening agents, as
desired.
[0200] Aqueous suspensions suitable for oral use can be made by
dispersing the finely divided active component in water with
viscous material, such as natural or synthetic gums, resins,
methylcellulose, sodium carboxymethylcellulose, or other well known
suspending agents.
[0201] Also included are solid form preparations which are intended
to be converted, shortly before use, to liquid form preparations
for oral administration. Such liquid forms include solutions,
suspensions, and emulsions. These preparations may contain, in
addition to the active component, colorants, flavors, stabilizers,
buffers, artificial and natural sweeteners, dispersants,
thickeners, solubilizing agents, and the like.
[0202] For topical administration to the epidermis the compounds
according to the invention can be formulated as ointments, creams
or lotions, or as a transdermal patch.
[0203] Ointments and creams may, for example, be formulated with an
aqueous or oily base with the addition of suitable thickening
and/or gelling agents. Lotions can be formulated with an aqueous or
oily base and will in general also contain one or more emulsifying
agents, stabilizing agents, dispersing agents, suspending agents,
thickening agents, or coloring agents.
[0204] Formulations suitable for topical administration in the
mouth include lozenges comprising active agent in a flavored base,
usually sucrose and acacia or tragacanth; pastilles comprising the
active ingredient in an inert base such as gelatin and glycerin or
sucrose and acacia; and mouthwashes comprising the active
ingredient in a suitable liquid carrier.
[0205] Solutions or suspensions are applied directly to the nasal
cavity by conventional means, for example with a dropper, pipette
or spray. The formulations can be provided in single or multi-dose
form. In the latter case of a dropper or pipette, this can be
achieved by the patient administering an appropriate, predetermined
volume of the solution or suspension. In the case of a spray, this
can be achieved for example by means of a metering atomizing spray
pump.
[0206] Administration to the respiratory tract may also be achieved
by means of an aerosol formulation in which the active ingredient
is provided in a pressurized pack with a suitable propellant. If
the compounds of the Formula (I) or pharmaceutical compositions
comprising them are administered as aerosols, for example as nasal
aerosols or by inhalation, this can be carried out, for example,
using a spray, a nebulizer, a pump nebulizer, an inhalation
apparatus, a metered inhaler or a dry powder inhaler.
Pharmaceutical forms for administration of the compounds of the
Formula (I) as an aerosol can be prepared by processes well-known
to the person skilled in the art. For their preparation, for
example, solutions or dispersions of the compounds of the Formula
(I) in water, water/alcohol mixtures or suitable saline solutions
can be employed using customary additives, for example benzyl
alcohol or other suitable preservatives, absorption enhancers for
increasing the bioavailability, solubilizers, dispersants and
others, and, if appropriate, customary propellants, for example
include carbon dioxide, CFC's, such as, dichlorodifluoromethane,
trichlorofluoromethane, or dichlorotetrafluoroethane; and the like.
The aerosol may conveniently also contain a surfactant such as
lecithin. The dose of drug can be controlled by provision of a
metered valve.
[0207] In formulations intended for administration to the
respiratory tract, including intranasal formulations, the compound
will generally have a small particle size for example of the order
of 10 microns or less. Such a particle size can be obtained by
means known in the art, for example by micronization. When desired,
formulations adapted to give sustained release of the active
ingredient can be employed.
[0208] Alternatively the active ingredients can be provided in the
form of a dry powder, for example, a powder mix of the compound in
a suitable powder base such as lactose, starch, starch derivatives
such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone
(PVP). Conveniently the powder carrier will form a gel in the nasal
cavity. The powder composition can be presented in unit dose form
for example in capsules or cartridges of, e.g., gelatin, or blister
packs from which the powder can be administered by means of an
inhaler.
[0209] The pharmaceutical preparations are preferably in unit
dosage forms. In such form, the preparation is subdivided into unit
doses containing appropriate quantities of the active component.
The unit dosage form can be a packaged preparation, the package
containing discrete quantities of preparation, such as packeted
tablets, capsules, and powders in vials or ampoules. Also, the unit
dosage form can be a capsule, tablet, cachet, or lozenge itself, or
it can be the appropriate number of any of these in packaged
form.
[0210] Tablets or capsules for oral administration and liquids for
intravenous administration are preferred compositions.
[0211] Compounds of the present invention can be converted to
"pro-drugs." The term "pro-drugs" refers to compounds that have
been modified with specific chemical groups known in the art and
when administered into an individual these groups undergo
biotransformation to give the parent compound. Pro-drugs can thus
be viewed as compounds of the invention containing one or more
specialized non-toxic protective groups used in a transient manner
to alter or to eliminate a property of the compound. In general,
the "pro-drug" approach is utilized to facilitate oral absorption.
A thorough discussion is provided in T. Higuchi and V. Stella,
"Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S.
Symposium Series, and in Bioreversible Carriers in Drug Design, ed.
Edward B. Roche, American Pharmaceutical Association and Pergamon
Press, 1987, both of which are hereby incorporated by reference in
their entirety.
Combination Therapy:
[0212] While the compounds of the present invention can be
administered as the sole active pharmaceutical agent (i.e.,
mono-therapy), they can also be used in combination with other
pharmaceutical agents (i.e., combination-therapy), such as, for the
treatment of the diseases/conditions/disorders described herein.
Therefore, another aspect of the present invention includes methods
of treatment of metabolic related diseases comprising administering
to an individual in need of such treatment a
therapeutically-effective amount of a compound of the present
invention in combination with one or more additional pharmaceutical
agent as described herein.
[0213] Suitable pharmaceutical agents that can be used in
combination with the compounds of the present invention include
anti-obesity agents such as apolipoprotein-B secretion/microsomal
triglyceride transfer protein (apo-B/MTP) inhibitors, MCR-4
agonists, cholescystokinin-A (CCK-A) agonists, serotonin and
norepinephrine reuptake inhibitors (for example, sibutramine),
sympathomimetic agents, .beta..sub.3 adrenergic receptor agonists,
dopamine agonists (for example, bromocriptine),
melanocyte-stimulating hormone receptor analogs, cannabinoid 1
receptor antagonists [for example, SR141716:
N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H--
pyrazole-3-carboxamide], melanin concentrating hormone antagonists,
leptons (the OB protein), leptin analogues, leptin receptor
agonists, galanin antagonists, lipase inhibitors (such as
tetrahydrolipstatin, i.e., Orlistat), anorectic agents (such as a
bombesin agonist), Neuropeptide-Y antagonists, thyromimetic agents,
dehydroepiandrosterone or an analogue thereof, glucocorticoid
receptor agonists or antagonists, orexin receptor antagonists,
urocortin binding protein antagonists, glucagon-like peptide-1
receptor agonists, ciliary neutrotrophic factors (such as
Axokine.TM. available from Regeneron Pharmaceuticals, Inc.,
Tarrytown, N.Y. and Procter & Gamble Company, Cincinnati,
Ohio), human agouti-related proteins (AGRP), ghrelin receptor
antagonists, histamine 3 receptor antagonists or reverse agonists,
neuromedin U receptor agonists, noradrenergic anorectic agents (for
example, phentermine, mazindol and the like) and appetite
suppressants (for example, bupropion).
[0214] Other anti-obesity agents, including the agents set forth
infra, are well known, or will be readily apparent in light of the
instant disclosure, to one of ordinary skill in the art.
[0215] In some embodiments, the anti-obesity agents are selected
from the group consisting of orlistat, sibutramine, bromocriptine,
ephedrine, leptin, and pseudoephedrine. In a further embodiment,
compounds of the present invention and combination therapies are
administered in conjunction with exercise and/or a sensible
diet.
[0216] It is understood that the scope of combination-therapy of
the compounds of the present invention with other anti-obesity
agents, anorectic agents, appetite suppressant and related agents
is not limited to those listed above, but includes in principle any
combination with any pharmaceutical agent or pharmaceutical
composition useful for the treatment of overweight and obese
individuals.
[0217] Other suitable pharmaceutical agents, in addition to
anti-obesity agents, that can be used in combination with the
compounds of the present invention include agents useful in the
treatment of concomitant disorders. Treatment of such disorders
include the use of one or more pharmaceutical agents known in the
art that belong to the classes of drugs referred to, but not
limited to, the following: sulfonylureas, meglitinides, biguanides,
.alpha.-glucosidase inhibitors, peroxisome proliferators-activated
receptor-.gamma. (i.e., PPAR-.gamma.) agonists, insulin, insulin
analogues, HMG-CoA reductase inhibitors, cholesterol-lowering drugs
(for example, fibrates that include: fenofibrate, bezafibrate,
gemfibrozil, clofibrate and the like; bile acid sequestrants which
include: cholestyramine, colestipol and the like; and niacin),
antiplatelet agents (for example, aspirin and adenosine diphosphate
receptor antagonists that include: clopidogrel, ticlopidine and the
like), angiotensin-converting enzyme inhibitors, angiotensin II
receptor antagonists and adiponectin. In accordance to one aspect
of the present invention, a compound of the present can be used in
combination with a pharmaceutical agent or agents belonging to one
or more of the classes of drugs cited herein.
[0218] It is understood that the scope of combination-therapy of
the compounds of the present invention with other pharmaceutical
agents is not limited to those listed herein, supra or infra, but
includes in principle any combination with any pharmaceutical agent
or pharmaceutical composition useful for the treatment of diseases,
conditions or disorders that are linked to metabolic-related
disorders.
[0219] Some embodiments of the present invention include methods of
treatment of a disease, disorder or condition as described herein
comprising administering to an individual in need of such treatment
a therapeutically effect amount or dose of a compound of the
present invention in combination with at least one pharmaceutical
agent selected from the group consisting of: sulfonylureas,
meglitinides, biguanides, .alpha.-glucosidase inhibitors,
peroxisome proliferators-activated receptor-.gamma. (i.e.,
PPAR-.gamma.) agonists, insulin, insulin analogues, HMG-CoA
reductase inhibitors, cholesterol-lowering drugs (for example,
fibrates that include: fenofibrate, bezafibrate, gemfibrozil,
clofibrate and the like; bile acid sequestrants which include:
cholestyramine, colestipol and the like; and niacin), antiplatelet
agents (for example, aspirin and adenosine diphosphate receptor
antagonists that include: clopidogrel, ticlopidine and the like),
angiotensin-converting enzyme inhibitors, angiotensin II receptor
antagonists and adiponectin. In some embodiments, the
pharmaceutical composition further comprises one or more agents
selected from the group consisting of .alpha.-glucosidase
inhibitor, aldose reductase inhibitor, biguanide, HMG-CoA reductase
inhibitor, squalene synthesis inhibitor, fibrate, LDL catabolism
enhancer, angiotensin converting enzyme inhibitor, insulin
secretion enhancer and thiazolidinedione.
[0220] One aspect of the present invention encompasses
pharmaceutical compositions comprising at least one compound
according to Formula (I), as described herein. In some embodiments,
the pharmaceutical composition further comprises one or more agents
selected from the group consisting of, for example,
.alpha.-glucosidase inhibitor, aldose reductase inhibitor,
biguanide, HMG-CoA reductase inhibitor, squalene synthesis
inhibitor, fibrate, LDL catabolism enhancer, angiotensin converting
enzyme inhibitor, insulin secretion enhancer and
thiazolidinedione.
[0221] Suitable pharmaceutical agents that can be used in
conjunction with compounds of the present invention include
.alpha.-glucosidase inhibitors. .alpha.-Glucosidase inhibitors
belong to the class of drugs which competitively inhibit digestive
enzymes such as .alpha.-amylase, maltase, .alpha.-dextrinase,
sucrase, etc. in the pancreas and or small intestine. The
reversible inhibition by .alpha.-glucosidase inhibitors retard,
diminish or otherwise reduce blood glucose levels by delaying the
digestion of starch and sugars. Some representative examples of
.alpha.-glucosidase inhibitors include acarbose,
N-(1,3-dihydroxy-2-propyl)valiolamine (generic name; voglibose),
miglitol, and .alpha.-glucosidase inhibitors known in the art.
[0222] Suitable pharmaceutical agents that can be used in
conjunction with compounds of the present invention include
sulfonylureas. The sulfonylureas (SU) are drugs which promote
secretion of insulin from pancreatic .beta. cells by transmitting
signals of insulin secretion via SU receptors in the cell
membranes. Examples of the sulfonylureas include glyburide,
glipizide, glimepiride and other sulfonylureas known in the
art.
[0223] Suitable pharmaceutical agents that can be used in
conjunction with compounds of the present invention include the
meglitinides. The meglitinides are benzoic acid derivatives
represent a novel class of insulin secretagogues. These agents
target postprandial hyperglycemia and show comparable efficacy to
sulfonylureas in reducing HbA.sub.1c. Examples of meglitinides
include repaglinide, nateglinide and other meglitinides known in
the art.
[0224] Suitable pharmaceutical agents that can be used in
conjunction with compounds of the present invention include the
biguanides. The biguanides represent a class of drugs that
stimulate anaerobic glycolysis, increase the sensitivity to insulin
in the peripheral tissues, inhibit glucose absorption from the
intestine, suppress of hepatic gluconeogenesis, and inhibit fatty
acid oxidation. Examples of biguanides include phenformin,
metformin, buformin, and biguanides known in the art.
[0225] Suitable pharmaceutical agents that can be used in
conjunction with compounds of the present invention include the
.alpha.-glucosidase inhibitors. The .alpha.-glucosidase inhibitors
competitively inhibit digestive enzymes such as .alpha.-amylase,
maltase, .alpha.-dextrinase, sucrase, etc. in the pancreas and or
small intestine. The reversible inhibition by .alpha.-glucosidase
inhibitors retard, diminish or otherwise reduce blood glucose
levels by delaying the digestion of starch and sugars. Examples of
.alpha.-glucosidase inhibitors include acarbose,
N-(1,3-dihydroxy-2-propyl)valiolamine (generic name; voglibose),
miglitol, and .alpha.-glucosidase inhibitors known in the art.
[0226] Suitable pharmaceutical agents that can be used in
conjunction with compounds of the present invention include the
peroxisome proliferators-activated receptor-.gamma. (i.e.,
PPAR-.gamma.) agonists. The peroxisome proliferators-activated
receptor-.gamma. agonists represent a class of compounds that
activates the nuclear receptor PPAR-.gamma. and therefore regulate
the transcription of insulin-responsive genes involved in the
control of glucose production, transport and utilization. Agents in
the class also facilitate the regulation of fatty acid metabolism.
Examples of PPAR-.gamma. agonists include rosiglitazone,
pioglitazone, tesaglitazar, netoglitazone, GW-409544, GW-501516 and
PPAR-.gamma. agonists known in the art.
[0227] Suitable pharmaceutical agents that can be used in
conjunction with compounds of the present invention include the
HMG-CoA reductase inhibitors. The HMG-CoA reductase inhibitors are
agents also referred to as Statin compounds that belong to a class
of drugs that lower blood cholesterol levels by inhibiting
hydroxymethylglutalyl CoA (HMG-CoA) reductase. HMG-CoA reductase is
the rate-limiting enzyme in cholesterol biosynthesis. The statins
lower serum LDL concentrations by upregulating the activity of LDL
receptors and are responsible for clearing LDL from the blood. Some
representative examples the statin compounds include, rosuvastatin,
pravastatin and its sodium salt, simvastatin, lovastatin,
atorvastatin, fluvastatin, cerivastatin, pitavastatin, BMS's
"superstatin", and HMG-CoA reductase inhibitors known in the
art.
[0228] Suitable pharmaceutical agents that can be used in
conjunction with compounds of the present invention include the
angiotensin converting enzyme (ACE) inhibitors. The angiotensin
converting enzyme inhibitors belong to the class of drugs that
partially lower blood glucose levels as well as lowering blood
pressure by inhibiting angiotensin converting enzymes. Examples of
the angiotensin converting enzyme inhibitors include captopril,
enalapril, alacepril, delapril; ramipril, lisinopril, imidapril,
benazepril, ceronapril, cilazapril, enalaprilat, fosinopril,
moveltopril, perindopril, quinapril, spirapril, temocapril,
trandolapril, and angiotensin converting enzyme inhibitors known in
the art.
[0229] Suitable pharmaceutical agents that can be used in
conjunction with compounds of the present invention include the
angiotensin II receptor antagonists. Angiotensin II receptor
antagonists target the angiotensin II receptor subtype 1 (i.e.,
AT1) and demonstrate a beneficial effect on hypertension. Examples
of angiotensin II receptor antagonists include losartan (and the
potassium salt form), and angiotensin II receptor antagonists known
in the art.
[0230] Other treatments for one or more of the diseases cited
herein include the use of one or more pharmaceutical agents known
in the art that belong to the classes of drugs referred to, but not
limited to, the following: amylin agonists (for example,
pramlintide), insulin secretagogues (for example, GLP-1 agonists;
exendin-4; insulinotropin (NN2211); dipeptyl peptidase inhibitors
(for example, NVP-DPP-728), acyl CoA cholesterol acetyltransferase
inhibitors (for example, Ezetimibe, eflucimibe, and like
compounds), cholesterol absorption inhibitors (for example,
ezetimibe, pamaqueside and like compounds), cholesterol ester
transfer protein inhibitors (for example, CP-529414, JTT-705,
CETi-1, torcetrapib and like compounds), microsomal triglyceride
transfer protein inhibitors (for example, implitapide, and like
compounds), cholesterol modulators (for example, NO-1886, and like
compounds), bile acid modulators (for example, GT103-279 and like
compounds) and squalene synthase inhibitors.
[0231] Squalene synthesis inhibitors belong to a class of drugs
that lower blood cholesterol levels by inhibiting synthesis of
squalene. Examples of the squalene synthesis inhibitors include
(S)-.alpha.-[Bis[2,2-dimethyl-1-oxopropoxy)methoxy]phosphinyl]-3-phenoxyb-
enzenebutanesulfonic acid, mono potassium salt (BMS-188494) and
squalene synthesis inhibitors known in the art.
[0232] In accordance with the present invention, the combination
can be used by mixing the respective active components either all
together or independently with a pharmaceutically acceptable
carrier, excipient, binder, diluent, etc., as described herein
above, and administering the mixture or mixtures either orally or
non-orally as a pharmaceutical composition. When a compound or a
mixture of compounds of Formula (I) are administered as a
combination therapy with another active compound the therapeutic
agents can be formulated as separate pharmaceutical compositions
given at the same time or at different times, or the therapeutic
agents can be given as a single composition.
[0233] In accordance with the present invention, the combination of
a compound of the present invention and pharmaceutical agent can be
prepared by mixing the respective active components either all
together or independently with a pharmaceutically acceptable
carrier, excipient, binder, diluent, etc., as described herein, and
administering the mixture or mixtures either orally or non-orally
as a pharmaceutical composition. When a compound or a mixture of
compounds of Formula (I) are administered as a combination therapy
with another active compound the therapeutic agents can be
formulated as a separate pharmaceutical compositions given at the
same time or at different times, or the therapeutic agents can be
given as a single composition.
Labeled Compounds and Assay Methods
[0234] Another object of the present invention relates to
radio-labeled compounds of Formula (I) that are useful not only in
radio-imaging but also in assays, both in vitro and in vivo, for
localizing and quantitating RUP25 in tissue samples, including
human, and for identifying RUP25 ligands by inhibition binding of a
radio-labeled compound. It is a further object of this invention to
include novel RUP25 assays of which comprise such radio-labeled
compounds.
[0235] The present invention embraces isotopically-labeled
compounds of Formula (I) and any subgenera herein, such as but not
limited to, Formulae (Ia) to (Iz); and (IIa) to (IId). An
"isotopically" or "radio-labeled" compounds are those which are
identical to compounds disclosed herein, but for the fact that one
or more atoms are replaced or substituted by an atom having an
atomic mass or mass number different from the atomic mass or mass
number typically found in nature (i.e., naturally occurring).
Suitable radionuclides that can be incorporated in compounds of the
present invention include but are not limited to .sup.2H (also
written as D for deuterium), .sup.3H (also written as T for
tritium), .sup.11C, .sup.13C, .sup.14C, .sup.13N, .sup.15N,
.sup.15O, .sup.17O, .sup.18O, .sup.18F, .sup.35S, .sup.36Cl,
.sup.82Br, .sup.75Br, .sup.76Br, .sup.77Br, .sup.123I, .sup.124I,
.sup.125I and .sup.131I. The radionuclide that is incorporated in
the instant radio-labeled compounds will depend on the specific
application of that radio-labeled compound. For example, for in
vitro RUP25 labeling and competition assays, compounds that
incorporate .sup.3H, .sup.14C, .sup.82Br, .sup.125I, .sup.131I,
.sup.35S or will generally be most useful. For radio-imaging
applications .sup.11C, .sup.18F, .sup.125I, .sup.123I, .sup.124I,
.sup.131I, .sup.75Br, .sup.76Br or .sup.77Br will generally be most
useful.
[0236] It is understood that a "radio-labeled" or "labeled
compound" is a compound of Formula (I) that has incorporated at
least one radionuclide; in some embodiments the radionuclide is
selected from the group consisting of .sup.3H, .sup.14C, .sup.125I,
.sup.35S and .sup.82Br.
[0237] Certain isotopically-labeled compounds of the present
invention are useful in compound and/or substrate tissue
distribution assays. In some embodiments the radionuclide .sup.3H
and/or .sup.14C isotopes are useful in these studies. Further,
substitution with heavier isotopes such as deuterium (i.e.,
.sup.2H) may afford certain therapeutic advantages resulting from
greater metabolic stability (e.g., increased in vivo half-life or
reduced dosage requirements) and hence can be preferred in some
circumstances. Isotopically labeled compounds of the present
invention can generally be prepared by following procedures
analogous to those disclosed in the Schemes supra and Examples
infra, by substituting an isotopically labeled reagent for a
non-isotopically labeled reagent. Other synthetic methods that are
useful are discussed infra. Moreover, it should be understood that
all of the atoms represented in the compounds of the invention can
be either the most commonly occurring isotope of such atoms or the
more scarce radio-isotope or nonradio-active isotope.
[0238] Synthetic methods for incorporating radio-isotopes into
organic compounds are applicable to compounds of the invention and
are well known in the art. These synthetic methods, for example,
incorporating activity levels of tritium into target molecules, and
are as follows:
[0239] A. Catalytic Reduction with Tritium Gas--This procedure
normally yields high specific activity products and requires
halogenated or unsaturated precursors.
[0240] B. Reduction with Sodium Borohydride [.sup.3H]--This
procedure is rather inexpensive and requires precursors containing
reducible functional groups such as aldehydes, ketones, lactones,
esters, and the like.
[0241] C. Reduction with Lithium Aluminum Hydride [.sup.3H]--This
procedure offers products at almost theoretical specific
activities. It also requires precursors containing reducible
functional groups such as aldehydes, ketones, lactones, esters, and
the like.
[0242] D. Tritium Gas Exposure Labeling--This procedure involves
exposing precursors containing exchangeable protons to tritium gas
in the presence of a suitable catalyst.
[0243] E. N-Methylation using Methyl Iodide [.sup.3H]--This
procedure is usually employed to prepare O-methyl or N-methyl
(.sup.3H) products by treating appropriate precursors with high
specific activity methyl iodide (.sup.3H). This method in general
allows for higher specific activity, such as for example, about
70-90 Ci/mmol.
[0244] Synthetic methods for incorporating activity levels of
.sup.125I into target molecules include:
[0245] A. Sandmeyer and like reactions--This procedure transforms
an aryl or heteroaryl amine into a diazonium salt, such as a
tetrafluoroborate salt, and subsequently to .sup.125I labeled
compound using Na.sup.125I. A represented procedure was reported by
Zhu, D.-G. and co-workers in J. Org. Chem. 2002, 67, 943-948.
[0246] B. Ortho .sup.125Iodination of phenols--This procedure
allows for the incorporation of .sup.125I at the ortho position of
a phenol as reported by Collier, T. L. and co-workers in J. Labeled
Compd Radiopharm. 1999, 42, S264-S266.
[0247] C. Aryl and heteroaryl bromide exchange with .sup.125I--This
method is generally a two step process. The first step is the
conversion of the aryl or heteroaryl bromide to the corresponding
tri-alkyltin intermediate using for example, a Pd catalyzed
reaction [i.e. Pd(Ph.sub.3P).sub.4] or through an aryl or
heteroaryl lithium, in the presence of a tri-alkyltinhalide or
hexaalkylditin [e.g., (CH.sub.3).sub.3SnSn(CH.sub.3).sub.3]. A
represented procedure was reported by Bas, M.-D. and co-workers in
J. Labeled Compd Radiopharm. 2001, 44, S280-S282.
[0248] A radio-labeled RUP25 compound of Formula (I) can be used in
a screening assay to identify/evaluate compounds. In general terms,
a newly synthesized or identified compound (i.e., test compound)
can be evaluated for its ability to reduce binding of the
"radio-labeled compound of Formula (I)" to the RUP25 receptor.
Accordingly, the ability of a test compound to compete with the
"radio-labeled compound of Formula (I)" for the binding to the
RUP25 receptor directly correlates to its binding affinity.
[0249] The labeled compounds of the present invention bind to the
RUP25 receptor. In one embodiment the labeled compound has an
IC.sub.50 less than about 500 .mu.M, in another embodiment the
labeled compound has an IC.sub.50 less than about 100 .mu.M, in yet
another embodiment the labeled compound has an IC.sub.50 less than
about 10 .mu.M, in yet another embodiment the labeled compound has
an IC.sub.50 less than about 1 .mu.M, and in still yet another
embodiment the labeled inhibitor has an IC.sub.50 less than about
0.1 .mu.M.
[0250] Other uses of the disclosed receptors and methods will
become apparent to those in the art based upon, inter alia, a
review of this disclosure.
[0251] As will be recognized, the steps of the methods of the
present invention need not be performed any particular number of
times or in any particular sequence. Additional objects,
advantages, and novel features of this invention will become
apparent to those skilled in the art upon examination of the
following examples thereof, which are intended to be illustrative
and not intended to be limiting.
EXAMPLES
[0252] The following Examples are provided for illustrative
purposes and not as a means of limitation. One of ordinary skill in
the art would be able to design equivalent assays and methods based
on the disclosure herein, all of which form part of the present
invention.
Example 1
Rodent Diabetes Models
[0253] Rodent models of type 2 diabetes associated with obesity and
insulin resistance have been developed. Genetic models such as
db/db and ob/ob [see Diabetes (1982) 31:1-6] in mice and fa/fa in
zucker rats have been developed for understanding the
pathophysiology of disease and for testing candidate therapeutic
compounds [Diabetes (1983) 32:830-838; Annu Rep Sankyo Res Lab
(1994) 46:1-57]. The homozygous animals, C57 BL/KsJ-db/db mice
developed by Jackson Laboratory are obese, hyperglycemic,
hyperinsulinemic and insulin resistant [J Clin Invest (1990)
85:962-967], whereas heterozygotes are lean and normoglycemic. In
the db/db model, mice progressively develop insulinopenia with age,
a feature commonly observed in late stages of human type 2 diabetes
when sugar levels are insufficiently controlled. Since this model
resembles that of human type 2 diabetes, the compounds of the
present invention are tested for activities including, but not
limited to, lowering of plasma glucose and triglycerides. Zucker
(fa/fa) rats are severely obese, hyperinsulinemic, and insulin
resistant {Coleman, Diabetes (1982) 31:1; E Shafrir in Diabetes
Mellitus, H Rifkin and D Porte, Jr, Eds [Elsevier Science
Publishing Co, New York, ed. 4, (1990), pp. 299-340]}, and the
fa/fa mutation may be the rat equivalent of the murine db mutation
[Friedman et al, Cell (1992) 69:217-220; Truett et al, Proc Natl
Acad Sci USA (1991) 88:7806]. Tubby (tub/tub) mice are
characterized by obesity, moderate insulin resistance and
hyperinsulinemia without significant hyperglycemia [Coleman et al,
Heredity (1990) 81:424].
[0254] The present invention encompasses the use of compounds of
the invention for reducing the insulin resistance and hyperglycemia
in any or all of the above rodent diabetes models, in humans with
type 2 diabetes or other preferred metabolic-related disorders or
disorders of lipid metabolism described previously, or in models
based on other mammals. Plasma glucose and insulin levels will be
tested, as well as other factors including, but not limited to,
plasma free fatty acids and triglycerides.
In Vivo Assay for Anti-Hyperglycemic Activity of Compounds of the
Invention
[0255] Genetically altered obese diabetic mice (db/db) (male, 7-9
weeks old) are housed (7-9 mice/cage) under standard laboratory
conditions at 22.degree. C. and 50% relative humidity, and
maintained on a diet of Purina rodent chow and water ad libitum.
Prior to treatment, blood is collected from the tail vein of each
animal and blood glucose concentrations are determined using One
Touch Basic Glucose Monitor System (Lifescan). Mice that have
plasma glucose levels between 250 to 500 mg/dl are used. Each
treatment group consists of seven mice that are distributed so that
the mean glucose levels are equivalent in each group at the start
of the study. db/db mice are dosed by micro-osmotic pumps, inserted
using isoflurane anesthesia, to provide compounds of the invention,
saline, or an irrelevant compound to the mice subcutaneously
(s.c.). Blood is sampled from the tail vein at intervals thereafter
and analyzed for blood glucose concentrations. Significant
differences between groups (comparing compounds of the invention to
saline-treated) are evaluated using Student t-test.
Example 2
Mouse Atherosclerosis Model
[0256] Adiponectin-deficient mice generated through knocking out
the adiponectin gene have been shown to be predisposed to
atherosclerosis and to be insulin resistant. The mice are also a
suitable model for ischemic heart disease [Matsuda, M et al. J Biol
Chem (2002) July, and references cited therein, the disclosures of
which are incorporated herein by reference in their entirety].
[0257] Adiponectin knockout mice are housed (7-9 mice/cage) under
standard laboratory conditions at 22.degree. C. and 50% relative
humidity. The mice are dosed by micro-osmotic pumps, inserted using
isoflurane anesthesia, to provide compounds of the invention,
saline, or an irrelevant compound to the mice subcutaneously
(s.c.). Neointimal thickening and ischemic heart disease are
determined for different groups of mice sacrificed at different
time intervals. Significant differences between groups (comparing
compounds of the invention to saline-treated) are evaluated using
Student t-test.
Example 3
In Vitro Biological Activity
[0258] A modified Flash Plate.TM. Adenylyl Cyclase kit (New England
Nuclear; Cat. No. SMP004A) was utilized for direct identification
of candidate compounds as agonists to hRUP25 in accordance with the
following protocol. The term hRUP25 includes the human sequences
found in GenBank Accession No. NM.sub.--177551 for the nucleotide
and GenBank Accession No. NP 808219 for the polypeptide, and
naturally-occurring allelic variants, mammalian orthologs, and
recombinant mutants thereof.
[0259] CHO cells stably transfected with an expression vector
encoding hRUP25 and cultured under condition permissive for cell
surface expression of the encoded hRUP25 receptor were harvested
from flasks via non-enzymatic means. The cells were washed in PBS
and resuspended in the manufacturer's Assay Buffer. Live cells were
counted using a hemacytometer and Trypan blue exclusion, and the
cell concentration was adjusted to 2.times.10.sup.6 cells/ml. cAMP
standards and Detection Buffer (comprising 2 .mu.Ci of tracer
[.sup.125I]-cAMP (100 .mu.l) to 11 ml Detection Buffer) were
prepared and maintained in accordance with the manufacturer's
instructions. Candidate compounds identified as per above (if
frozen, thawed at room temperature) were added to their respective
wells (preferably wells of a 96-well plate) at increasing
concentrations (3 .mu.l/well; 12 .mu.M final assay concentration).
To these wells, 100,000 cells in 50 .mu.l of Assay Buffer were
added and the mixture was then incubated for 30 minutes at room
temperature, with gentle shaking. Following the incubation, 100
.mu.l of Detection Buffer was added to each well, followed by
incubation for 2-24 hours. Plates were counted in a Wallac
MicroBeta.TM. plate reader using "Prot. #31" (as per manufacturer
instructions).
[0260] Certain compounds of the invention have an EC.sub.50 in the
cAMP Whole Cell method of about 25 .mu.M or less.
Example 4
In Vitro Biological Activity
.sup.35S-GTP.gamma.S Binding Assay:
[0261] Membranes prepared from Chinese Hamster Ovary (CHO)-K1 cells
stably expressing the niacin receptor or vector control (7
.mu.g/assay) were diluted in assay buffer (100 mM HEPES, 100 mM
NaCl and 10 mM MgCl.sub.2, pH 7.4) in Wallac Scintistrip plates and
pre-incubated with test compounds diluted in assay buffer
containing 40 .mu.M GDP (final [GDP] was 10 .mu.M) for .about.10
minutes before addition of .sup.35S-GTP.gamma.S to 0.3 nM. To avoid
potential compound precipitation, all compounds were first prepared
in 100% DMSO and then diluted with assay buffer resulting in a
final concentration of 3% DMSO in the assay. Binding was allowed to
proceed for one hour before centrifuging the plates at 4000 rpm for
15 minutes at room temperature and subsequent counting in a
TopCount scintillation counter. Non-linear regression analysis of
the binding curves was performed in GraphPad Prism.
Membrane Preparation
Materials:
[0262] CHO-K1 cell culture medium: F-12 Kaighn's Modified Cell
Culture Medium with 10% FBS, 2 mM L-Glutamine, 1 mM Sodium Pyruvate
and 400 .mu.gml G418 [0263] Membrane Scrape Buffer: 20 mM HEPES
[0264] 10 mM EDTA, pH 7.4 [0265] Membrane Wash Buffer: 20 mM HEPES
[0266] 0.1 mM EDTA, pH 7.4 [0267] Protease Inhibitor Cocktail:
P-8340, (Sigma, St. Louis, Mo.) Procedure: [0268] Aspirate cell
culture media off the 15 cm.sup.2 plates, rinse with 5 mL cold PBS
and aspirate. [0269] Add 5 mL Membrane Scrape Buffer and scrape
cells. Transfer scrape into 50 mL centrifuge tube. Add 50 .mu.L
Protease Inhibitor Cocktail. [0270] Spin at 20,000 rpm for 17
minutes at 4.degree. C. [0271] Aspirate off the supernatant and
resuspend pellet in 30 mL Membrane Wash Buffer. Add 50 .mu.L
Protease Inhibitor Cocktail. [0272] Spin at 20,000 rpm for 17
minutes at 4.degree. C. [0273] Aspirate the supernatant off the
membrane pellet. The pellet may be frozen at -80.degree. C. for
later use or it can be used immediately. Assay Materials: [0274]
Guanosine 5'-diphosphate sodium salt (GDP, Sigma-Aldrich Catalog
#87127) [0275] Guanosine 5'-[.gamma..sup.35S] thiotriphosphate,
triethylammonium salt ([.sup.35S]GTP.gamma.S, Amersham Biosciences
Catalog #SJ1320, .about.1000 Ci/mmol) [0276] 96 well Scintiplates
(Perkin-Elmer #1450-501) [0277] Binding Buffer: 20 mM HEPES, pH 7.4
[0278] 100 mM NaCl [0279] 10 mM MgCl.sub.2 [0280] GDP Buffer:
binding buffer plus GDP, ranging from 0.4 to 40 .mu.M, make fresh
before assay Procedure: [0281] (total assay volume=100.mu./well)
[0282] 25 .mu.L GDP buffer with or without compounds (final GDP 10
.mu.M--so use 40 .mu.M stock) [0283] 50 .mu.L membrane in binding
buffer (0.4 mg protein/mL) [0284] 25 .mu.L [.sup.35S]GTP.gamma.S in
binding buffer. This is made by adding 5 .mu.l
[.sup.35S]GTP.gamma.S stock into 10 mL binding buffer (This buffer
has no GDP) [0285] Thaw compound plates to be screened (daughter
plates with 5 .mu.L compound@2 mM in 100% DMSO) [0286] Dilute the 2
mM compounds 1:50 with 245 .mu.L GDP buffer to 40 .mu.M in 2% DMSO.
Thaw frozen membrane pellet on ice [0287] Homogenize membranes
briefly until in suspension using a POLYTRON PT3100 (probe PT-DA
3007/2 at setting of 7000 rpm). Determine the membrane protein
concentration by Bradford assay. Dilute membrane to a protein
concentrations of 0.40 mg/ml in Binding Buffer. (Note: the final
assay concentration is 20 .mu.g/well). [0288] Add 25 .mu.L
compounds in GDP buffer per well to Scintiplate. [0289] Add 50
.mu.L of membranes per well to Scintiplate. [0290] Pre-incubate for
5-10 minutes at room temperature. [0291] Add 25 .mu.L of diluted
[.sup.35S]GTP.gamma.S. Incubate on shaker (Lab-Line model #1314,
shake at setting of 4) for 60 minutes at room temperature. [0292]
Assay is stopped by spinning plates sealed with plate covers at
2500 rpm for 20 minutes at 22.degree. C. [0293] Read on TopCount
NXT scintillation counter--35S protocol.
[0294] Certain compounds of the invention have an EC.sub.50 in the
functional in vitro GTP.gamma.S binding assay within the range of
about 10-100 .mu.M. More advantageous compounds of the invention
have an EC.sub.50 value in this assay within the range of about
1-10 .mu.M. Still more advantages compounds have an EC50 value in
this assay of less than about 1 uM.
Example 5
In Vivo Animal Model
[0295] One utility of the compound of the present invention as a
medical agent in the prophylaxis and treatment of a high total
cholesterol/HDL-cholesterol ratio and conditions relating thereto
is demonstrated by the activity of the compound in lowering the
ratio of total cholesterol to HDL-cholesterol, in elevating
HDL-cholesterol, or in protection from atherosclerosis in an in
vivo pig model. Pigs are used as an animal model because they
reflect human physiology, especially lipid metabolism, more closely
than most other animal models. An illustrative in vivo pig model
not intended to be limiting is presented here.
[0296] Yorkshire albino pigs (body weight 25.5.+-.4 kg) are fed a
saturated fatty acid rich and cholesterol rich (SFA-CHO) diet
during 50 days (1 kg chow 35 kg.sup.-1 pig weight), composed of
standard chow supplemented with 2% cholesterol and 20% beef tallow
[Royo T et al., European Journal of Clinical Investigation (2000)
30:843-52; which disclosure is hereby incorporated by reference in
its entirety]. Saturated to unsaturated fatty acid ratio is
modified from 0.6 in normal pig chow to 1.12 in the SFA-CHO diet.
Animals are divided into two groups, one group (n=8) fed with the
SFA-CHO diet and treated with placebo and one group (n=8) fed with
the SFA-CHO diet and treated with the compound (3.0 mg kg.sup.-1).
Control animals are fed a standard chow for a period of 50 days.
Blood samples are collected at baseline (2 days after the reception
of the animals), and 50 days after the initiation of the diet.
Blood lipids are analyzed. The animals are sacrificed and
necropsied.
[0297] Alternatively, the foregoing analysis comprises a plurality
of groups each treated with a different dose of the compound.
Preferred said doses are selected from the group consisting of: 0.1
mg kg.sup.-1, 0.3 mg kg.sup.-1, 1.0 mg kg.sup.-1, 3.0 mg kg.sup.-1,
10 mg kg.sup.-1, 30 mg kg.sup.-1 and 100 mg kg.sup.-1.
Alternatively, the foregoing analysis is carried out at a plurality
of timepoints. Preferred said timepoints are selected from the
group consisting of 10 weeks, 20 weeks, 30 weeks, 40 weeks, and 50
weeks.
HDL-Cholesterol
[0298] Blood is collected in trisodium citrate (3.8%, 1:10). Plasma
is obtained after centrifugation (1200 g 15 min) and immediately
processed. Total cholesterol, HDL-cholesterol, and LDL-cholesterol
are measured using the automatic analyzer Kodak Ektachem DT System
(Eastman Kodak Company, Rochester, N.Y., USA). Samples with value
parameters above the range are diluted with the solution supplied
by the manufacturer and then re-analyzed. The total
cholesterol/HDL-cholesterol ratio is determined. Comparison is made
of the level of HDL-cholesterol between groups. Comparison is made
of the total cholesterol/HDL-cholesterol ratio between groups.
[0299] Elevation of HDL-cholesterol or reduction of the total
cholesterol/HDL-cholesterol ratio on administration of the compound
is taken as indicative of the compound having the aforesaid
utility.
Atherosclerosis
[0300] The thoracic and abdominal aortas are removed intact, opened
longitudinally along the ventral surface, and fixed in
neutral-buffered formalin after excision of samples from standard
sites in the thoracic and abdominal aorta for histological
examination and lipid composition and synthesis studies. After
fixation, the whole aortas are stained with Sudan IV and pinned out
flat, and digital images are obtained with a TV camera connected to
a computerized image analysis system (Image Pro Plus; Media
Cybernetics, Silver Spring, Md.) to determine the percentage of
aortic surface involved with atherosclerotic lesions [Gerrity R G
et al, Diabetes (2001) 50:1654-65; Cornhill J F et al,
Arteriosclerosis, Thrombosis, and Vascular Biology (1985) 5:415-26;
which disclosures are hereby incorporated by reference in their
entirety]. Comparison is made between groups of the percentage of
aortic surface involved with atherosclerotic lesions.
[0301] Reduction of the percentage of aortic surface involved with
atherosclerotic lesions on administration of the compound is taken
as indicative of the compound having the aforesaid utility.
Example 6
Receptor Binding Assay
[0302] In addition to the methods described herein, another means
for evaluating a test compound is by determining binding affinities
to the RUP25 receptor. This type of assay generally requires a
radiolabelled ligand to the RUP25 receptor. Absent the use of known
ligands for the RUP25 receptor and radiolabels thereof, compounds
of Formula (I) can be labelled with a radioisotope and used in an
assay for evaluating the affinity of a test compound to the RUP25
receptor.
[0303] A radiolabelled RUP25 compound of Formula (I) can be used in
a screening assay to identify/evaluate compounds. In general terms,
a newly synthesized or identified compound (i.e., test compound)
can be evaluated for its ability to reduce binding of the
"radiolabelled compound of Formula (I)" to the RUP25 receptor.
Accordingly, the ability to compete with the "radio-labelled
compound of Formula (I)" or Radiolabelled RUP25 Ligand for the
binding to the RUP25 receptor directly correlates to its binding
affinity of the test compound to the RUP25 receptor.
Assay Protocol for Determining Receptor Binding for RUP25:
[0304] A. RUP25 Receptor Preparation
[0305] 293 cells (human kidney, ATCC), transiently transfected with
10 ug human RUP25 receptor and 60 ul Lipofectamine (per 15-cm
dish), are grown in the dish for 24 hours (75% confluency) with a
media change and removed with 10 ml/dish of Hepes-EDTA buffer (20
mM Hepes+10 mM EDTA, pH 7.4). The cells are centrifuged in a
Beckman Coulter centrifuge for 20 minutes, 17,000 rpm (JA-25.50
rotor). Subsequently, the pellet is resuspended in 20 mM Hepes+1 mM
EDTA, pH 7.4 and homogenized with a 50-ml Dounce homogenizer and
again centrifuged. After removing the supernatant, the pellets are
stored at -80.degree. C., until used in binding assay. When used in
the assay, membranes are thawed on ice for 20 minutes and then 10
mL of incubation buffer (20 mM Hepes, 1 mM MgCl.sub.2, 100 mM NaCl,
pH 7.4) added. The membranes are vortexed to resuspend the crude
membrane pellet and homogenized with a Brinkmann PT-3100 Polytron
homogenizer for 15 seconds at setting 6. The concentration of
membrane protein is determined using the BRL Bradford protein
assay.
[0306] B. Binding Assay
[0307] For total binding, a total volume of 50 ul of appropriately
diluted membranes (diluted in assay buffer containing 50 mM Tris
HCl (pH 7.4), 10 mM MgCl.sub.2, and 1 mM EDTA; 5-50 ug protein) is
added to 96-well polyproylene microtiter plates followed by
addition of 100 ul of assay buffer and 50 ul of Radiolabelled RUP25
Ligand. For nonspecific binding, 50 ul of assay buffer is added
instead of 100 ul and an additional 50 ul of 10 uM cold RUP25 is
added before 50 ul of Radiolabelled RUP25 Ligand is added. Plates
are then incubated at room temperature for 60-120 minutes. The
binding reaction is terminated by filtering assay plates through a
Microplate Devices GF/C Unifilter filtration plate with a Brandell
96-well plate harvestor followed by washing with cold 50 mM Tris
HCl, pH 7.4 containing 0.9% NaCl. Then, the bottom of the
filtration plate are sealed, 50 ul of Optiphase Supermix is added
to each well, the top of the plates are sealed, and plates are
counted in a Trilux MicroBeta scintillation counter. For compound
competition studies, instead of adding 100 ul of assay buffer, 100
ul of appropriately diluted test compound is added to appropriate
wells followed by addition of 50 ul of Radiolabelled RUP25
Ligand.
[0308] C. Calculations
[0309] The test compounds are initially assayed at 1 and 0.1 .mu.M
and then at a range of concentrations chosen such that the middle
dose would cause about 50% inhibition of a Radio-RUP25 Ligand
binding (i.e., IC.sub.50). Specific binding in the absence of test
compound (B.sub.O) is the difference of total binding (B.sub.T)
minus non-specific binding (NSB) and similarly specific binding (in
the presence of test compound) (B) is the difference of
displacement binding (B.sub.D) minus non-specific binding (NSB).
IC.sub.50 is determined from an inhibition response curve,
logit-log plot of % B/B.sub.O vs concentration of test
compound.
[0310] K.sub.i is calculated by the Cheng and Prustoff
transformation: K.sub.i=IC.sub.50/(1+[L]/K.sub.D)
[0311] where [L] is the concentration of a Radio-RUP25 Ligand used
in the assay and K.sub.D is the dissociation constant of a
Radio-RUP25 Ligand determined independently under the same binding
conditions.
[0312] D. Alternative Binding Assay Procedure
[0313] .sup.3H-Nicotinic Acid Binding Competition Assay.
[0314] CHO-K1 cells stably expressing the niacin receptor were used
to make membrane for binding analysis. Cells were grown to
.about.80% confluence in growth medium (F-12 Kaighn's modified
medium (ATCC, #30-2004) containing 10% FBS (GIBCO, #10438-026), 1
mg/ml G418 (GIBCO, #10131-027) and 1.times. Pen-Strep (Sigma
P-0871), harvested by scraping, and centrifuged at 12 000.times.g,
4.degree. Celsius, 10 minutes. Cell pellets were resuspended in
harvest buffer (20 mM HEPES, 10 mM EDTA, pH 7.4) and homogenized
with 4.times.10 second bursts of a 12 mm Polytron homogenizer,
setting 5. Lysate was centrifuged at 2 000.times.g, 4.degree., 10
minutes to remove unlysed cells and nuclei, and the resulting
supernatant centrifuged at 39 000.times.g, 4.degree., 45 minutes to
pellet membranes. The resulting pellet was resuspended in wash
buffer (20 mM HEPES, 0.1 mM EDTA, pH 7.4), homogenized with
3.times.10 second bursts of a 12 mm Polytron, setting 4, and
re-centrifuged at 39 000.times.g, 4.degree., 45 minutes. The
resulting pellet was resuspended in wash buffer and stored in
liquid nitrogen before use. The concentration of membrane proteins
in this preparation was determined using the Pierce BCA protein
assay, with BSA as a standard.
[0315] Equilibrium binding of .sup.3H-nicotinic acid was performed
in 96-well polypropylene plates. Reactions contained 140 .mu.l
membrane diluted in assay buffer (20 mM HEPES, pH 7.4, 1 mM MgCl2,
and 0.01% CHAPS; 15-30 .mu.g membrane protein/assay), 20 .mu.l test
compounds diluted in assay buffer (compound stocks were in 100%
DMSO; final DMSO concentration in the assay was 0.25%), and 40
.mu.l 250 nM tritiated niacin ([5,6-.sup.3H]--nicotinic acid:
American Radiolabeled Chemicals, Inc., 20 .mu.M in ethanol; final
ethanol concentration in each assay was 1.5%). Non-specific binding
was determined in the presence of 250 .mu.M unlabeled nicotinic
acid. After mixing at 3-4 hours at room temperature, reactions were
filtered through Packard Unifilter GF/C plates using a Packard
Harvester, and washed with 8.times.200 .mu.l ice-cold binding
buffer. Plates were dried overnight and their backs sealed using
PerkinElmer tape designed for GF/C plates. 40 .mu.l PerkinElmer
Microscint-20 scintillation fluid was added to each well, the tops
sealed, and plates analyzed in a Packard TopCount scintillation
counter.
[0316] Calculations were preformed as in C above.
[0317] Certain compounds of the invention have an EC.sub.50 in the
.sup.3H-nicotinic acid binding competition assay within the range
of about 10 to about 100 .mu.M. More advantageous compounds of the
invention have an EC.sub.50 value in this assay within the range of
about 1 to about 10 .mu.M. Still more advantages compounds have an
EC.sub.50 value in this assay of less than about 1 uM.
Example 7
Flushing via Laser Doppler
[0318] Procedure--
[0319] Male C57Bl6 mice (.about.25 g) are anesthetized using 10
mg/ml/kg Nembutal sodium. When antagonists are to be administered
they are co-injected with the Nembutal anesthesia. After ten
minutes the animal is placed under the laser and the ear is folded
back to expose the ventral side. The laser is positioned in the
center of the ear and focused to an intensity of 8.4-9.0 V (with is
generally .about.4.5 cm above the ear). Data acquisition is
initiated with a 15 by 15 image format, auto interval, 60 images
and a 20 sec time delay with a medium resolution. Test compounds
are administered following the 10th image via injection into the
peritoneal space. Images 1-10 are considered the animal's baseline
and data is normalized to an average of the baseline mean
intensities.
[0320] Materials and Methods--
[0321] Laser Doppler Pirimed PimII; Niacin (Sigma); Nembutal
(Abbott labs).
Example 8
Inhibition of Free Fatty-Acid Production, in Vivo, in Catheterized
Male Sprague-Daly Rats
[0322] Non-esterified free-fatty acid (NEFA) assays were done on
serum derived from live, freely moving rats. Jugular vein catheters
were surgically implanted into the jugular veins and the animals
were allowed to recover at least 48 hr post surgery. Food was
removed from the animals approximately 16 hours prior to the assay.
A draw of .about.200 .mu.l blood was pulled from the catheter and
represents the baseline NEFA serum sample. Drug was administered
intra-peritoneally (IP) at various concentrations to individual
rats and then .about.200 .mu.l blood draws were pulled from the
catheter at the indicated time points for further NEFA analysis.
NEFA assays were performed according to the manufacturer's
specifications (Wako Chemicals, USA; NEFA C) and free fatty acid
concentrations were determined via regression analysis of a known
standard curve (range of known free fatty acids). Data was analyzed
using Excel and PrismGraph.
Example 9
[0323] The invention will now be illustrated by the following
non-limiting examples in which, unless stated otherwise: [0324] (i)
all operations were carried out at room or ambient temperature,
that is, at a temperature in the range 18-25.degree. C.; [0325]
(ii) evaporation of solvent was carried out using a rotary
evaporator under reduced pressure (4.5-30 mmHg) with a bath
temperature of up to 50.degree. C.; [0326] (iii) the course of
reactions was followed by thin layer chromatography (TLC) and/or
tandem high performance liquid chromatography (HPLC) followed by
mass spectroscopy (MS), herein termed LCMS, and any reaction times
are given for illustration only; [0327] (iv) the structure of all
final compounds was assured by at least one of the following
techniques: MS or proton nuclear magnetic resonance (.sup.1H NMR)
spectrometry, and the purity was assured by at least one of the
following techniques: TLC or HPLC; [0328] (v) yields, if given, are
for illustration only; [0329] (vi) .sup.1H NMR spectra were
recorded on either a Bruker Avance-400 or a Varian Unity or a
Varian Inova instrument at 400 or 500 or 600 MHz using the
indicated solvent; when line-listed, NMR data is in the form of
delta (.delta.) values for major diagnostic protons, given in parts
per million (ppm) relative to residual solvent peaks (multiplicity
and number of hydrogens); conventional abbreviations used for
signal shape are: s. singlet; d. doublet (apparent); t. triplet
(apparent); m. multiplet; br. broad; [0330] (vii) MS data were
recorded on a Waters Micromass unit or API 150EX, interfaced with a
Hewlett-Packard (Agilent 1100) or Shimadzu (LC-10AD VP) HPLC
instrument, and operating on MassLynx/OpenLynx or Analyst 1.2
software; electrospray ionization was used with positive (ES+) or
negative ion (ES-) detection; the method for LCMS ES+ was 1-2
mL/min, 10-95% B linear gradient over 5.5 min (B=0.05%
TFA-acetonitrile, A=0.05% TFA-water), and the method for LCMS ES-
was 1-2 mL/min, 10-95% B linear gradient over 5.5 min (B=0.1%
formic acid-acetonitrile, A=0.1% formic acid-water), Waters XTerra
C18-3.5 um-50.times.3.0 mmID and diode array detection; [0331]
(viii) the purification of compounds by preparative reverse phase
HPLC (RPHPLC) was conducted on either a Waters Symmetry Prep C18-5
um-30.times.100 mmID, or a Waters Atlantis Prep dC18-5
um-20.times.100 mmID; 20 mL/min, 10-100% B linear gradient over 15
min (B=0.05% TFA-acetonitrile, A=0.05% TFA-water), and diode array
detection; [0332] (ix) the automated purification of compounds by
preparative reverse phase HPLC was performed on a Gilson system
using a YMC-Pack Pro C18 column (150.times.20 mm i.d.) eluting at
20 mL/min with 0-50% acetonitrile in water (0.1% TFA); [0333] (x)
the purification of compounds by preparative thin layer
chromatography (PTLC) was conducted on 20.times.20 cm glass prep
plates coated with silica gel, or centrifugal chromatography on a
chromatotron using glass rotors coated with silica gel, both
commercially available from Analtech; [0334] (xi) column
chromatography was carried out on a silica gel column using
Kieselgel 60, 0.063-0.200 mm (Merck). [0335] (xii) microwave
irradiations were carried out using the Smith Synthesizer (Personal
Chemistry). [0336] (xiii) chemical symbols have their usual
meanings; the following abbreviations have also been used v
(volume), w (weight), b.p. (boiling point), m.p. (melting point), L
(litre(s)), mL (millilitres), g (gram(s)), mg (milligrams(s)), mol
(moles), mmol (millimoles), eq or equiv (equivalent(s)), IC.sub.50
(molar concentration which results in 50% of maximum possible
inhibition), EC.sub.50 (molar concentration which produces 50% of
the maximum possible efficacy or response), uM (micromolar), nM
(nanomolar).
[0337] The following examples are provided so that the invention
might be more fully understood. They should not be construed as
limiting the invention in any way.
Example 9.1
3-(2H-Tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole
(Compound 1)
[0338] ##STR54## Method A: Preparation of Compound 1.
[0339] 1,4,5,6-Tetrahydro-cyclopentapyrazole-3-carbonitrile (0.022
g, 0.165 mmol) and sodium azide (0.086 g, 1.30 mmol) were taken up
in DMF (3 cm.sup.3) at heated under microwave irradiation to
175.degree. C. for 20 minutes. The solution was cooled to room
temperature, filtered and the filtered solid washed with ethyl
acetate. The combined solutions was added to saturated aqueous
sodium bicarbonate (20 cm.sup.3) and washed with ethyl acetate. The
aqueous layer was acidified to pH 1 with the addition of 1M aqueous
hydrochloric acid and extracted into ethyl acetate. The ethyl
acetate washes were combined and solvent removed under reduced
pressure, the resulting solid purified by preparative HPLC to give
3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole as a
white solid (0.012 g, 0.068 mmol, 41%). .sup.1H NMR .delta.
(CD.sub.3OD): 2.88 (t-like, 2H, J=7.0), 2.82 (t-like, 2H, J=7.3),
2.64 (quintet-like, 2H, J=7.1); m/z (ES.sup.+): 177
[M+H].sup.+.
[0340] The intermediate
1,4,5,6-Tetrahydro-cyclopentapyrazole-3-carbonitrile was prepared
using the following procedure.
[0341] Step A: 1,4,5,6-Tetrahydro-cyclopentapyrazole-3-carboxylic
acid ethyl ester ##STR55##
[0342] Cyclopentanone (10.0 g, 118.9 mmol) was taken up in absolute
ethanol (30 cm.sup.3) and sodium ethoxide (53 cm.sup.3, 21% in
ethanol, 143 mmol) was added. The resulting solution was stirred
under argon for 10 minutes, then diethyl oxalate (19.1 g, 131 mmol)
added. Further ethanol (10 cm.sup.3) was added and the solution
heated at 75.degree. C. for 3 hours and cooled to room temperature.
Hydrazine hydrochloride (8.15 g, 119 mmol), taken up in water (20
cm.sup.3) was added and the solution heated to 75.degree. C.
overnight. Solvent was removed under reduced pressure and the
resulting taken up in ethyl acetate (200 cm.sup.3) and washed with
water (200 cm.sup.3), dried (Na.sub.2SO.sub.4), filtered and
solvent removed under reduced pressure to give
1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid ethyl ester
as an off white solid (16.16 g, 90.0 mmol, 76%). .delta..sub.H
(CD.sub.3OD): 4.34 (q, 2H, J=7.1, OCH.sub.2CH.sub.3), 2.78 (t like,
2H, J=7.0), 2.72 (br s, 2H), 2.49 (br s, 2H), 1.36 (t, 3H, J=7.1,
OCH.sub.2CH.sub.3). m/z (ES.sup.+): 181 [M+H].sup.+.
[0343] Step B: 1,4,5,6-Tetrahydro-cyclopentapyrazole-3-carboxylic
acid amide. ##STR56##
[0344] 1,4,5,6-Tetrahydro-cyclopentapyrazole-3-carboxylic acid
ethyl ester (0.808 g, 4.48 mmol) was taken up in methanolic ammonia
(ca 7 M, 12 cm.sup.3) and stirred overnight at 95.degree. C. The
resulting solution was chilled and the precipitated
1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid amide
collected by vacuum filtration as a white crystalline solid (0.438
g, 2.90 mmol, 65%). .delta..sub.H (CD.sub.3OD): 2.79 (t like, 2H,
J=6.9), 2.73 (t like, 2H, J=7.3), 2.55 (br s, 2H); m/z (ES.sup.+):
152 [M+H].sup.+.
[0345] Step C:
1,4,5,6-Tetrahydro-cyclopentapyrazole-3-carbonitrile. ##STR57##
[0346] 1,4,5,6-Tetrahydro-cyclopentapyrazole-3-carboxylic acid
amide (0.210 g, 1.39 mmol) was added to anhydrous acetonitrile (12
cm.sup.3), heated to 80.degree. C. and sodium chloride (2.0 g, 34
mmol) added. After 15 minutes phosphorus oxychloride (0.128 g, 0.83
mmol) was added and the solution heated to 80.degree. C. overnight,
cooled, filtered, and the collected solid washed with acetonitrile.
Solvent was removed from the combined solutions under reduced
pressure and the resulting solid purified by preparative HPLC to
give 1,4,5,6-tetrahydro-cyclopentapyrazole-3-carbonitrile as a deep
purple coloured solid (0.031 g, 0.23 mmol, 17%). .delta..sub.H
(CD.sub.3OD): 2.79 (t like, 2H, J=7.3), 2.73 (t like, 2H, J=7.1),
2.65-2.55 (m, 2H); m/z (ES.sup.+): 134 [M+H].sup.+. Method B:
Preparation of Compound 1. ##STR58##
[0347] Air was bubbled through a stirring solution of
1-benzyl-3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole
(1.92 g, 7.21 mmol) and KOt-Bu (65 mL of a 1M solution in THF) in
DMSO (50 mL) for a period of 2.0 h. The reaction was acidified to
pH=2 by the addition of HCl (3M aq). The mixture was filtered and
the filtrate was concentrated in vacuo to remove volatiles. The
material was purified by reverse-phase HPLC: Phenomenex.RTM. Luna
C18 column (10.mu., 250.times.50 mm), 5% (v/v) CH.sub.3CN
(containing 1% v/v TFA) in H.sub.2O (containing 1% v/v TFA)
gradient to 50% H.sub.2O, 60 ml/min, .lamda.=214 nm. The product
was further purified by loading material on a Varian BondElut.RTM.
60 mL, 10 g SCX cartridge. MeOH (150 mL) was passed through the
column to remove unbound impurities. The product was then eluted by
passing a solution of 2N NH.sub.3 in MeOH (150 mL) through the
column. Concentration of the eluant yielded the ammonium salt of
Compound 1 (947 mg, 5.38 mmol, 75% yield) as a white solid. .sup.1H
NMR (ammonium salt, 400 MHz, CD.sub.3OD): .delta. 2.88 (2H, t,
J=6.8 Hz), 2.74 (2H, t, J=6.8 Hz), 2.52 (2H, quin, J=6.8 Hz).
HPLC/MS: Discovery.RTM. C18 column (5.mu., 50.times.2.1 mm), 5% v/v
CH.sub.3CN (containing 1% v/v TFA) in H.sub.2O (containing 1% v/v
TFA) gradient to 99% v/v CH.sub.3CN in H.sub.2O, 0.75 mL/min,
t.sub.r=1.22 min, ESI.sup.+=177.3 (M+H). Anal Calcd for
C.sub.7H.sub.8N.sub.6 (neutral compound): C, 47.72; H, 4.58. Found:
C, 47.27; H, 4.16. Anal Calcd for C.sub.7H.sub.11N.sub.7 (ammonium
salt): C, 43.51; H, 5.74. Found: C, 42.94; H, 5.30.
[0348] The intermediate
1-benzyl-3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole
was prepared using the following procedure.
[0349] Step A: Preparation of
1-Benzyl-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid
amide and
2-Benzyl-2,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid
amide. ##STR59##
[0350] To a stirring solution of
1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid amide (2.57
g, 17.0 mmol) in DMF (34 mL) at 25.degree. C. was added
K.sub.2CO.sub.3 (5.87 g, 42.5 mmol) followed by benzyl bromide
(4.36 g g, 25.5 mmol). The reaction was stirred at ambient
temperature for 16 h at which time the mixture was diluted with
EtOAc (75 mL) and filtered. The filtrate was washed with H.sub.2O
(100 mL) and the aqueous phase was back-extracted with EtOAc (75
mL) and CH.sub.2Cl.sub.2 (75 mL). The combined organic extracts
were dried over MgSO.sub.4, filtered, and concentrated in vacuo.
Purification by silica gel chromatography (50% EtOAc in hexanes
gradient to 95% EtOAc in hexanes) gave
2-benzyl-2,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid
amide (739 mg, 3.07 mmol, 18% yield) isolated as a white solid
followed by
1-benzyl-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid
amide (3.24 g, 13.4 mmol, 79% yield) isolated as a white solid.
[0351] 1-Benzyl-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic
acid amide.
[0352] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 7.37-7.30 (3H,
m), 7.19 (2H, m), 6.67 (1H, bs), 5.34 (1H, bs), 5.19 (2H, s), 2.82
(2H, m), 2.51 (4H, m). .sup.13C APT NMR (100 MHz, CDCl.sub.3):
.delta. up: 164.8, 155.2, 139.0, 136.0, 129.5, 55.3, 31.2, 24.1;
down: 129.0, 128.3, 127.8. HPLC/MS: Alltech.RTM. Prevail C18 column
(5.mu., 50.times.4.6 mm), 5% v/v CH.sub.3CN (containing 1% v/v TFA)
in H.sub.2O (containing 1% v/v TFA) gradient to 99% v/v CH.sub.3CN
in H.sub.2O, 3.5 mL/min, t.sub.r=2.13 min, ESI.sup.+=242.2
(M+H).
[0353] 2-Benzyl-2,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic
acid amide .
[0354] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 7.34-7.21 (5H,
m), 5.76 (2H, s), 5.70-5.38 (2H, bs), 2.78 (4H, m), 2.49 (2H, m).
.sup.13C APT NMR (100 MHz, CDCl.sub.3): .delta. up: 161.9, 160.1,
138.3, 128.3, 127.1, 55.1, 29.9, 24.8, 24.7; down: 128.6, 128.0,
127.6. HPLC/MS: Alltech.RTM. Prevail C18 column (5.mu.,
50.times.4.6 mm), 5% v/v CH.sub.3CN (containing 1% v/v TFA) in
H.sub.2O (containing 1% v/v TFA) gradient to 99% v/v CH.sub.3CN in
H.sub.2O, 3.5 mL/min, t.sub.r=1.98 min, ESI.sup.+=242.1 (M+H).
[0355] Step B: Preparation of
1-Benzyl-3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole
##STR60##
[0356] To a solution of
1-benzyl-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid
amide (3.02 g, 12.53 mmol) in DMF (25 mL) at rt was added thionyl
chloride (1.94 g, 16.3 mmol). The reaction was stirred for 18 h at
which time NaHCO.sub.3 (sat. aq., 6 mL) was added to quench excess
thionyl chloride. The mixture was diluted with EtOAc (150 mL) and
washed sequentially with NaHCO.sub.3 (sat. aq., 100 mL) and brine
(100 mL). The aqueous washes were back-extracted with EtOAc
(2.times.100 mL) and the combined organics were dried over
MgSO.sub.4, filtered, and concentrated in vacuo to yield a crude
yellow oil.
[0357] The concentrate was dissolved in DMF (20 mL) and placed in a
heavy walled sealed reaction vessel at which time to which
ZnBr.sub.2 (4.70 g, 18.0 mmol) and NaN.sub.3 (2.73 g, 42.0 mmol)
were added sequentially. The vessel was sealed and heated to
120.degree. C. for 18 h. The mixture was cooled to rt and HCl (3M
aq., 2 mL) was added and stirring was continued for 5 min. The
mixture was diluted with EtOAc (150 mL) and washed with HCl (1M,
aq., 100 mL). The organics were dried over MgSO.sub.4, filtered,
and concentrated. Purification by silica gel chromatography
(50:50:0.2, hexanes:EtOAc:AcOH gradient to 100:0.2, EtOAc:AcOH)
gave
1-benzyl-3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole
(2.06 g, 7.74 mmol, 62% yield) as a white solid. .sup.1H NMR (400
MHz, CD.sub.3OD): .delta. 7.36-7.25 (5H, m), 5.30 (2H, s), 2.84
(2H, t, J=6.4 Hz), 2.62-2.56 (4H, m). .sup.13C APT NMR (100 MHz,
CD.sub.3OD): .delta. up: 153.8, 151.9, 137.6, 131.5, 128.9, 55.8,
31.9, 24.8, 24.6; down: 129.9, 129.1, 129.0. HPLC/MS:
Discovery.RTM. C18 column (5.mu., 50.times.2.1 mm), 5% v/v
CH.sub.3CN (containing 1% v/v TFA) in H.sub.2O (containing 1% v/v
TFA) gradient to 99% v/v CH.sub.3CN in H.sub.2O, 0.75 mL/min,
t.sub.r=2.18 min, ESI.sup.+=267.1 (M+H). Method C: Preparation of
Compound 1. ##STR61##
[0358] To a solution of
1-benzyl-3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole
(59.4 g, 223 mmol) in 10% formic acid/MeOH (vol/vol, 900 mL) was
added palladium black (39.8 g, 374 mmol). The mixture was
mechanically stirred under N.sub.2 atmosphere for 24 h. The
reaction was filtered and concentrated. The product was further
purified and converted to the ammonium salt by the following by
loading material (as a solution in MeOH) on to a column containing
Bondesil SCX SPE resin (750 g). The column was flushed with MeOH
(2.0 L) to remove unbound impurities. The product was eluted using
2N NH.sub.3/MeOH (approx. 1.5 L). Upon concentration the ammonium
salt of the tetrazole (39.3 g, 203 mmol, 91% yield) was obtained as
a white solid.
[0359] The intermediate
1-benzyl-3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole
was prepared using the following procedure.
[0360] Step A: Preparation of
1,4,5,6-Tetrahydro-cyclopentapyrazole-3-carboxylic acid ethyl
ester. ##STR62##
[0361] To a solution of cyclopentanone (42.0 g, 0.50 mol) and
diethyl oxalate (73.1 g, 0.50 mol) in EtOH (2.5 L) at rt under
N.sub.2 was added a solution of KOt-Bu in THF (500 mL of a 1M
solution, 0.50 mol) over 0.5 h via an addition funnel. The reaction
was stirred for 3.5 h at which time the flask was cooled to
0.degree. C. Hydrazine hydrochloride (37.6 g, 0.55 mol) in H.sub.2O
(250 mL) was added via addition funnel over 0.5 h. The reaction was
warmed to rt and stirred for 16 h. The volatiles were removed in
vacuo and the resulting solid was washed with NaHCO.sub.3 (sat.
aq., 500 mL) and H.sub.2O (500 mL). Further concentration in vacuo
gave pure 1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid
ethyl ester (63.6 g, 0.35 mol, 71% yield) as a yellow solid.
[0362] Step B: Preparation of
1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid amide.
##STR63##
[0363] 1,4,5,6-Tetrahydro-cyclopentapyrazole-3-carboxylic acid
ethyl ester (63.5 g, 0.35 mmol) was dissolved in a solution of 7N
NH.sub.3/MeOH (1.0 L). The solution was divided into four equal
portions each of which was transferred to 350 mL heavy-walled
sealed reaction vessel. The vessels were heated to 95.degree. C.
and stirred for 20 h. The reactions were cooled to rt at which time
a solid precipitated. The solution was filtered and the solid was
washed with NaOH (1N aq., 200 mL) giving pure
1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid amide (42.0
g, 0.20 mol, 80% yield) as a white solid.
[0364] Step C: Preparation of
1-Benzyl-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid
amide and
2-Benzyl-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid
amide. ##STR64##
[0365] To a solution of
1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid amide (41.5
g, 275 mmol) in THF (460 mL) at rt was added a solution of NaOH (5N
aq., 110 mL, 0.54 mol). After stirring for 5 min benzyl bromide
(49.2 g, 0.29 mol) was added and the reaction was stirred for 16 h.
The volatiles were removed in vacuo and the resulting solid was
washed with H.sub.2O (3.times.250 mL). Further concentration gave
regioisomers of
1-benzyl-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid
amide and
2-benzyl-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid
amide (65.3 g, 270 mmol, 98% yield) as a 20:1 mixture and was used
without separation).
[0366] Step D: Preparation of
1-Benzyl-3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole
##STR65##
[0367] A flask equipped with a drying tube under N.sub.2 atmosphere
was charged with anhydrous DMF (250 mL). The flask was cooled to
0.degree. C. and thionyl chloride (36.7 g, 309 mmol) was added via
syringe over a period of 5 min. After stirring for an additional 10
min, a solution of
1-benzyl-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid
amide (67.7 g, 281 mmol) in DMF (310 mL) was added over 5 min using
an addition funnel. The mixture was slowly warmed to rt and stirred
for 16 hr. NaHCO.sub.3 (sat. aq., 100 mL) was added and the mixture
was stirred for 10 min. The volatiles were removed in vacuo and the
residue was diluted with EtOAc (700 mL) and NaHCO.sub.3 (sat. aq.,
700 mL). The layers were separated and the aqueous phase was
back-extracted with EtOAc (400 mL). The combined organics were
washed with NaHCO.sub.3 (sat. aq., 600 mL) and brine (600 mL),
dried over MgSO.sub.4, filtered, and concentrated to give 63.1 g of
nitrile as a brown solid.
[0368] To a solution of the nitrile (from above) in DMF (560 mL)
was added ZnBr.sub.2 (95.6 g, 425 mmol) followed by NaN.sub.3 (55.2
g, 849 mmol). The mixture was heated to 120.degree. C. and stirred
for 14 h. The reaction was cooled to rt and the DMF was removed in
vacuo. HCl (2N aq., 800 mL) was added and the mixture was stirred
for 15 min followed by filtration. The solid was added to a
biphasic mixture of EtOAc (500 mL) and HCl (5N aq., 300 mL) and
stirred for 0.5 h. The solution was filtered and the layers
separated. The remaining solid was again treated with EtOAc and HCl
(5N aq.) as described above and this process (stir, filter,
separate) was repeated until all solid material was dissolved. The
combined organic filtrates were concentrated to give
1-benzyl-3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole
(61.0 g, 229 mmol, 81% yield from the amide) as a light brown
solid.
Example 9.2
3-(1H-Tetrazol-5-yl)-2,6-dihydro-4H-thieno[3,4-c]pyrazole (Compound
2)
[0369] ##STR66##
[0370] Compound 2 was prepared in a similar manner as described in
Example 9.1, and was characterized by NMR and MS; .sup.1H NMR (400
MHz, MeOD): (400 MHz, CD.sub.3OD) .delta. 4.11 (dd, J=4.0, 2.2 Hz,
2H), 4.03 (dd, J=3.6, 2.2 Hz, 2H). HPLC/MS: Waters.RTM. YMC ODS-A
C18 column (5.mu., 50.times.4.6 mm), 5% v/v CH.sub.3CN (containing
1% v/v TFA) in H.sub.2O (containing 1% v/v TFA) gradient to 99% v/v
CH.sub.3CN in H.sub.2O, 3.5 mL/min, t.sub.r=1.27 min, ESI.sup.+=194
(M+H).
Example 9.3
6-Methyl-3-(1H-tetrazol-5-yl)-2,6-dihydro-4H-furo[3,4-c]pyrazole
(Compound 3)
[0371] ##STR67##
[0372] Compound 3 was prepared in a similar manner as described in
Example 9.1, a separation by column chromatography of the
regioisomers was performed after the formation of the pyrazole.
[0373] Compound 3 was characterized by NMR and MS; .sup.1H NMR (400
MHz, DMSO): .delta. 5.20 (m, 1H), 4.94 (dd, J=34.7, 10.3 Hz, 2H),
1.39 (d, J=4.4 Hz, 3H). HPLC/MS: Alltech.RTM. Prevail C18 column
(5.mu., 50.times.4.6 mm), 5% v/v CH.sub.3CN (containing 1% v/v TFA)
in H.sub.2O (containing 1% v/v TFA) gradient to 99% v/v CH.sub.3CN
in H.sub.2O, 3.5 mL/min, t.sub.r=1.03 min, ESI.sup.+=192 (M+H).
Example 9.4
3-(1H-Tetrazol-5-yl)-1,4-dihydro-cyclopentapyrazole (Compound 4)
and 3-(1H-Tetrazol-5-yl)-1,6-dihydro-cyclopentapyrazole (Compound
5)
[0374] ##STR68##
[0375] Compound 9.4A
[0376] A solution of Compound 9.4A, as an isomeric mixture, (50 mg,
0.38 mmol), sodium azide (86.5 mg, 1.33 mmol) and zinc bromide (300
mg, 1.33 mmol) in DMF (2 mL) was irradiated under microwave at
200.degree. C. for 6 hours. After cooling to room temperature, the
reaction mixture was treated with a 2 N HCl solution, extracted
with EtOAc, washed with H.sub.2O and concentrated in vacuo. HPLC
separation (C18 column, 5 to 99% CH.sub.3CN in H.sub.2O) afforded
40.3 mg (61%) of the desired product as a 2:1 mixture of olefinic
isomers. LC-MS m/z 175 (M+1); .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 6.94 (m, 0.5H), 6.87 (m, 1H), 6.76 (m, 1H), 6.40 (m, 0.5H),
3.35 (m, 3H).
[0377] The isomers were separated by reverse-phase HPLC:
Phenomenex.RTM. Luna C18 column (10.mu., 250.times.21.2 mm), 5%
(v/v) CH.sub.3CN (containing 1% v/v TFA) in H.sub.2O (containing 1%
v/v TFA) gradient to 70% H.sub.2O, 20 ml/min, .lamda.=280 nm.
[0378] Alternatively the isomers were separated by normal-phase
HPLC: Dynamax Micorsorb Si (prep) column (8.mu., 250.times.10 mm),
80% (v/v) EtOAc (containing 2% v/v AcOH) in hexanes (containing 2%
v/v AcOH) gradient to 99% EtOAc, 7.5 ml/min, .lamda.=280 nm.
The order of isomer elution is the same for both normal- and
reverse-phase columns.
[0379] Isomer 1 (High Rf Isomer):
[0380] .sup.1H NMR (400 MHz, MeOD): .delta. 6.79 (2H, m), 3.42 (2H,
m). HPLC/MS: Discovery.RTM. C18 column (5.mu., 50.times.2.1 mm), 5%
v/v CH.sub.3CN (containing 1% v/v TFA) in H.sub.2O (containing 1%
v/v TFA) gradient to 99% v/v CH.sub.3CN in H.sub.2O, 0.75 mL/min,
t.sub.r=1.10 min, ESI.sup.+=174.9 (M+H).
[0381] Isomer 2 (Low Rf Isomer):
[0382] .sup.1H NMR (400 MHz, MeOD): .delta. 6.98 (1H, m), 6.44 (1H,
m), 3.33 (2H, m). HPLC/MS: Discovery.RTM. C18 column (5.mu.,
50.times.2.1 mm), 5% v/v CH.sub.3CN (containing 1% v/v TFA) in
H.sub.2O (containing 1% v/v TFA) gradient to 99% v/v CH.sub.3CN in
H.sub.2O, 0.75 mL/min, t.sub.r=1.11 min, ESI.sup.+=175.1 (M+H).
[0383] The intermediate Compound 9.4A, as an isomeric mixture, was
prepared using the following steps:
[0384] Step A: Preparation of
2,6-Dihydro-cyclopentapyrazole-3-carboxylic acid ethyl ester and
2,4-Dihydro-cyclopentapyrazole-3-carboxylic acid ethyl ester
(Mixture). ##STR69##
[0385] Compound 9.4B was prepared from the corresponding ketone
using a similar method as described herein for the preparation of
pyrazole esters (see Example 14.2). A solution of Compound 9.4B
(2.0 g, 8.19 mmol) in phenyl ether (25 mL) was heated at reflux
(250.about.260.degree. C.) under nitrogen for 2 hours.
[0386] After cooling down the solution to room temperature, it was
loaded on a SiO.sub.2 column, flushed with DCM to push out the
phenyl ether, and eluted with EtOAc/Hex (1/3) to afford 1.05 g
(72%) of Compound 9.4C as a mixture of olefinic isomers. LC-MS m/z
179 (M+1).
[0387] Step B: Preparation of
2,6-Dihydro-cyclopentapyrazole-3-carboxylic acid amide and
2,4-Dihydro-cyclopentapyrazole-3-carboxylic acid amide (Mixture).
##STR70##
[0388] Compound 9.4C, as an isomeric mixture, (1.0 g, 5.61 mmol)
was dissolved in smallest amount of dioxane (<5 mL) and mixed
with 28% ammonium hydroxide solution (100 mL) in a tightly sealed
container. The solution was stirred at room temperature for 24
hours and concentrated in vacuo to afford Compound 9.4D, as an
isomeric mixture, as a solid in quantitative yield. LC-MS m/z 150
(M+1).
[0389] Step C: Preparation of
2,6-Dihydro-cyclopentapyrazole-3-carbonitrile and
2,4-Dihydro-cyclopentapyrazole-3-carbonitrile (Mixture).
##STR71##
[0390] To a suspension of Compound 9.4D, as an isomer mixture,
(0.80 g, 5.36 mmol) and potassium carbonate (0.445 g, 3.22 mmol) in
acetonitrile (30 mL) was added POCl.sub.3 (0.785 mL, 8.58 mmol) at
room temperature. The reaction mixture was heated at reflux for 2
hours. After concentration in vacuo, the residue was diluted with
EtOAc (150 mL), washed with H.sub.2O and brine, dried
(Na.sub.2SO.sub.4), and concentrated to afford 141 mg (20%) of
Compound 9.4A as an isomer mixture. LC-MS m/z 132 (M+1).
Example 9.5
3-(1H-Tetrazol-5-yl)-2,6-dihydro-4H-furo[3,4-c]pyrazole (Compound
6)
[0391] ##STR72##
[0392] Compound 6 was prepared in a similar manner as described in
Example 9.1, and was characterized by NMR and MS; LC-MS m/z 179
(M+1); .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 5.07 (t, J=2.2 Hz,
2H), 4.92 (t, J=2.2 Hz, 2H).
Example 9.6
5-Ethyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
(Compound 7)
[0393] ##STR73##
[0394] Compound 7 was prepared in a similar manner as described in
Example 9.1, and was characterized by NMR and MS; .sup.1H NMR
(MeOD, 400 MHz): .delta. 3.07 (1H, dd, J=14.8, 7.6 Hz),
2.94-2.82(2H, m), 2.51 (1H, dd, J=15.2, 6.8 Hz), 2.41 (1H, dd,
J=13.6, 5.6 Hz), 1.6 (2H, m), 1.02 (3H, t, J=7.2 Hz). HPLC/MS:
Discovery.RTM. C18 column (5.mu., 50.times.2.1 mm), 5% v/v
CH.sub.3CN (containing 1% v/v TFA) in H.sub.2O (containing 1% v/v
TFA) gradient to 99% v/v CH.sub.3CN in H.sub.2O, 0.75 mL/min,
t.sub.r=1.42 min, ESI.sup.+=205.2 (M+H).
Example 9.7
Preparation of Intermediate
1-Benzyl-5-hydroxy-1,4,5,6-tetrahydrocyclo-penta[c]pyrazole-3-carbonitril-
e
[0395] ##STR74##
[0396] Step A: Preparation of
1-Benzyl-1,6-dihydro-cyclopentapyrazole-3-carboxylic acid ethyl
ester and 1-Benzyl-1,4-dihydro-cyclopentapyrazole-3-carboxylic acid
ethyl ester (Mixture). ##STR75##
[0397] To a solution of the pyrazole (Compound 9.4C, see Example
9.4, Step A, 2.0 g, 11.22 mmol) in anhydrous THF (100 mL) was added
benzyl bromide (5.36 mmol, 44.88 mmol) and NaOH (1.79 g, 44.88
mmol). After stirring at room temperature for 1 hour, the reaction
was quenched with 1N HCl (100 mL). The resulting mixture was
extracted with ethyl acetate, washed with 1N HCl, saturated
NaHCO.sub.3 solution, brine and dried over anhydrous
Na.sub.2SO.sub.4. The solution was filtered and concentrated in
vacuo. This material was purified on the biotage flash 40M column
(SiO.sub.2) using 30% ethyl acetate-hexanes. A colorless oil was
obtained. LC-MS: 3.22 min; (M+Na)=291.1.
[0398] Step B: Preparation of
1-Benzyl-1,6-dihydro-cyclopentapyrazole-3-carboxylic acid and
1-Benzyl-1,4-dihydro-cyclopentapyrazole-3-carboxylic acid
(Mixture). ##STR76##
[0399] To a solution of the intermediate from step A (3.55 g, 13.23
mmol) in 1:1 THF/MeOH (40 mL) was added NaOH solution (5N, 3.9 mL,
20 mmol). After 3 hours at room temperature, the reaction was
quenched by adding 1N HCl (22 mL). The aqueous layer was extracted
with ethyl acetate (3.times.) dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. A yellow
solid was obtained which was used in the next step without any
further purification. LC-MS: 2.62 min; (M+H)=241.1.
[0400] Step C: Preparation of
1-Benzyl-1,6-dihydro-cyclopentapyrazole-3-carboxylic acid
2,5-dioxo-pyrrolidin-1-yl ester and
1-Benzyl-1,4-dihydro-cyclopentapyrazole-3-carboxylic acid
2,5-dioxo-pyrrolidin-1-yl ester (Mixture). ##STR77##
[0401] To a solution of the intermediate from step B (3.17 g, 13.23
mmol) in CH.sub.2Cl.sub.2 (200 mL) was added N-hydroxy succinimide
(3.04 g, 26.46 mmol) followed by EDC (5.07 g, 26.46 mmol). After
stirring the reaction mixture at room temperature for 18 hours, it
was concentrated in vacuo. The residue was diluted with ethyl
acetate (200 mL), washed with saturated NaHCO.sub.3 solution and
brine. The organic layer was dried over anhydrous Na.sub.2SO.sub.4,
filtered and concentrated in vacuo. A yellow solid was obtained.
LC-MS: 2.99 min; (M+H)=338.1.
[0402] Step D: Preparation of
1-Benzyl-1,6-dihydro-cyclopentapyrazole-3-carboxylic acid amide and
1-Benzyl-1,4-dihydro-cyclopentapyrazole-3-carboxylic acid amide
(Mixture). ##STR78##
[0403] To a solution of the intermediate from step C (4.45 g, 13.22
mmol) in 1,4-dioxane (150 mL) was added NH.sub.4OH (14.8 N, 10.0
eq, 9.1 mL). A precipitate formed immediately. After stirring at
room temperature for 15 minutes the reaction mixture was filtered
through a sintered funnel and the precipitate washed with
1,4-dioxane. The filtrate was concentrated in vacuo to give a
yellow solid. LC-MS: 2.55 min; (M+H)=240.1.
[0404] Step E: Preparation of
1-Benzyl-1,6-dihydro-cyclopentapyrazole-3-carbonitrile and
1-Benzyl-1,4-dihydro-cyclopentapyrazole-3-carbonitrile (Mixture).
##STR79##
[0405] To a solution of the intermediate from step D in anhydrous
DMF (50 mL) was added cyanuric chloride (2.33 g, 13.2 mmol). After
stirring at room temperature for 15 minutes the reaction was
quenched by pouring into water (100 mL). The resulting mixture was
extracted with ethyl acetate, washed with saturated NaHCO.sub.3,
brine, dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. The residue was purified on the biotage
flash 40 M column (SiO.sub.2) using 20% ethyl acetate-hexanes. A
white solid was obtained. LC-MS: 3.22 min; (M+H)=222.2.
[0406] Step F: Preparation of
1-Benzyl-5-hydroxy-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carbonitrile.
##STR80##
[0407] To a solution of the intermediate from step E (0.95 g, 4.29
mmol) in anhydrous THF (40 mL) cooled to 0.degree. C. under a
N.sub.2 atmosphere was added Borane-THF (23 mmol, 5.36 eq, 1.0 M
solution). The reaction was warmed to room temperature and stirred
for 1 hour. The reaction was then cooled to 0.degree. C. Water was
added (3 mL) followed by NaOH (4.29 mmol, 1.43 mL, 3N) and
H.sub.2O.sub.2 (12.88 mmol, 1.32 mL, 30% solution in water). After
heating the reaction at 50.degree. C. for 30 minutes, it was cooled
to room temperature and quenched by the addition of water. The
resulting mixture was extracted with ethyl acetate (3.times.). The
organic layer was dried over anhydrous Na.sub.2SO.sub.4 filtered
and concentrated in vacuo. The residue was purified by flash
chromatography using 30% ethyl acetate-hexanes to give a 1:1
mixture of the C-5 and C-6 alcohols.
[0408] Less polar isomer (C-6 alcohol, Compound 17) .sup.1H NMR
(500 MHz, CDCl.sub.3): .delta. 7.2 (m, 5H), 5.35 (d, J=14.9 Hz,
1H), 5.31 (d, J=14.6 Hz, 1H), 4.99 (dd, J=3.4, 6.9 Hz, 1H), 2.9 (m,
2H), 2.6 (m, 1H), 2.35 (m, 1H). LC-MS: 2.76 min; (M+H)=240.1.
[0409] More polar isomer (C-5 alcohol) .sup.1H NMR (500 MHz,
CDCl.sub.3): .delta. 7.4-7.2 (m, 5H), 5.28 (d, J=14.8 Hz, 1H), 5.25
(d, J=14.9 Hz, 1H), 5.01 (m, 1H), 3.13 (dd, J=6.4, 15.8 Hz, 1H),
2.89 (dd, J=6.6, 16.2 Hz, 1H), 2.68 (dd, J=3.7, 16.0 Hz, 1H), 2.52
(dd, J=3.4, 16.2 Hz, 1H). LC-MS: 2.60 min; (M+H)=240.1.
Example 9.8
Preparation of Intermediate Trifluoro-methanesulfonic Acid
1-benzyl-3-cyano-1,6-dihydro-cyclopentapyrazol-5-yl ester and
Trifluoro-methanesulfonic acid
1-benzyl-3-cyano-1,4-dihydro-cyclopentapyrazol-5-yl ester as a
Regio-Isomeric Mixture
[0410] ##STR81##
[0411] Step A: Preparation of
(4-Ethoxy-2-oxo-cyclopent-3-enyl)oxo-acetic acid tert-butyl ester.
##STR82##
[0412] To a solution, of 3-ethoxy cyclopentenone (2.12 g, 16.82
mmol) in anhydrous THF (40 mL) cooled to -78.degree. C. under a
nitrogen atmosphere was added lithium diisopropyl amide (12 mL, 24
mmol, 2.0 M in THF). After 15 minutes, a solution of di-tert-butyl
dioxalate (3.73 g, 18.5 mmol) in THF (15 mL) was added. The
reaction mixture was stirred at -78.degree. C. for 15 minutes and
then warmed to -20.degree. C. and stirred for an additional 15
minutes. The reaction was quenched with 1N HCl (40 mL) and
extracted with ethyl acetate (3.times.). The organic layer was
washed with brine, dried over anhydrous Na.sub.2SO.sub.4, filtered
and concentrated in vacuo. The residue was purified by flash
chromatography (SiO.sub.2) using 35% ethyl acetate-hexanes to give
the desired product (2.53 g) as an off-white solid.
[0413] Step B: Preparation of
1-Benzyl-5-oxo-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic
acid tert-butyl ester. ##STR83##
[0414] To a solution of the intermediate from step A (2.15 g, 8.45
mmol) in ethanol (100 mL) was added benzyl hydrazine hydrochloride
(1.8 g, 9.22 mmol) and HOAc (10 mL). The reaction mixture was
stirred at room temperature for 16 hours and then refluxed at
70.degree. C. for 30 minutes. The reaction was cooled to room
temperature and concentrated in vacuo. The residue was dissolved in
ethyl acetate and washed with water, saturated NaHCO.sub.3, and
brine. The organic layer was dried over anhydrous Na.sub.2SO.sub.4
filtered and concentrated in vacuo. The residue was purified by
flash chromatography (SiO.sub.2) using 30% ethyl acetate-hexanes to
give the desired product (1.64 g) a brown oil.
[0415] Step C: Preparation of
1-Benzyl-5-oxo-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic
acid. ##STR84##
[0416] To a solution of the intermediate from step, B (1.64 g, 5.25
mmol) in dichloromethane (20 mL) was added trifluroacetic acid (20
mL) and the resulting solution stirred at room temperature for 4
hours. The reaction mixture was concentrated in vacuo and
azeotroped with toluene (3.times.). This material was carried on to
the next step without any further purification.
[0417] Step D: Preparation of
1-Benzyl-5-oxo-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic
acid 2,5-dioxo-pyrrolidin-1-yl ester ##STR85##
[0418] To a solution of the intermediate from step C (1.34 g, 5.25
mmol) in CH.sub.2Cl.sub.2 (50 mL) was added N-hydroxy succinimide
(1.21 g, 10.5 mmol) followed by EDC (2.01 g, 10.5 mmol). After
stirring at room temperature for 18 hours, the reaction mixture was
concentrated in vacuo. The residue was diluted with ethyl acetate
(200 mL), washed with saturated NaHCO.sub.3, solution and brine.
The organic layer was dried over anhydrous Na.sub.2SO.sub.4,
filtered and concentrated in vacuo. A yellow solid was
obtained.
[0419] Step E: Preparation of
1-Benzyl-5-oxo-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic
acid amide. ##STR86##
[0420] To a solution of the intermediate from step D (2.0 g, 5.25
mmol) in 1,4-dioxane (50 mL) was added NH.sub.4OH (14.8 N, 10.0 eq,
3.53 mL). A precipitate formed immediately. After stirring at room
temperature for 15 minutes the reaction mixture was filtered
through a fritted funnel and the precipitate washed with
1,4-dioxane. The filtrate was concentrated in vacuo to give a
solid.
[0421] Step F: Preparation of
1-Benzyl-5-oxo-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carbonitrile.
##STR87##
[0422] To a solution of the intermediate from step E (5.25 mmol) in
DMF (60 mL) was added cyanuric chloride (3.12g, 17 mmol) in three
portions. After 30 minutes at room temperature, the reaction was
quenched with water and extracted with ethyl acetate (2.times.).
The organic layer was washed with water, brine and dried over
anhydrous Na.sub.2SO.sub.4, filtered, and concentrated in vacuo.
The residue was purified by flash chromatography (SiO.sub.2) using
30% ethyl acetate-hexanes to give the desired product (0.95 g) as a
yellow solid.
[0423] Step G: Preparation of Trifluoro-methanesulfonic acid
1-benzyl-3-cyano-1,6-dihydro-cyclopentapyrazol-5-yl ester and
Trifluoro-methanesulfonic acid
1-benzyl-3-cyano-1,4-dihydro-cyclopentapyrazol-5-yl ester
(Mixture)
[0424] To a solution of the intermediate from step F (447 mg, 1.87
mmol) in anhydrous THF (14 mL) at -78.degree. C. was added a
solution of freshly prepared lithium diisopropyl amide (1.89 mmol)
in THF (6 mL). After stirring the reaction at -78.degree. C. for 30
minutes 2[N,N-Bis(trifluromethyl-sufonyl)amine]-5-chloropyridine
(1.4 g, 3.6 mmol) was added. The reaction was warmed to -20.degree.
C. and stirred for 3 hours. The reaction was quenched with
saturated NH.sub.4Cl solution, and the resulting mixture was
extracted with ethyl acetate, washed with 1N HCl solution,
saturated NaHCO.sub.3 solution and dried over anhydrous
Na.sub.2SO.sub.4. The solution was filtered and concentrated in
vacuo. The residue was purified on the chromatotron using a
2000-micron rotor (SiO.sub.2) and 5% ethyl acetate-hexanes as
eluant to afford 393 mg of the desired product as a 2:1 mixture of
double bond regio-isomers. .sup.1H NMR (500 MHz, CDCl.sub.3):
(Major isomer) .delta. 7.45-7.3 (m, 5H), 6.06 (bt, 1H), 5.41 (s,
2H), 3.56 (bd, 2H). .sup.1H NMR (500 MHz, CDCl.sub.3): (Minor
isomer) .delta. 7.45-7.3 (m, 5H), 6.63 (bt, 1H), 5.39 (s, 2H), 3.18
(bd, 2H). LC-MS: (M+H)=370.25.
Example 9.9
5-Propoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
(Compound 12)
[0425] ##STR88## ##STR89##
[0426] Step A: Preparation of
1-Benzyl-5-propoxy-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carbonitrile.
##STR90##
[0427] To a solution of
1-benzyl-5-hydroxy-1,4,5,6-tetrahydrocyclo-penta[c]pyrazole-3-carbonitril-
e (see Example 9.7, 30 mg, 0.125 mmol) in anhydrous DMF (2 mL) was
added sodium hydride (6 mg, 0.15 mmol, 60% dispersion in oil).
After stirring for 3 minutes propyl bromide was added (14 .mu.L,
0.15 mmol) and the resulting mixture stirred for an hour. At the
end of this time sodium hydride (6 mg, 0.15 mmol, 60% dispersion in
oil) and propyl bromide were added. After 30 minutes the reaction
was quenched by adding saturated NH.sub.4Cl (3 mL). The resulting
mixture was extracted with ethyl acetate, washed with brine, dried
over anhydrous Na.sub.2SO.sub.4, filtered and concentrated in
vacuo. The residue was purified by PTLC (SiO.sub.2) using 15% ethyl
acetate-hexanes to give the desired product.
[0428] Step B: Preparation of
1-Benzyl-5-propoxy-3-(2H-tetrazol-5-y)-1,4,5,6-tetrahydro-cyclopentapyraz-
ole. ##STR91##
[0429] To a solution of the intermediate from step A (25 mg, 0.089
mmol) in 2-propanol (1 mL) was added water (2 mL), sodium azide (14
mg, 0.222 mmol) and zinc bromide (10 mg, 0.04 mmol). After heating
the reaction mixture at 90.degree. C. for 18 hours, it was cooled
to room temperature and HCl (3 mL, 3N) was added. The reaction
mixture was extracted with ethyl acetate, washed with brine, dried
over anhydrous Na.sub.2SO.sub.4 filtered and concentrated in vacuo.
The residue was purified by PTLC (SiO.sub.2) using 100% ethyl
acetate to give the desired product.
[0430] Step C.
5-Propoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
(Compound 12).
[0431] To a solution of the intermediate from step B (26 mg, 0.08
mmol) in DMSO (0.6 mL) was added potassium-t-butoxide (0.6 mL, 0.6
mmol, 1.0 M in THF). Oxygen gas was bubbled through the reaction
mixture for 15 minutes. The reaction was quenched with HCl (3 mL,
3N). The resulting mixture was extracted with ethyl acetate
(5.times.) dried over anhydrous Na.sub.2SO.sub.4 filtered and
concentrated in vacuo. The residue was purified by reverse phase
HPLC to afford the title compound. .sup.1H NMR (CDCl.sub.3) .delta.
4.80 (m, 1H), 3.51 (m, 2H), 3.24 (dd, J=6.8, 15.5 Hz, 1H), 3.18
(dd, J=6.9, 16.0 Hz, 1H), 2.85 (dd, J=4.1, 15.6 Hz, 1H), 2.79 (dd,
J=4.4, 16.1 Hz, 1H), 1.62 (m, 2H), 0.96 (t, J=7.6 Hz, 3H). LC-MS:
2.15 min; (M+H)=235.
Example 9.10
5-Isobutoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
(Compound 15)
[0432] ##STR92##
[0433] The title compound was prepared from
1-benzyl-5-hydroxy-1,4,5,6-tetrahydrocyclo-penta[c]pyrazole-3-carbonitril-
e (see Example 9.7) using a similar procedure described for the
synthesis of Example 9.8. .sup.1H NMR (CDCl.sub.3) .delta. 4.77 (m,
1H), 3.33 (m, 2H), 3.23 (dd, J=6.9, 15.5 Hz, 1H), 3.17 (dd, J=6.9,
16.0 Hz, 1H), 2.85 (dd, J=4.1, 15.6 Hz, 1H), 2.79 (dd, J=4.2, 15.9
Hz, 1H), 1.85 (m, 1H), 0.94 (d, J=6.7 Hz, 3H). LC-MS: 2.42 min;
(M+H)=249.
Example 9.11
5-Butoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
(Compound 16)
[0434] ##STR93##
[0435] The title compound was prepared from
1-benzyl-5-hydroxy-1,4,5,6-tetrahydrocyclo-penta[c]pyrazole-3-carbonitril-
e (see Example 9.7) using a similar procedure described for the
synthesis of Example 9.8. .sup.1H NMR (CDCl.sub.3) .delta. 4.78 (m,
1H), 3.56 (m, 2H), 3.24 (dd, J=6.8, 15.6 Hz, 1H), 3.17 (dd, J=6.9,
15.9 Hz, 1H), 2.84 (dd, J=4.1, 15.6 Hz, 1H), 2.77 (dd, J=4.6,
16.0Hz, 1H), 1.58 (m, 2H), 1.42 (m, 2H), 0.95 (t, J=7.3 Hz, 3H).
LC-MS: 2.50 min; (M+H)=249.
Example 9.12
5-Fluoro-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
(Compound 14)
[0436] ##STR94##
[0437] Step A: Preparation of
1-Benzyl-5-fluoro-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carbonitrile.
##STR95##
[0438] To a solution of
1-benzyl-5-hydroxy-1,4,5,6-tetrahydrocyclo-penta[c]pyrazole-3-carbonitril-
e (see Example 9.7, 30 mg, 0.125 mmol) in anhydrous dichloromethane
(0.9 mL) was added DAST (33 .mu.L, 0.25 mmol) under a nitrogen
atmosphere. After stirring at room temperature for 15 minutes, the
reaction mixture was diluted with ethyl acetate, washed with
saturated NaHCO.sub.3 solution and brine. The organic layer was
dried over anhydrous Na.sub.2SO.sub.4 filtered and concentrated in
vacuo. The residue was purified by PTLC (SiO.sub.2) using 30% ethyl
acetate-hexanes to give the desired compound (16 mg).
[0439] Step B: Preparation of
1-Benzyl-5-fluoro-3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyraz-
ole. ##STR96##
[0440] The compound was prepared from the cyano intermediate from
Step A using a similar procedure described in Example 9.8, Step
B.
[0441] Step C.
5-Fluoro-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
(Compound 14).
[0442] To a solution of the intermediate from step B (13 mg, 0.04
mmol) in MeOH (1 mL) was added formic acid (0.1 mL) followed by
palladium black (10 mg). After stirring the reaction mixture under
nitrogen atmosphere for 96 hours, it was filtered and concentrated
in vacuo. The residue was purified by reverse phase HPLC (Gilson)
to give the title compound (4.9 mg). .sup.1H NMR (CD.sub.3OD, 500
MHz) .delta. 5.8 (d, J=51.9 Hz, 1H), 3.31-3.17 (m, 2H), 3.14-2.92
(m, 2H). LC-MS: 0.99 min; (M+H)=195.17.
Example 9.13
5-Propyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
(Compound 11)
[0443] ##STR97##
[0444] Step A: Preparation of
5-Allyl-1-benzyl-1,6-dihydro-cyclopentapyrazole-3-carbonitrile and
5-Allyl-1-benzyl-1,4-dihydro-cyclopentapyrazole-3-carbonitrile
(Mixture). ##STR98##
[0445] To a solution of the trifluoromethansulfonic ester
intermediate described in Example 9.8 (114 mg, 0.307 mmol) in
anhydrous THF (2 mL) was added tri-n-butyl allyl tin (112 mg, 0.338
mmol), lithium chloride (39 mg, 0.923 mmol) and tetrakis triphenyl
phosphine palladium (0) (7.1 mg, 0.006 mmol). After refluxing the
reaction mixture for 6 hours, it was cooled to room temperature and
filtered. The residue was concentrated in vacuo and purified on the
chromatotron using a 2000-micron rotor (SiO.sub.2) and 20% ethyl
acetate-hexanes as the eluant to give the desired product (33
mg).
[0446] Step B: Preparation of
5-Allyl-1-benzyl-3-(1H-tetrazol-5-yl)-1,6-dihydro-cyclopentapyrazole
and
5-Allyl-1-benzyl-3-(1H-tetrazol-5-yl)-1,4-dihydro-cyclopentapyrazole
(Mixture). ##STR99##
[0447] The compound was prepared from the intermediate obtained in
step A above using a similar procedure described in Example 9.8,
step B.
[0448] Step C.
5-Propyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole.
[0449] To a solution of the intermediate from step, B (18 mg, 0.059
mmol) in methanol was added a few drops of concentrated HCl until
the reaction was homogeneous. Pd/C (1.8 mg) was added and the
resulting mixture was stirred under a hydrogen atmosphere (balloon)
for 24 hours. The reaction mixture was filtered, concentrated in
vacuo and purified by reverse phase HPLC to give the title
compound. .sup.1H NMR (CD.sub.3OD, 500 MHz) .delta. 3.06 (m, 2H),
2.97 (dd, J=7.5, 15.1 Hz, 1H), 2.5 (m, 2H), 1.6 (m, 2H), 1.4 (m,
2H), 0.98 (t, J=7.3 Hz, 3H). LC-MS: 2.60 min; (M+H)=219.36.
Example 9.14
5-Cyclopentyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
(Compound 13)
[0450] ##STR100##
[0451] Step A: Preparation of
1-Benzyl-5-cyclopent-1-enyl-1,6-dihydro-cyclopentapyrazole-3-carbonitrile
and
1-Benzyl-5-cyclopent-1-enyl-1,4-dihydro-cyclopentapyrazole-3-carbonit-
rile (Mixture). ##STR101##
[0452] To a solution of the trifluoromethansulfonic ester
intermediate described in Example 9.8 (185 mg, 0.501 mmol) in
1,4-dioxane was added cyclopenten-1-yl-boronic acid (62 mg, 0.551
mmol), potassium phosphate (160 mg, 0.751 mmol) and tetrakis
triphenyl phosphine palladium (0). The reaction mixture was heated
at 85.degree. C. After the reaction was complete, it was diluted
with ethyl acetate, washed with 1N NaOH, brine and dried over
anhydrous Na.sub.2SO.sub.4. The solution was filtered and
concentrated in vacuo. The residue was purified on the chromatotron
using a 2000-micron rotor (SiO.sub.2) and 20% ethyl acetate-hexanes
as the eluant.
[0453] Step B: Preparation of
1-Benzyl-5-cyclopent-1-enyl-3-(1H-tetrazol-5-yl)-1,6-dihydro-cyclopentapy-
razole and
1-Benzyl-5-cyclopent-1-enyl-3-(1H-tetrazol-5-yl)-1,4-dihydro-cy-
clopentapyrazole (Mixture). ##STR102##
[0454] The compound was prepared from the intermediate obtained in
step A above using a similar procedure described in Example 9.8,
step B.
[0455] Step C.
5-Cyclopentyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
(Compound 13).
[0456] To a solution of the intermediate from step B (16 mg, 0.048
mmol) in methanol (2 mL) was added formic acid (200 .mu.L).
Palladium black (8.2 mg, 0.078 mmol) was added, and the resulting
mixture was purged with nitrogen and stirred for 24 hours. Another
portion of palladium black was added (8.2 mg, 0.078 mmol). After
stirring for 48 hours, the reaction was filtered, concentrated in
vacuo, and purified by reverse phase HPLC to give the title
compound.
[0457] .sup.1H NMR (CD.sub.3OD, 500 MHz) .delta. 3.1-2.9 (m, 2H),
2.6 (m, 2H), 2.03 (m, 2H), 1.87 (m, 2H), 1.63 (m, 2H), 1.59 (m,
2H), 1.28 (m, 2H). LC-MS: 2.99 min; (M+H)=245.46.
Example 9.15
5-Butyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
(Compound 8)
[0458] ##STR103##
[0459] Step A: Preparation of
1-Benzyl-5-butyl-1,6-dihydro-cyclopentapyrazole-3-carbonitrile and
1-Benzyl-5-butyl-1,4-dihydro-cyclopentapyrazole-3-carbonitrile
(Mixture). ##STR104##
[0460] To a solution of the trifluoromethansulfonic ester
intermediate described in Example 9.8 (180 mg, 0.486 mmol) in
toluene (3 mL) was added n-butyl boronic acid (99 mg, 0.973 mmol),
K.sub.2CO.sub.3 (201 mg, 1.46 mmol), PdCl.sub.2(dppf).sub.2 (12 mg,
0.0146 mmol) and Ag.sub.2O (225 mg, 0.973 mmol). After refluxing
the reaction mixture for 6 hours, it was cooled to room temperature
and filtered. The residue was concentrated in vacuo and purified on
the chromatotron using a 2000-micron rotor (SiO.sub.2) and 5% ethyl
acetate-20% ethyl acetate-hexanes as the eluant to give the desired
product (52 mg).
[0461] Step B: Preparation of
1-Benzyl-5-butyl-3-(1H-tetrazol-5-yl)-1,6-dihydro-cyclopentapyrazole
and
1-Benzyl-5-butyl-3-(1H-tetrazol-5-yl)-1,4-dihydro-cyclopentapyrazole
(Mixture). ##STR105##
[0462] The compound was prepared from the intermediate obtained in
step A above using a similar procedure described in Example 9.8
step B.
[0463] Step C.
5-Butyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole
(Compound 8).
[0464] The compound was prepared from the intermediate obtained in
step B above using a similar procedure described in Example 5 step
C. .sup.1H NMR (CD.sub.3OD, 500 MHz) .delta. 3.1 (m, 2H), 2.9 (m,
1H), 2.5 (m, 2H), 1.6 (m, 2H), 1.4 (m, 4H), 0.9 (t, J=7.0 Hz, 3H).
LC-MS: 2.86 min; (M+H)=233.34.
Example 9.16
5-Methyl-3-(1H-tetrazol-5-yl)-2,6-dihydro-cyclopentapyrazole
(Compound 9) and
5-Methyl-3-(1H-tetrazol-5-yl)-2,4-dihydro-cyclopentapyrazole
(Compound 10)
[0465] ##STR106##
[0466] Step A: Preparation of
5-Ethoxy-1,4-dihydro-cyclopentapyrazole-3-carboxylic acid
tert-butyl ester. ##STR107##
[0467] To an ethanol (5 mL) solution of the ketoester (254 mg, 1.0
mmol), prepared from 3-ethoxy cyclopentenone as in step A of
Example 9.8 above, was added hydrazine hydrate (34 .mu.L, 1.1
mmol), followed by acetic acid (0.5 mL). After refluxing the
reaction mixture for 1.5 hours, it was cooled to room temperature
and concentrated in vacuo. The residue was suspended in water and
extracted with ethyl acetate. The organic layer was dried over
anhydrous Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The
residue was purified by flash chromatography (SiO.sub.2) using 25%
ethyl acetate-hexanes to give the desired product as a white
solid.
[0468] Step B: Preparation of
5-Ethoxy-1-(toluene-4-sulfonyl)-1,4-dihydro-cyclopentapyrazole-3-carboxyl-
ic acid tert-butyl ester. ##STR108##
[0469] To a solution of the pyrazole intermediate from step A (275
mg, 1.1 mmol) above in CH.sub.2Cl.sub.2 (5 mL) was added pyridine
(178 .mu.L, 2.2 mmol) and p-toluene sulfonyl chloride (230 mg, 1.21
mmol). After stirring the resulting reaction mixture at room
temperature for 3 hours it was diluted with CH.sub.2Cl.sub.2,
washed with 1N HCl, saturated NaHCO.sub.3, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The residue
was purified by flash chromatography (SiO.sub.2) using 10% ethyl
acetate-hexanes.
[0470] Step C: Preparation of
5-Oxo-1-(toluene-4-sulfonyl)-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carb-
oxylic acid. ##STR109##
[0471] To a solution of the intermediate from step B above, (414
mg, 1.02 mmol) in CH.sub.2Cl.sub.2 (2 mL) was added trifluoroacetic
acid (2 mL). After stirring the reaction at room temperature for
1.5 hours it was concentrated in vacuo and azeotroped with toluene
(2.times.). This material was used in the next step without any
further purification.
[0472] Step D: Preparation of
5-Oxo-1-(toluene-4-sulfonyl)-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carb-
oxylic acid 2,5-dioxo-pyrrolidin-1-yl ester. ##STR110##
[0473] To a solution of the intermediate from step C above, (320
mg, 1.0 mmol) in CH.sub.2Cl.sub.2 (20 mL) was added N-hydroxy
succinimide (230 mg, 2.0 mmol) followed by EDC (384 mg, 2.0 mmol).
After stirring at room temperature for 18 hours, the reaction
mixture was concentrated in vacuo. The residue was diluted with
ethyl acetate (20 mL), washed with saturated NaHCO.sub.3, solution
and brine. The organic layer was dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. A yellow
solid was obtained.
[0474] Step E: Preparation of
5-Oxo-1-(toluene-4-sulfonyl)-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carb-
oxylic acid amide. ##STR111##
[0475] To a solution of the intermediate from step D above, (380
mg, 0.91 mmol) in 1,4-dioxane (10 mL) was added NH.sub.4OH (14.8 N,
10.0 eq, 0.61 mL). A precipitate formed immediately. After stirring
at room temperature for 15 minutes the reaction mixture was
filtered through a sintered funnel and the precipitate washed with
1,4-dioxane. The filtrate was concentrated in vacuo to give a
yellow oil.
[0476] Step F: Preparation of
5-Oxo-1-(toluene-4-sulfonyl)-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carb-
onitrile. ##STR112##
[0477] To a solution of the intermediate from step E above (0.91
mmol) in anhydrous DMF (5 mL) was added cyanuric chloride (334 mg,
2.0 mmol) in two portions. After stirring at room temperature for
15 minutes, the reaction was quenched by pouring into water (10
mL). The resulting mixture was extracted with ethyl acetate, washed
with saturated NaHCO.sub.3, brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The residue
was purified by flash chromatography (SiO.sub.2) using 25% ethyl
acetate-hexanes. A white solid was obtained.
[0478] Step G: Preparation of Trifluoro-methanesulfonic acid
3-cyano-1-toluene-4-sulfonyl)-1,6-dihydro-cyclopentapyrazol-5-yl
ester and Trifluoro-methanesulfonic acid
3-cyano-1-(toluene-4-sulfonyl)-1,4-dihydro-cyclopentapyrazol-5-yl
ester (Mixture). ##STR113##
[0479] To a solution of the intermediate from step F (100 mg, 0.33
mmol) in anhydrous THF (5 mL) at -78.degree. C. was added a
solution of lithium diisopropyl amide (0.33 mmol, 166 .mu.L, 2.0 M
in THF) in THF (6 mL). After stirring the reaction at -78.degree.
C. for 30 minutes
2[N,N-Bis(trifluromethylsufonyl)amine]-5-chloropyridine (195 mg,
0.496 mmol) was added. The reaction was warmed to 0.degree. C. and
stirred for 45 minutes. The reaction was quenched with 1N HCl
solution, and the resulting mixture was extracted with ethyl
acetate, washed with saturated NaHCO.sub.3 solution and dried over
anhydrous Na.sub.2SO.sub.4. The solution was filtered and
concentrated in vacuo. The residue was purified by flash
chromatography (SiO2) using 5% ethyl acetate-hexanes as eluant to
afford 79 mg of the desired product as a 4:1 mixture of double bond
regio-isomers.
[0480] Step H: Preparation of
5-Methyl-1-(toluene-4-sulfonyl)-1,6-dihydro-cyclopentapyrazole-3-carbonit-
rile and
5-Methyl-1-(toluene-4-sulfonyl)-1,4-dihydro-cyclopentapyrazole-3--
carbonitrile (Mixture). ##STR114##
[0481] To a solution of the intermediate from step G above, (79 mg,
0.182 mmol) in toluene (1.5 mL) was added lithium chloride (39 mg,
0.912 mmol), tetramethyl tin (126 .mu.L, 0.912 mmol) and tetrakis
triphenyl phosphine palladium (0). After refluxing the reaction
mixture for 45 minutes it was cooled to room temperature, diluted
with ethyl acetate, washed with water. The organic layer was dried
over anhydrous Na.sub.2SO.sub.4, filtered and concentrated in
vacuo. The residue was purified by flash chromatography (SiO.sub.2)
using 30% ethyl acetate-hexanes to give (28 mg) the desired
product.
[0482] Step I: Preparation of
5-Methyl-1,6-dihydro-cyclopentapyrazole-3-carbonitrile and
5-Methyl-1,4-dihydro-cyclopentapyrazole-3-carbonitrile (Mixture).
##STR115##
[0483] To a solution of the intermediate from step H above, (28 mg,
0.093 mmol) in anhydrous THF (3 mL) was added tetrabutyl ammonium
fluoride (93 .mu.L, 0.093 mmol, 1.0 M in THF). After refluxing the
reaction mixture for 30 minutes, it was cooled to room temperature
and concentrated in vacuo. The residue was dissolved in ethyl
acetate, washed with saturated NaHCO.sub.3, brine, dried over
anhydrous Na.sub.2SO4, filtered and concentrated in vacuo. The
residue was purified by flash chromatography (SiO.sub.2) using 30%
ethyl acetate-hexanes to give a white solid.
[0484] Step J:
5-Methyl-3-(1H-tetrazol-5-yl)-2,6-dihydro-cyclopentapyrazole
(Compound 9) and
5-Methyl-3-(1H-tetrazol-5-yl)-2,4-dihydro-cyclopentapyrazole
(Compound 10).
[0485] To a solution of the intermediate from step I above (9.0 mg,
0.062 mmol) in 2-propanol (1 mL) was added water (0.5 mL), sodium
azide (12 mg, 0.186 mmol) and zinc bromide (6.5 mg, 0.031 mmol).
After heating the reaction mixture at 90.degree. C. for 18 hours,
it was cooled to room temperature and HCl (1.5 mL, 3N) was added.
The reaction mixture was extracted with ethyl acetate, washed with
brine, dried over anhydrous Na.sub.2SO.sub.4 filtered and
concentrated in vacuo to give the desired product as a 2:1 ratio of
double bond regio-isomers. Isomer (a): .sup.1H NMR (CD.sub.3OD, 500
MHz) .delta. 6.43 (bs, 1H), 3.3 (s, 2H), 2.2 (s, 3H). Isomer (b):
.sup.1H NMR (CD.sub.3OD, 500 MHz) .delta. 6.58 (bs, 1H), 3.24 (s,
2H), 2.15 (s, 3H). LC-MS: 1.86 min, (M+H)=189.1.
[0486] Throughout this application, various publications, patents
and published patent applications are cited. The disclosures of
these publications, patents and published patent applications
referenced in this application are hereby incorporated by reference
in their entirety into the present disclosure. Modifications and
extension of the disclosed inventions that are within the purview
of the skilled artisan are encompassed within the above disclosure
and the claims that follow.
[0487] Although a variety of expression vectors are available to
those in the art, for purposes of utilization for both the
endogenous and non-endogenous human GPCRs, it is most preferred
that the vector utilized be pCMV. This vector was deposited with
the American Type Culture Collection (ATCC) on Oct. 13, 1998 (10801
University Blvd., Manassas, Va. 20110-2209 USA) under the
provisions of the Budapest Treaty for the International Recognition
of the Deposit of Microorganisms for the Purpose of Patent
Procedure. The DNA was tested by the ATCC and determined to be
viable. The ATCC has assigned the following deposit number to pCMV:
ATCC #203351.
* * * * *